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The cannabinoid type one receptor (CB1R) is one of the most abundant G-protein 
coupled receptors (GPCRs) in the central nervous system. CB1R activation at the 
presynaptic terminal by ligand released retrogradely from the postsynapse 
dampens down neurotransmitter release. Consistent with its presynaptic role, 
CB1R is only stably surface expressed in axons. How this tightly regulated axonal 
surface polarity is established and maintained is unclear.  
To address this question, I applied retention using selective hooks (RUSH) to 
visualise the trafficking of CB1R from biosynthesis to mature polarised localisation 
in cultured rat hippocampal neurons. I show that axonal surface polarity is initially 
established through axonally biased delivery of newly synthesized CB1R by the 
secretory pathway. Axonal surface polarity is subsequently enhanced and 
maintained by selective removal from the dendritic membrane and stable retention 
at the axonal surface.  
This dual mechanism is mediated by the CB1R C-terminus and involves the Helix 
9 (H9) domain. Removal of the H9 domain (CB1RΔH9) both increases secretory 
pathway delivery to dendrites and decreases surface stability. Furthermore, 
CB1RΔH9 is more sensitive to agonist-induced internalisation and less efficient at 
downstream signalling than CB1RWT.  
A screen for H9 interacting proteins highlighted SH3-containing GRB2-like protein 
3-interacting protein 1 (SGIP1), a protein linked to clathrin-mediated endocytosis. 
SGIP1 stabilises CB1R at the surface, likely through interaction with the H9 
domain. 
Together, these results shed new light on how polarity of CB1R is mediated and 
indicate that the C-terminal H9 domain plays key roles in this process. This is 
important because defining the trafficking pathways and protein interactions that 
mediate axonal CB1R localisation could provide novel targets to enhance or 
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Chapter 1 –   INTRODUCTION 
1.1 NEURONAL POLARITY 
Neurons are highly polarised cells with complex morphologies. Neurons generally 
possess long processes, typically multiple dendrites and a single axon, which 
extend far from the soma – axons of spinal motor neurons extend up to a meter 
away from the soma (Bonifacino, 2014). Dendrites receive information, the soma 
integrates information, and the axon passes on information in the form of an action 
potential (Figure 1-1). Each compartment requires distinct receptors, ion channels, 
structural proteins, cytosolic proteins, etc. that must be sorted, targeted to, and 
retained in the correct location, often far away from the cell body, for the proper 
function of the neuron (Bentley and Banker, 2016). Other specialised structural 
elements within the compartments – e.g. postsynaptic densities, the axon initial 
segment, nodes of Ranvier, internodes, presynaptic terminals, and axonal growth 
cones – also require the strict and accurate control of local composition. 
 
Figure 1-1 Neurons are polarised cells. 
Dendrites receive information, the soma integrates information, and the axon passes information on. 
The axon initial segment acts as a surface diffusion barrier and intracellular filter to separate the 
somatodendritic compartment from the axon. The secretory pathway machinery – the rough 
endoplasmic reticulum (rER) and the Golgi apparatus are in the somatodendritic compartment. 
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1.1.1 Membrane trafficking 
Broadly, neurons are separated into the somatodendritic compartment and the 
axonal compartment, separated by the axon initial segment (AIS; Figure 1-1). 
Transmembrane receptors required for each compartment are trafficked by 
vesicular transport. De novo transmembrane receptors are delivered to the plasma 
membrane by the secretory pathway, which is located in the somatodendritic 
compartment (Figure 1-1 and Figure 1-2). Surface expressed transmembrane 
receptors can be retrieved from the plasma membrane of either compartment by 
endocytosis (Figure 1-3 and Figure 1-4). The trans-Golgi Network (TGN) of the 
secretory pathway and the endosomal system constitute the main sorting stations 
for polarised transmembrane proteins. 
1.1.1.1 Secretory pathway 
1.1.1.1.1 Endoplasmic Reticulum (ER) 
Synthesis begins in the rough endoplasmic reticulum (rER), the ribosome studded 
matrix of ER responsible for protein translation (Figure 1-2; (Reid and Nicchitta, 
2015). The N-terminus of transmembrane proteins generally comprises of a 
cleavable signal peptide that is recognised by the signal recognition particle (SRP) 
as it is emerges from the ribosome (Zheng and Gierasch, 1996; Nyathi et al., 2013; 
Janda et al., 2010). The SRP then directs the nascent protein to the translocon 
pore Sec61, which translocates the peptide across the ER membrane co-
translationally, threading the transmembrane domains according to its topology 
(Nyathi et al., 2013; von Heijne, 2006; Janda et al., 2010). After delivery to the 
translocon, the signal peptide is cleaved to produce the mature protein (Nyathi et 
al., 2013; Janda et al., 2010; Auclair et al., 2012). N-linked glycosylation, the 
addition of glycans to asparagine residues, occurs by resident ER enzymes to aid 
the correct folding and stability of the transmembrane protein (Hanson et al., 2009; 
Live et al., 1996; Ruiz-Canada et al., 2009). Proteins must be correctly folded to 
exit the ER or they are sent for degradation by ER associated protein degradation 
(ERAD; (Guerriero and Brodsky, 2012)). The correctly folded protein then leaves 
the ER at specialised sites called ER exit sites (ERES; (Langhans et al., 2012)) by 
vesicular transport in COPII-coated vesicles, traveling via the ER-Golgi 
intermediate compartment (ERGIC) to the Golgi (Stagg et al., 2006; Fath et al., 
2007). 




Figure 1-2 Schematic of the canonical secretory pathway. 
Plasma membrane proteins are synthesised, processed, and correctly folded in the rough 
endoplasmic reticulum (rER). Cargo leaves the ER at ER exit sites (ERES) by vesicular transport in 
COPII-coated vesicles to the cis face of the Golgi Apparatus where it is further modified. The trans 
face of the Golgi network (TGN) acts as a sorting station, sending cargo to its proper location in the 
plasma membrane or endosomal system.  
 
1.1.1.1.2 Golgi Apparatus  
Cargo enters the Golgi at the cis face, traverses the Golgi cisternae, and exits at 
the trans-Golgi network (TGN) (Figure 1-2; (Klumperman, 2011)). Cargo ‘matures’ 
as it traverses the cisternae, undergoing additional modifications, including the 
processing of the glycans added by the ER during N-linked glycosylation, resulting 
in a mature glycosylation profile (Kornfeld and Kornfeld, 1985). The TGN acts as a 
central sorting station, sending cargo to the plasma membrane as well as the 
endosomal system (Rothman and Simons, 1981). 
How cargo traffics within the Golgi is controversial and two different models have 
been proposed: the vesicular transport model and the cisternae maturation model 
(Martínez-Alonso et al., 2013). The vesicular transport model proposes that cargo 
is packaged into vesicles to move along to the next static stack following a cis-
medial-trans trajectory (Martínez-Alonso et al., 2013). The cisternae maturation 
model suggests that the cisternae themselves are dynamic, moving with their 
Chapter 1 –   Introduction 
4 
 
cargo as a whole to the trans side, (Martínez-Alonso et al., 2013). These models 
are not mutually exclusive and may work in tandem (Pelham and Rothman, 2000; 
Rabouille and Klumperman, 2005; Luini, 2011). 
 
1.1.1.2 Endocytosis 
Transmembrane proteins are removed from the plasma membrane by 
endocytosis. Several different pathways for of endocytosis exist (see (Doherty and 
McMahon, 2009) for a review), but clathrin-mediated endocytosis (CME) is the best 
understood (Figure 1-3).  
1.1.1.2.1 Clathrin-mediated endocytosis (CME) 
During CME, cargo and docking factors (e.g. phosphoinositides) recruit adaptor 
complex 2 (AP-2), a heterotetrameric complex consisting of α, β2, µ2, and σ2 
subunits (Guardia et al., 2018). AP-2 in turn recruits clathrin, a three-legged 
scaffold protein, forming clathrin-coated pits. The membrane scission protein 
dynamin pinches off the neck of the pit to form a clathrin coated vesicle. See 
(Mousavi et al., 2004) for a review. 
1.1.1.2.2 The endosomal system 
The endosomal system constitutes another complex and interconnected sorting 
station, sorting cargo either back to the plasma membrane (recycling), back to the 
TGN, or to lysosomes for degradation (Cullen and Steinberg, 2018; Cullen, 2008). 
The endosomal system can be functionally compartmentalised into ‘Rab domains’ 
(Figure 1-4). Rab proteins are small GTPases that act as membrane organisers 
and different Rabs occupy distinct types of endosomal compartments (e.g. Rab5 = 
early endosome, Rab 7 = late endosome etc.; (Sönnichsen et al., 2000; Zerial and 
McBride, 2001)). 
 




Figure 1-3 Schematic of clathrin mediated endocytosis (CME). 
Adaptor protein complex 2 (AP-2) is made up of four subunits: α, β2, µ2, and σ2. AP-2 binds cargo 
and docking factors (phosphoinositides) and recruits clathrin to form clathrin-coated pits.  
Figure adapted from (Guardia et al., 2018). 
 
 
Figure 1-4 The endocytic system compartmentalised by Rab GTPase ‘domains’. 
Figure from http://zerial.mpi-cbg.de/page/project-rab-gtpases; (Sönnichsen et al., 2000; Zerial and 
McBride, 2001).  
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1.1.2 Polarised trafficking 
1.1.2.1 Somatodendritic sorting signals 
Sorting of polarised cargo in the TGN and endosomal system relies on intrinsic 
sorting motifs usually located in the C-terminus or intracellular loops of the 
transmembrane protein. Several canonical dileucine-like and tyrosine sorting 
motifs and non-canonical motifs have been identified for sorting cargo to dendrites 
(see (Bentley and Banker, 2016) for a review). Sorting signals for axonal proteins 
are far less understood and no canonical sorting signals have been identified 
(Bentley and Banker, 2016).  
1.1.2.2 Adaptor proteins sort polarised cargo 
Sorting and packaging of axonal and somatodendritic cargo into distinct vesicles 
occurs via binding of specific adaptor protein complexes to sorting signals (Figure 
1-5; (Bonifacino, 2014; Guardia et al., 2018)). There are 5 types of adaptor 
complexes (AP-1 to AP-5), each made up of 4 subunits (see Figure 1-3 for 
example), and each with a characteristic distribution, signal recognition ability, and 
function (Guardia et al., 2018). 
AP-1 mediates sorting of somatodendritic proteins, budding off from both the TGN 
and endosomes in the soma to traffic to the plasma membrane (Margeta et al., 
2009; Farías et al., 2012; Dwyer et al., 2001; Li et al., 2016). Furthermore, AP-1 
retrieves somatodendritic proteins from the axon by retrograde transport (Margeta 
et al., 2009). AP-4 also sorts a subset of somatodendritic proteins from the TGN 
(Matsuda et al., 2008). 
Axonal sorting is less well understood, although AP-3 is reported to sort axonal 
proteins from the TGN in C. elegans (Li et al., 2016). AP-3 has other specialised 
axonal functions including contributing to the generation of synaptic vesicles from 
synaptic vesicle precursors (Nakatsu et al., 2004; Salazar et al., 2004). 
1.1.2.3 Polarised vesicular transport 
Once cargo is sorted into somatodendritic or axonal vesicles, the vesicles 
themselves need to be trafficked to the right compartment. Vesicle trafficking is 
driven by motors proteins that travel along specific cytoskeletal tracks. The 
organisation of the neuronal cytoskeleton plays a vital role in establishing and 
maintaining polarity (see (Kapitein and Hoogenraad, 2011) for a review).  




Figure 1-5 Role of adaptor proteins in polarised sorting of cargo. 
Adaptor proteins sort cargo from TGN and the endosomal network. Dendritic cargo is sorted by AP-
1 and AP-4 whereas axonal cargo is sorted by AP-3. Recent evidence from C. elegans suggests that 
AP-3 can sort axonal cargo from the TGN (dotted line arrow; (Li et al., 2016)). 
Figure adapted from (Guardia et al., 2018). 
 
1.1.2.3.1 The axon initial segment (AIS) 
The axon initial segment (AIS) is a specialised segment incorporating the first 30-
50 µm of the axon that separates the somatodendritic compartment from the 
axonal compartment. While its main function is cluster and maintain a high density 
voltage gated ion channels in order to initiate action potentials, the AIS also plays 
an important function as a surface diffusion barrier and intracellular filter, only 
allowing in vesicles with axonal motor proteins, and refusing entry for dendritic 
proteins driven by dendritic motor proteins (Figure 1-6; (Leterrier and Dargent, 
2014; Song et al., 2009; Farias et al., 2015).  
 




Figure 1-6 The axon initial segment acts as a surface diffusion barrier and intracellular filter. 
(A) The AIS diffusion barrier. Lipids and membrane proteins (red) diffusion is impeded in the AIS, 
due to corralling from the submembrane scaffold (green) and the concentration of AIS membrane 
proteins (grey). Diffusion along distal axon and soma is less restricted, as measured from trajectories 
of individual molecules (above, red), despite the presence of the distal axon ankB/βII-spectrin scaffold 
(orange).  
(B) The AIS traffic filter. Vesicles containing somatodendritic proteins (blue) are excluded from 
entering the axon (blue arrow), whereas vesicles transporting axonal proteins (orange) can proceed 
through the AIS (orange arrow). Specific recruitment of axonal kinesins is helped by cues on 
microtubule such as post-translational modifications (light orange). 
Figure and legend from (Leterrier and Dargent, 2014). 
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1.1.2.4 Axon sorting 
Establishing axonal polarity is more complex than establishing dendritic polarity 
since axonal cargo cannot be excluded from the somatodendritic compartment due 
to the simple fact that the secretory pathway components are located in the soma 
(although see (Luarte et al., 2018; González et al., 2018) for reviews on the 
possibility of the existence of an axonal local secretory pathway). 
Three main routes through the secretory pathway and the endosomal system 
pathways have been described for generating axonal polarity (Figure 1-7; 
reviewed in (Lasiecka and Winckler, 2011; Bentley and Banker, 2016)).  
1) A direct pathway whereby cargo is sorted at the TGN and sorted into 
axonal or somatodendritic secretory vesicles and delivered directly to the 
correct compartment. 
2) Non-polarized delivery of secretory vesicles by the TGN followed by 
selective retrieval from the somatodendritic compartment and/or 
selective retention at the axonal compartment. 
3) Delivery by TGN of secretory vesicles solely to the dendritic membrane 
followed by internalisation of axonal cargo and delivery of cargo-containing 
endosomes to the axonal membrane, a process known as transcytosis. 
These three pathways are not necessarily mutually exclusive, and multiple 
pathways have been attributed to the same cargo – for example, both direct 
(Sampo et al., 2003) and transcytotic (Wisco et al., 2003; Yap et al., 2008b) 
pathways have been described for the axonally polarised cell adhesion molecule 
L1/NgCAM. 
 




Figure 1-7 Models of 3 pathways of polarised trafficking. 
(1) Direct polarized delivery from the TGN. Axonal and somatodendritic proteins are sorted in TGN 
into axonally- and somatodendritically-targeted secretory vesicles. Those vesicles are transported 
and fuse with axonal and somatodendritic membranes, respectively.  
(2) Non-polarized delivery followed by selective retrieval and retention. Axonal and somatodendritic 
cargo exits TGN into secretory vesicles, which can fuse with both somatodendritic and axonal 
membranes. After this initial non-polarized insertion, proper polarized distribution of proteins is 
achieved by subsequent endocytic removal of missorted proteins (presumably for degradation) and 
retention of the properly targeted proteins at the plasma membrane. 
(3) Indirect polarized delivery via endosomes (transcytosis). Proteins coming out of TGN are sorted 
into somatodendritically-targeted secretory vesicles, and then inserted into somatodendritic 
membrane and subsequently endocytosed into axonally-targeted endosomal compartments, which 
finally fuse with axonal membrane. 
Figure and legend from (Lasiecka and Winckler, 2011). 
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1.2 ENDOCANNABINOID SYSTEM (ECS) 
The endocannabinoid system (ECS) is an important neuromodulatory system in 
the brain that plays a role in a wide range of behaviours, including appetite, pain, 
and memory (Busquets-Garcia et al., 2015).  
1.2.1 Discovery 
Cannabis sativa has been used for thousands of years for its medicinal and mind-
altering properties. In the past decade there has been a resurgence in interest in 
cannabis for therapeutic use, with newly legalised medical marijuana and its 
derivatives being touted as a kind of cure-all for a multitude of diseases and 
conditions.  
The ECS field began in 1964 with the discovery of Δ9-Tetrahydrocannabinol (Δ9-
THC), a lipophilic compound that is the main psychoactive component of cannabis 
(Gaoni and Mechoulam, 1964). Almost 30 years later, the cannabinoid type 1 
receptor (CB1R) was identified as the receptor that mediates the psychoactive 
effects of Δ9-THC (Matsuda et al., 1990). The discovery of a second receptor 
(CB2R; (Munro et al., 1993)) as well as two lipophilic endogenous cannabinoids 
(endocannabinoids; eCBs), N-arachidonoylethanolamide (named anandamide, 
from the Sanskrit word ‘ananda’ meaning ‘inner bliss’; (Devane et al., 1992)) and 
2-arachidonylglycerol (2-AG; (Sugiura et al., 1995; Mechoulam et al., 1995)) soon 
followed. 
1.2.2 Retrograde transmission 
In 2001, it was found that the ECS mediates retrograde signalling at synapses in 
the central nervous system (CNS; Figure 1-8; (Wilson and Nicoll, 2001; Ohno-
Shosaku et al., 2001; Maejima et al., 2001; Kreitzer and Regehr, 2001)). Activation 
of the postsynapse causes the on-demand synthesis of 2-AG which traverses the 
synaptic cleft retrogradely activating CB1R and dampening down further 
neurotransmission. Thus, the ECS acts as a negative feedback loop to modulate 
synaptic activity. For a thorough review see (Kano et al., 2009). 




Figure 1-8 The principle of retrograde transmission. 
Information transfer at the synapse generally flows anterogradely from presynapse to postsynapse. 
An action potential (yellow lightning bolt) traveling down the presynaptic axon triggers the release of 
synaptic vesicles filled with neurotransmitter, which cross the synaptic cleft and bind to ionotropic and 
metabotropic receptors on the postsynaptic membrane. In certain cases, activation of the 
postsynapse triggers the production of endocannabinoids such at 2-AG, which is synthesised by 
diacylglycerol lipase alpha (DAGLα), a plasma membrane protein located at postsynaptic spines. 2-
AG then travels retrogradely across the synaptic clef to activate the presynaptically-localised 
cannabinoid type 1 receptor (CB1R). Activation of CB1R triggers downstream signalling cascades 
that prevent the release of additional neurotransmitter. Therefore, the endocannabinoid system 
(ECS) acts as a retrograde feedback mechanism to regulate and modulate synaptic activity. 
 
1.2.3 Beyond retrograde transmission 
Over the past few decades, it has become abundantly clear that the ECS is 
extremely complex, pleiotropic, and ubiquitous, extending far beyond its classical 
role in retrograde transmission (see (Castillo et al., 2012; Araque et al., 2017; 
Busquets-Garcia et al., 2018; Pertwee et al., 2010; Howlett et al., 2002; Howlett, 
2005; Di Marzo, 2009; Piomelli, 2003; Ahn et al., 2008; Kano et al., 2009; Katona 
and Freund, 2012) for reviews on the ECS). A more complete overview of synaptic 
ECS function is summarised in Figure 1-9 and aspects are discussed below.




Figure 1-9 Schematic of eCB signalling at the synapse from (Araque et al., 2017)
Chapter 1 –   Introduction 
14 
 
1.3 CANNABINOID TYPE 1 RECEPTOR (CB1R) 
1.3.1 Identification and characterisation 
While the effects of cannabis on the brain has been known for thousands of years, 
CB1R was first cloned and identified in 1990 from rat cortex as the receptor that 
mediates the effects of Δ9-THC, the psychoactive component of cannabis 
(Matsuda et al., 1990). Discovery of the human (Gérard et al., 1991) and mouse 
(Gérard et al., 1991) homologues soon followed. CB1R is the most abundant 
GPCR expressed in the brain, with protein levels comparable to that of NMDA and 
GABAA receptors (Herkenham et al., 1991; Busquets-Garcia et al., 2018). 
 
Figure 1-10 Rat CB1R topology. 
The predicted topology of CB1Rs based on hydrophobicity plots and analysis from crystal structures 
of rhodopsin-family GPCRs. Sites of post-translation modification via N-terminal glycosylation (Song 
and Howlett, 1995) or C-terminal palmitoylation (Oddi et al., 2012, 2017, 2018) are indicated by the 
(Y) symbol and zigzag line respectively. Putative phosphorylation residues, important for mediating 
activity-dependent internalization and/or desensitization are shown in red (Daigle et al., 2008b; Hsieh 
et al., 2002; Jin et al., 1999; Straiker et al., 2012b), whilst two residues located within the 2nd and 
3rd transmembrane domains (TM2/TM3), required for constitutive internalization are shown in pink 
(D’Antona et al., 2006; Roche et al., 1999). Within the second extracellular loop (2EC) a disulphide 
bridge between to cysteine residues is depicted with a single line, whilst the yellow residues denote 
putative amino acids involved in ER exit and receptor surface expression (Ahn et al., 2009a). The 
blue residues indicate the sites of the highly conserved NPXXY motif. Within the C-terminal tail, two 
helical structural motifs, helix 8 (H8) and helix 9 (H9) are highlighted in purple and green respectively 
(Ahn et al., 2009b; Stadel et al., 2011).  
Figure is from (Hildick, 2013) and (Stadel et al., 2011). Figure legend is from (Hildick, 2013). 
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CB1R is a G-protein-coupled receptor (GPCR) of the Rhodopsin (class A) family, 
subgroup α. It comprises of an extracellular N-terminal tail, 7 transmembrane 
helical domains (TM1-7), and an intracellular C-terminal tail with two additional 
helices (helix 8 and helix 9; Figure 1-10). 
1.3.2 Expression profile of CB1R in the CNS 
1.3.2.1 Neurons 
CB1R is expressed in a wide variety of cell types in the CNS at varying levels. For 
review, see (Marsicano and Kuner, 2008; Busquets-Garcia et al., 2018; Mackie, 
2005). 
However, strangely, the expression level of CB1R does not always correlate with 
level of activity. For example, while the hypothalamus expresses lower levels of 
CB1R than the cortex and hippocampus, it displays higher levels of cannabinoid-
dependent activity than areas with high levels of CB1R (Breivogel et al., 1997).  
Furthermore, deletion of CB1R in cortical glutamatergic neurons reduces total 
CB1R protein by about 10% while deletion of CB1R in GABAergic interneurons 
reduces CB1R protein by about 90% (Steindel et al., 2013). However, deletion of 
CB1R in cortical glutamatergic neurons has a several fold larger effect on 
cannabinoid-dependent G-protein activation than deletion of CB1R in GABAergic 
interneurons, suggesting that cannabinoid activation of CB1R in excitatory cells is 
much more efficacious and requires a lower threshold of activation (Steindel et al., 
2013). A higher dose is required to activate CB1R in GABAergic neurons. 
Interestingly, this can explain why cannabinoid administration often display a 
bimodal/biphasic behavioural response with increased dosage. For example, low 
doses of Δ9-THC have an anxiolytic effect whereas high dose have an anxiogenic 
effect (Rey et al., 2012). Similarly, low doses of Δ9-THC induce hyperphagia 
(excessive eating) whereas high doses induce hypophagia (Bellocchio et al., 
2010). Understanding this dual effect is critical for the development of future 
cannabinoid-based therapies. 
1.3.2.2 Glia: astrocytes 
Astrocytes express even lower levels of CB1R (Navarrete et al., 2014; Navarrete 
and Araque, 2008, 2010). Endocannabinoid activation of astroglial CB1R 
increases intracellular Ca2+ levels, likely via Gq protein coupling rather than Gi/o 
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(Navarrete and Araque, 2008). This causes astrocytes to release gliotransmitters, 
e.g. D-serine (Robin et al., 2018), thus modulating synaptic activity and certain 
types of memory (see (Araque et al., 2017; Navarrete et al., 2014) for review).  
1.3.3 Subcellular localisation of CB1R 
1.3.3.1 Plasma membrane localisation 
1.3.3.1.1 Presynaptic 
Consistent with its role in attenuating presynaptic neurotransmitter release (Katona, 
2009), CB1R has a highly polarised axonal surface expression (Irving et al., 2000; 
Coutts et al., 2001; Leterrier et al., 2006; Thibault et al., 2013; Rozenfeld and Devi, 
2008; McDonald et al., 2007a). Within the axonal membrane, CB1R displays a 
disto-proximal gradient of expression (Simon et al., 2013) and 
immunocytochemistry in brain sections using immunogold electron microscopy 
(Katona et al., 1999; Nyíri et al., 2005) or STORM super-resolution imaging (Dudok 
et al., 2015) detect CB1R predominantly at the presynaptic terminal. 
1.3.3.1.2 Plasma membrane microdomains 
CB1R contains several cholesterol binding motifs (Wickert et al., 2018; Oddi et al., 
2011) and is enriched at cholesterol-rich microdomains of plasma membrane 
called lipid rafts (Asimaki et al., 2011; Sarnataro et al., 2005). See 1.3.5.2 
Internalisation for more details. 
1.3.3.2 Intracellular localisation 
Due to the lipophilic nature of endocannabinoids, CB1R activation is likely not 
limited to the plasma membrane but occurs intracellularly as well.  
1.3.3.2.1 Endosomal 
Around 80% of CB1R is located in endosomes (Leterrier et al., 2006; Rozenfeld 
and Devi, 2008). This pool is reportedly activatable (Rozenfeld and Devi, 2008; 
Brailoiu et al., 2011). See 1.3.4.3 Third wave: intracellular signalling for more 
details. 
1.3.3.2.2 Mitochondrial 
Recently, the Marsicano group has made the surprising discovery that a small, but 
significant, proportion of CB1R is associated with the mitochondrial outer 
membrane and activation of this pool reduces mitochondrial respiration (Bénard et 
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al., 2012). Despite some initial controversy (Morozov et al., 2013; Hebert-Chatelain 
et al., 2014), this finding has since been verified independently and in other tissues 
(Mendizabal-Zubiaga et al., 2016; Koch et al., 2015), and has been shown to be 
important for certain types of memory (Hebert-Chatelain et al., 2016).  
1.3.4 CB1R signalling 
CB1R signalling is highly complex and pleiotropic, with a multitude of downstream 
effectors and signalling pathways that emerge under specific spatiotemporal and 
contextual constraints (Busquets-Garcia et al., 2018; Araque et al., 2017). In 
general, CB1R signalling occurs over three spatiotemporal waves: 1) activation of 
heterotrimeric G proteins (<10 minutes), 2) β-arrestin mediated activation of 
mitogen kinases (>5 minutes), and 3) intracellular signalling by either G-proteins 
or β-arrestin (>30 minutes) (Nogueras-Ortiz and Yudowski, 2016). For extensive 
reviews of CB1R signalling, see (Howlett, 2005; Turu and Hunyady, 2010; Irving et 
al., 2008; Araque et al., 2017; Hunter et al., 2017; Busquets-Garcia et al., 2018). 
1.3.4.1 First wave: G protein-mediated signalling 
The classical signalling pathway of GPCRs such as CB1R is mediated through 
activation of heterotrimeric G proteins (Figure 1-11; see (Ritter and Hall, 2009; 
Jong et al., 2018; Pavlos and Friedman, 2017; Rajagopal and Shenoy, 2018; 
Dupré et al., 2009; Sánchez-Fernández et al., 2014; Pierce et al., 2002) for reviews 
on canonical and non-canonical GPCR signalling). Activation of a GPCR by 
binding of an extracellular ligand causes a conformational change allowing it to 
interact with a heterotrimeric G protein complex comprised of α, β, and γ subunits. 
Guanine nucleotide exchange activates the Gα subunit, causing it to dissociate it 
from the Gβγ subunit. The activated Gα subunit binds downstream effectors and 
regulates the activity downstream signalling pathways depending on the subtype 
of Gα. 
Four major families of subtypes exist: Gαs, Gαi, Gαq/11, and Gα12/13. These effectors 
and downstream signalling pathways of each family are summarised in Figure 
1-11 (see also (Ritter and Hall, 2009; Pierce et al., 2002)). Briefly, Gαs and Gαi 
family subtypes activate and inhibit adenylyl cyclase (AC), respectively. AC 
catalyses the cyclization of adenosine triphosphate (ATP) to the second 
messenger Adenosine 3',5'-cyclic monophosphate (cAMP). cAMP signalling is 
complex and has a multitude of effects but most classically the downstream target 
of cAMP is protein kinase A (PKA) (Antoni, 2012). Thus Gi/o proteins inhibit the 
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PKA phosphorylation pathway and Gs proteins activate it. Gαq/11 family subunits 
activate the downstream effector phospholipase C type β (PLCβ), a Ca2+-
dependent enzyme that catalyses the hydrolysis of phosphatidylinositol 4,5 
bisphosphate (PI(4,5) P2) to inositol 1,4,5 trisphosphate (Ins(1,4,5)P3) and 
diacylglycerol (DAG). Ins(1,4,5)P3 and DAG are second messengers which 
together increase Ca2+ levels by opening intracellular ER Ca2+ stores and activate 
protein kinase C (PKC). The downstream effector for Gα12/13 are RhoGEFs, thus 
regulating actin cytoskeleton remodelling by activation of RhoA. Signalling of the 
Gβγ subunit is less well understood but Gβγ can regulate downstream effectors 
such as various ion channels and PLCβ.  
1.3.4.1.1 CB1R coupling to Gi/o proteins  
Characterisation of the signalling of CB1R started even before CB1R was identified 
with the observation that application of exogenous cannabinoids, including Δ9-
THC, to neuroblastoma cells inhibited adenylyl cyclase (AC), causing a reduction 
in cAMP levels (Howlett and Fleming, 1984; Howlett, 1987, 1984). The 
cannabinoid-mediated inhibition of cAMP was blocked in the presence of pertussis 
toxin (PTX), which specifically blocks Gαi-protein signalling by keeping it in the 
inactive GDP-bound state (Howlett et al., 1986). Thus, the first characterised 
signalling pathway of CB1R described was through coupling with Gi/o proteins, 
which, when activated by cannabinoid binding, inhibits AC, causing a decrease in 
cAMP levels, thus inactivating the PKA phosphorylation pathway (Figure 1-11 A). 
1.3.4.1.2 Other G protein coupling 
CB1R has been shown to not only couple to Gi/o proteins but also to Gs, Gq, and 
G12/13 depending on the cell type (Busquets-Garcia et al., 2015), agonist type (Diez-
Alarcia et al., 2016), or cellular/protein context (Kearn et al., 2005) in which CB1R 
is expressed (Figure 1-11 B; for review, see (Busquets-Garcia et al., 2018)). 
1.3.4.1.2.1 Gs  
Heterodimerisation of CB1R with dopamine D2 receptors can switch the signalling 
of CB1R and D2 from Gi/o to Gs, generating the opposite effect: an increase in 
cAMP levels (Kearn et al., 2005; Glass and Felder, 1997; Jarrahian et al., 2004). 
A limited subpopulation of neurons in the basal ganglia co-express D2 and CB1R 
(Hermann et al., 2002; Marsicano and Kuner, 2008), suggesting that these cells 
may have different properties in terms of their CB1R signalling because of the 
cellular/protein context. 




Figure 1-11 G-protein signalling of CB1R. 
(A) Classically, CB1R signalling is mediated by Gi/o signalling. CB1R is activated by ligand (green 
triangle), generating a conformational change that allows for heterotrimeric G-protein (α, β, and γ 
subunits) binding. The receptor then acts as a guanine nucleotide exchange factor (GEF), activating 
Gα by GDP-to-GTP exchange. This triggers the dissociation of Gα from Gβγ. Gαi/o inhibits adenylyl 
cyclase (AC), a membrane protein that catalyses that conversion of ATP to cAMP+PP i, causing a 
decrease in cAMP levels and inhibiting the PKA phosphorylation pathway. Gβγ inhibits voltage gated 
Ca2+ channels (VGCCs) and activates G protein-coupled inwardly rectifying K+ channels (GIRKs). 
(B) CB1R has also been shown to couple to Gαq, Gα12/13, and Gαs subunits. The classical downstream 
effectors of these subunits are depicted.  
Redrawn and adapted from (Ritter and Hall, 2009). 
 
1.3.4.1.2.2 Gq 
Application of endocannabinoids to astrocytes leads to an PLCβ-dependent 
increase in Ca2+ levels from intracellular stores, suggesting that CB1R in astrocytes 
couples to Gq/11 rather than Gi/o (Navarrete and Araque, 2008; Navarrete et al., 
2014) (see also 1.3.2.2 Glia: astrocytes). Cannabinoid-mediated Gq/11 coupling has 
also been observed in certain cell lines (Lauckner et al., 2005) and upon activation 
with certain agonists, specifically WIN55212-2, Δ9-THC, and ACEA in the mouse 
cortex (Diez-Alarcia et al., 2016). 
1.3.4.1.2.3 G12/13 
Anandamide was shown to induce rounding in B103 rat neuroblastoma cells in a 
PTX-insensitive, but Rho inhibitor-sensitive manner, suggesting the potential to 
couple to G12/13 (Wilson and Nicoll, 2002). Furthermore, WIN55212-2, but not Δ9-
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THC and ACEA, was able to stimulate G12/13 subunit in mouse cortex (Diez-Alarcia 
et al., 2016).This biased agonism of CB1R is an important and emerging concept 
in the field. 
1.3.4.1.3 CB1R ion channel modulation 
1.3.4.1.3.1 Ca2+ channels 
CB1R activation inhibits N-type (Pan et al., 1996; Mackie and Hille, 1992; Twitchell 
et al., 1997), L-type (Gebremedhin et al., 1999), and P/Q type (Fisyunov et al., 
2006; Twitchell et al., 1997) voltage gated Ca2+ channels (VGCCs) in a PTX-
dependent manner, likely through Gβγ (Figure 1-11 A; (Wilson and Nicoll, 2002)).  
1.3.4.1.3.2 K+ channels 
Endocannabinoid stimulation of CB1R leads to activation of G protein-coupled 
inwardly rectifying K+ channels (GIRKs) (Mackie et al., 1995; Henry and Chavkin, 
1995; Ho et al., 1999; McAllister et al., 1999). CB1R activation of GIRKs is blocked 
by PTX, indicating that it is dependent on Gi/o activation, likely through Gβγ (Figure 
1-11 A; (Ho et al., 1999; Mackie et al., 1995; Yamada et al., 1998)). 
1.3.4.2 Second wave: Beta-arrestin mediated signalling 
The second wave of CB1R signalling is by β-arrestin binding, a common non-G 
protein mechanism of GPCR desensitisation and internalisation (Figure 1-12; 
(Zastrow, 2003)). Desensitization and internalisation are important for regulation of 
GPCR signalling, dampening the signal even in the presence of continued agonist. 
As with G protein-mediated signalling, CB1R β-arrestin-mediated signalling is 
highly complex, and depends strongly on the cell-type, agonist bias, and cellular 
milieu (Nogueras-Ortiz and Yudowski, 2016). 
1.3.4.2.1 Desensitisation 
Upon activation by extracellular ligands, CB1R is desensitised in a matter of 
minutes by phosphorylation of two serine residues (S426 and S430) in the C-
terminal tail by GPCR kinases 2/3 (GRK2/3) and subsequent recruitment of β-
arrestin1/2 recruitment, preventing further G protein coupling (Figure 1-12 1) (Jin 
et al., 1999; Kouznetsova et al., 2002; Daigle et al., 2008a; Morgan et al., 2014). 
Further phosphorylation of six serines and threonines in the extreme C-terminal tail 
modulates β-arrestin1/2 recruitment and is necessary for internalisation (Straiker 
et al., 2012b; Daigle et al., 2008b). 
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1.3.4.2.2 Activation of kinase signalling cascades 
β-arrestin1/2 recruitment to desensitised CB1R facilitates the activation of several 
kinase signalling cascades (Figure 1-12 2, 3b). For example, ORG27569 
activation of exogenously expressed CB1R in HEK293 cells strongly elicited 
ERK1/2, Src, and MEK1/2 phosphorylation (Ahn et al., 2013). This kinase 
activation was dependent on β-arrestin1 recruitment, but not on β-arrestin2 
recruitment (Ahn et al., 2013). Furthermore, 2-AG activated ERK1/2, JNK1/2/3, 
CREB, and P38α activation via β-arrestin1 in mouse cortex (Delgado-Peraza et 
al., 2016). Interestingly, β-arrestin2 recruitment was instead required for receptor 
internalisation, suggesting that the two isoforms of β-arrestins play different roles 
(Ahn et al., 2013; Delgado-Peraza et al., 2016). However, anandamide activation 
of CB1R in smooth muscle activated ERK1/2 and Src kinase via both β-arrestin1 
and β-arrestin2 (Mahavadi et al., 2014). This suggests that β-arrestin signalling of 
CB1R is heavily ligand-dependent. 
1.3.4.2.3 Internalisation 
β-arrestins act as a scaffold for the recruitment of the endocytic machinery, binding 
the desensitised receptor by its N-terminus and clathrin/adaptor protein 1 (AP-2) 
by its C-terminus, leading to internalisation of the desensitised receptor by clathrin-
mediated endocytosis (Goodman et al., 1996; Laporte et al., 1999). Upon agonist 
stimulation, CB1R is rapidly internalised (Figure 1-12 3a; (Grimsey et al., 2010; Jin 
et al., 1999; Hsieh et al., 2002)), although rate and amount of internalisation is 
dependent on agonist type (Wu et al., 2008; Hsieh et al., 2002). Following 
internalisation into early endosomes, CB1R is mainly sorted for lysosomal 
degradation by GASP1 (see also 1.3.7.3.1 G-protein coupled receptor associate 
protein 1 (GASP1); (Grimsey et al., 2010; Tappe-Theodor et al., 2007; Martini et 
al., 2007, 2010; Blume et al., 2016)), although resensitisation and recycling of the 
receptor back to the cell surface can occur with short-term agonist treatment (Hsieh 
et al., 2002). 
1.3.4.3 Third wave: intracellular signalling 
Interestingly, GPCRs can continue to signal when in endosomes by G protein or β 
arrestin signalling pathways (Irannejad, 2014). Furthermore, CB1Rs are unique for 
GPCRs in that their agonists are lipophilic, and thus cell permeable. Therefore, it 
is likely that prolonged CB1R signalling can endure intracellularly, by either G 
protein- or β-arrestin-dependent means (Nogueras-Ortiz and Yudowski, 2016). 




Figure 1-12 β-arrestin signalling of CB1R. 
1) Following agonist binding, GPCR kinases (GRKs) phosphorylate the C-terminal tail of CB1R.  
2) Phosphorylation of ctCB1R leads to recruitment of β-arrestins. 
3) β-arrestin recruitment a) acts as scaffold for recruitment of AP-2 and clathrin and b) elicits the 
activation of downstream kinase cascades, most classically, the phosphorylation of ERK1/2. 
4) The desensitised CB1R is internalised by resulting in clathrin-mediated endocytosis (CME). 
5) Endosomal CB1R is sorted for lysosomal degradation. 
 
1.3.4.3.1 Endosomal signalling 
CB1R is particularly enriched in endosomes of both Neuro2A (Rozenfeld and Devi, 
2008) and hippocampal neurons (Leterrier et al., 2006; McDonald et al., 2007a). 
Evidence for endosomal signalling came from the observation that treatment with 
agonist WIN55212-2 induced ERK1/2 phosphorylation even when surface CB1Rs 
were blocked by hemopressin, a cell impermeable antagonist (Rozenfeld and Devi, 
2008). Furthermore, CB1R was found to associate with Gαi in Rab7 positive 
endosomal fractions (Rozenfeld and Devi, 2008). Lastly, intracellular injection of 
anandamide into HEK293 cells expressing CB1R induced Ca2+ release from 
intracellular stores (Brailoiu et al., 2011). 
1.3.4.3.2 Mitochondrial signalling 
CB1R is also localised to mitochondrial membranes where activation leads to 
decreased mitochondrial respiration (Bénard et al., 2012). CB1R-dependent 
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decrease in mitochondrial respiration is sensitive to PTX, indicating that it is 
mediated by Gαi/o activation of a soluble form of adenylyl cyclase (sAC) (Hebert-
Chatelain et al., 2016).  
1.3.5 CB1R trafficking 
1.3.5.1 Forward trafficking 
GPCRs such as CB1R are trafficked to the plasma membrane via the secretory 
pathway (Figure 1-2). Like many GPCRs, CB1R does not have a canonical, 
cleavable signal peptide, but rather, the first transmembrane domain is thought to 
act as a ‘reverse anchoring sequence’ which is recognized by the signal recognition 
particle (SRP) and translocated across the ER membrane (Andersson et al., 2003; 
Nordström and Andersson, 2006). The large size of N-terminal tail of CB1R 
impedes its reverse translocation across the membrane, meaning that the majority 
of synthesized CB1R is likely misfolded and sent for proteosomal degradation 
(Andersson et al., 2003; Nordström and Andersson, 2006). Furthermore, an N-
terminally truncated form of CB1R is produced, probably truncated in the cytosol 
in the small amount of time before translocation can occur (Nordström and 
Andersson, 2006). 
In the ER, CB1R is modified by N-linked glycosylation at two sites (N78, N84) which 
undergo further processing in the Golgi before it is trafficked to the plasma 
membrane (Song and Howlett, 1995). 
1.3.5.2 Internalisation 
Typically agonist-induced internalisation of GPCRs, including of CB1R, occurs by 
clathrin-mediated endocytosis (Figure 1-3; (Jin et al., 1999; Hsieh et al., 2002; Ahn 
et al., 2013; Blume et al., 2016)). However, blocking CME only partially impairs 
CB1R internalisation (Keren and Sarne, 2003; Wu et al., 2008). 
CB1R is associated with lipid rafts (Asimaki et al., 2011; Sarnataro et al., 2005), 
specialised microdomains of plasma membranes rich in sphingolipids and 
cholesterol (Figure 1-13 A; (Allen et al., 2007)). Cargo in lipid rafts can be 
internalised by caveolin-mediated endocytosis (Figure 1-13 B; (Razani et al., 
2002). Membrane cholesterol depletion by methyl-β-cyclodextrin (MβCD) is an 
effective way of preventing CB1R endocytosis (Leterrier et al., 2006, 2004; Keren 
and Sarne, 2003). Conversely, a mutation that increases lipid raft association of 
CB1R also increased constitutive endocytosis of CB1R (Wickert et al., 2018).  
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CB1R undergoes both agonist-induced and constitutive internalisation, reportedly 
by different mechanisms – β-arrestin2 binding is required for agonist-induced 
internalisation but not constitutive internalisation (Gyombolai et al., 2013; 
McDonald et al., 2007a) 
 
Figure 1-13 Lipid rafts and caveolae mediated endocytosis. 
(A) Lipid rafts are microdomains in the plasma membrane that are enriched in sphingolipids and 
cholesterol. 
(B) Caveolin-1 integrates with lipid rafts to form small invaginations called caveolae to initiate 
caveolin-mediated endocytosis. 
Figure from (Razani et al., 2002). 
 
1.3.6 Three currently proposed models of CB1R polarity 
Different research groups have proposed different mechanisms for the polarised 
surface distribution of CB1R.  
1.3.6.1 Model 1: Differential endocytosis rates due to differential 2-AG 
production in somatodendritic and axonal membranes 
1.3.6.1.1 Differential rates of internalisation 
The Lenkei group suggest that CB1R is delivered in a non-polarised manner to the 
plasma membrane but is then selectively endocytosed away from the 
somatodendritic membrane in an agonist-dependent manner (Figure 1-7, pathway 
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2; (Leterrier et al., 2006)). The Lenkei group propose that any CB1R that reaches 
the somatodendritic membrane is immediately activated by the tonal presence 2-
AG specifically in the somatodendritic membrane and therefore undergoes 
agonist-induced internalisation (Leterrier et al., 2006; Simon et al., 2013; Thibault 
et al., 2013; Ladarre et al., 2015; Ladarre and Lenkei, 2017). 2-AG is constitutively 
present in the somatodendritic membrane because the 2-AG synthetic enzyme 
DAGLα is specifically located in the somatodendritic compartment, but excluded 
from the axonal compartment (Ladarre et al., 2015; Zhou et al., 2016). Conversely, 
the 2-AG degradative enzyme MAGL is exclusively located in axons (Gulyas et al., 
2004; Ludányi et al., 2011). 
This model is supported by the fact that, in their hands, application of the 
antagonist/inverse agonist AM281 caused an increase in surface localisation of 
somatodendritic CB1R (Leterrier et al., 2006) and a constitutively inactive version 
of CB1R (T210A) displayed a non-polarised surface distribution (Simon et al., 
2013). Furthermore, application of AM281 inhibited constitutive cAMP/PKA 
signalling in dendrites but not in axons, indicating that there is more constitutive 
activation of CB1R in dendrites than in axons (Ladarre et al., 2015) 
1.3.6.1.2 Transcytosis 
What happens to somatodendritic CB1R following internalisation from the 
somatodendritic membrane is unclear. The Lenkei group presented evidence that 
CB1R may traffic in a transcytotic manner, with endosomal somatodendritic CB1R 
being sorted and sent to the axonal membrane, particularly to more distal areas 
(Figure 1-7, pathway 3; (Simon et al., 2013)). To investigate this, they grew primary 
neurons in microfluidic chambers, which allows for the separation of the 
somatodendritic and axonal domains. Interestingly, a small amount of N-terminal 
antibody fed into the somatodendritic compartment of the chamber was picked up 
after 4 hours on the surface of the axonal membrane, especially in the very distal 
end of the axon (Simon et al., 2013).  
Furthermore, the Lenkei group examined the forward trafficking of CB1R using 
Brefeldin A block and release protocol (Leterrier et al., 2006). Brefeldin A blocks 
ARF1-dependent cis- and trans-Golgi transport (Figure 1-14) and has been used 
historically to inhibit canonical secretory pathway trafficking, although it has also 
been shown to affect endocytosis and recycling (Wood et al., 1991; Hunziker et al., 
1991; Damke et al., 1991; Miller et al., 1992; Hunziker et al., 1992; Graham et al., 
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1993). By incubating with BFA for 20 hours post transfection followed by a BFA 
washout, Leterrier et al. were able to pulse chase FCB1R-EGFP (N-terminal FLAG 
tag, C-terminal EGFP tag), and examine CB1R trafficking either under control 
conditions or in the presence of the antagonist/inverse agonist AM281. Under 
control conditions, they found that 4-8 hours after BFA washout, the majority of 
neurons displayed a non-polarised or somatodendritically polarised surface 
distribution, indicating that CB1R is non-discriminately sent to the plasma 
membrane. Axonal polarisation was established 24 hours after washout. Strikingly, 
under AM281, the majority of neurons exhibited a non-polarised distribution even 
24 hours after BFA washout, supporting a role in endosomal somatodendritic 
CB1R transcytosis to the axonal membrane (Leterrier et al., 2006). 
 
Figure 1-14 Brefeldin A (BFA) and Golgicide A (GCA) inhibit Golgi transport. 
BFA reversibly inhibits ARF1-dependent cis- and trans-Golgi transport. GCA is a more specific ARF-
1 inhibitor, only inhibiting the cis-Golgi 
Figure and caption adapted from (Evans, 2017). 
 
1.3.6.1.3 Lenkei model of polarity: differential endocytosis rates due to differential 
2-AG production in somatodendritic and axonal membranes 
The Lenkei group thus proposed a model whereby newly synthesized CB1R is 
delivered non-discriminately to the plasma membrane of either compartment. 
Because of the higher concentration of 2-AG present in the somatodendritic 
Chapter 1 –   Introduction 
27 
 
membrane than the axonal membrane, CB1R is selectively internalised from the 
dendritic membrane, but remains in the axonal membrane. Endosomes containing 
CB1R are then actively sorted, targeted, and recycled to the distal ends of axons 
(Simon et al., 2013; Ladarre and Lenkei, 2017). This model is summarised in 
Figure 1-15. 
 
Figure 1-15 Model 1: Differential endocytosis rates due to differential 2-AG production in 
somatodendritic and axonal membranes. 
The presence of DAGLα exclusively on the somatodendritic surface causes a polarised production 
of 2-AG with high levels in the somatodendritic membrane. Therefore, de novo CB1R delivered to 
the somatodendritic membrane is immediately activated and internalised. Internalised CB1R is either 
degraded or rerouted to distal end of axons. On the other hand, the absence of DAGLα as well as 
the presence of the degradative enzyme MAGL in the axonal compartment means that newly 
delivered CB1R is retained on the axonal surface. This results in the axonally polarised distribution, 
where it is available to be bound by retrogradely crossing endocannabinoids produced under specific 
synaptic conditions. 
 
1.3.6.2 Model 2: differential constitutive endocytosis 
The Irving group also suggests that CB1R polarity is established by differential 
rates of endocytosis between the somatodendritic and axonal compartments 
(McDonald et al., 2007a; Irving et al., 2008). However, the Irving group differs in 
opinion on what causes CB1R to selectively internalise from the somatodendritic 
membrane, but not the axonal membrane. This is because they did not observe an 
increase in dendritic surface CB1R with AM281 incubation (McDonald et al., 
2007a). Furthermore, truncated (ctΔ14) and point mutated (D164N) versions of 
CB1R that should also lack agonist-induced internalisation did not display a 
different pattern of surface polarity in their hands (McDonald et al., 2007a). 
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Nevertheless, blocking constitutive internalisation with the expression of a 
dominant negative dynamin-1 (K44A) did cause the accumulation of CB1R on the 
somatodendritic membrane, thus still supporting pathway 2 (Figure 1-7), but 
through a constitutive, agonist-independent means (summarised in Figure 1-16).  
 
Figure 1-16 Model 2: differential rates of constitutive internalisation. 
CB1R is delivered to the surface in a nonpolarised manner, but selectively removed from the 
somatodendritic surface via an agonist-independent, dynamin-dependent pathway and sent for 
degradation. This results in the axonally polarised distribution of CB1R. 
 
1.3.6.3 Model 3: Constitutive AP-3-mediated lysosome delivery 
An alternative model by Rozenfeld and Devi suggests that CB1R does not, in fact, 
reach the somatodendritic surface. In work done primarily in Neuro2A cells, they 
show that an untagged CB1R expressed very poorly at the cell surface, and instead 
mostly colocalised with Rab7-positive late endosomes/lysosomes (Rozenfeld and 
Devi, 2008).  
In co-immunoprecipitate studies they detected the delta subunit of AP-3 (AP-3), 
but not AP-2, in CB1R immunoprecipitates (Rozenfeld and Devi, 2008), suggesting 
that CB1R associates with AP-3, an adapter complex that mediates trafficking 
between the TGN and lysosomes (Odorizzi et al., 1998; Scales et al., 1999; 
Guardia et al., 2018), but not AP-2 which mediated endocytosis. Furthermore, AP-
3 siRNA knockdown increased the surface expression of CB1R in both Neuro2A 
cells and in primary hippocampal neurons (Rozenfeld and Devi, 2008). The site of 
CB1R/AP-3 interaction was determined, although AP-3 generally binds to 
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dileucine- or tyrosine-based sorting signals (Ohno et al., 1998; Darsow et al., 
1998). 
They therefore propose that CB1R is constitutively targeted for lysosomal 
degradation by AP-3 association at the TGN (Rozenfeld and Devi, 2008; 
Rozenfeld, 2011). However, a small proportion of CB1R rescued from degradation 
and rerouted to the axon. 
AP-3 isoforms have been proposed to play additional specialised roles in neurons 
including biogenesis of synaptic vesicle and sorting of transmembrane proteins 
from endosomes to synaptic vesicles (Nakatsu et al., 2004; Salazar et al., 2004; 
Guardia et al., 2018; Danglot and Galli, 2007). Recently, AP-3 has been suggested 
to sort polarised proteins from the TGN to axons in C. elegans (Li et al., 2016). 
These data suggest the possibility of additional roles of AP-3 in trafficking of CB1R 
to axons and further investigation is required determine the role of AP-3/CB1R 
interaction on CB1R trafficking. Figure 1-17 summarises this model. 
 
Figure 1-17 Model 3: Constitutive sorting somatodendritic lysosomes. 
CB1R is constitutively sorted by AP-3 from the TGN to somatodendritic lysosomes. Under unknown 
conditions, CB1R is rescued from degradation and rerouted to axons (arrow with question mark). It 
is possible that this unknown mechanism is also AP-3-dependent since in AP-3 sorts cargo from the 
TGN to axons in C. elegans (dotted arrow). AIS = axon initial segment. 
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The discrepancies can, in part, be attributed to differences in tagging CB1R (e.g. 
N-terminal vs. C-terminal; small affinity tags vs. fluorophore tags), as well as 
differences in methodology and cell type used. Lenkei’s group use a CB1R tagged 
C-terminally with EGFP and N-terminally tagged with FLAG, whereas the Irving 
and Devi groups use an N-terminally-tagged construct. C-terminally tagged 
constructs run the risk of interfering with sorting motifs and/or interactions with 
trafficking proteins. Indeed, comparisons between C- and N-terminally tagged 
versions of CB1R expressed in HEK293 cells or Neuro2A cells indicate that C-
terminal tagging interfered with CB1R trafficking, causing a 2-3-fold increase in 
surface expression compared to N-terminal tagging, which, while not directly 
compared, was closer in phenotype to endogenous CB1R (Rozenfeld and Devi, 
2008). Importantly, C-terminal interacting proteins have been reported to modulate 
surface expression and internalisation of CB1R (see 1.3.7.3 Interacting proteins). 
Therefore, the difference in surface expression of N- and C-terminally tagged 
constructs is likely due to interfering with binding of these proteins. Further studies 
are needed to address this issue by comparing the surface distribution of N-, and 
C-terminally tagged CB1R to untagged or endogenous CB1R in primary 
hippocampal neurons. 
 
Figure 1-18 Schematic of rat ctCB1R. 
Amino acid sequence (A) and topology (B) of rat CB1R. Two amphipathic helical domains, H8 and 
H9, are highlighted in blue and green, respectively. A cysteine residue (red) located C-terminally of 
H8 is palmitoylated, modulating signalling and internalisation of CB1R. Another cysteine residue 
located in H9 has the potential to be modified. In the event of agonist stimulation, phosphorylation of 
the two serine residues between the helices is required for desensitisation, whereas phosphorylation 
of 6 serine and threonine residues in the distal C-terminal tail are required for internalisation (yellow). 
The residues required for CRIP1a binding are highlighted in purple. Phosphorylation of T468 (box) 
reduces binding efficiency of CRIP1a. The exact binding site of SGIP1 is unknown but occurs within 
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1.3.7 Carboxy-terminus of CB1R (ctCB1R) 
The CB1R carboxy-terminal tail has 73 residues (rat CB1R = R401-L473; human 
CB1R = R400-L472; Figure 1-18). It contains two structural motifs, Helix 8 (H8) 
and Helix 9 (H9), and several post-translationally modifiable residues.  
Like all GPCRs the ctCB2R mediates signalling, by direct interactions with G-
proteins and β-arrestins and by interactions with other intracellular loops, and 
trafficking, especially internalisation, of CB1R (see (Stadel et al., 2011) for review). 
Here, the focus is mainly on the role of the ctCB1R in its trafficking.  
1.3.7.1 Structure 
ctCB1R contains two putative amphipathic helices, H8 and H9, that likely associate 
with the plasma membrane along their non-polar faces (Figure 1-19; Figure 1-18; 
(Ahn et al., 2009b; Stadel et al., 2011; Ahn et al., 2010)). 
 
Figure 1-19 Predicted primary and secondary structure ctCB1R H8 and H9.  
(A) Aligned human, rat, and mouse ctCB1R sequences. TM7 (cyan), helix 8 (purple), and helix 9 
(green) are highlighted. While H9 is only highlighted in the human sequence, the single amino acid 
difference between human and rodent sequences (Val to Met; highlighted in yellow), is not predicted 
to perturb the proposed helical nature of conformation of H9 (personal communications, Dr Drew 
Thompson, Woolfson Lab). 
(B) Helical wheel projections of amphipathic helices H8 (left) and H9 (right). The black bar in the 
middle separates the hydrophobic face (red = non-polar residues) from the polar face (dark blue = 
positively charged residues, light blue = serines/threonines in light blue, turquoise = negatively 
charged residues). 
(C) Ribbon illustrations of H8 (left) and H9 (right). 
This figure is from (Stadel et al., 2011). Legend is modified from (Hildick, 2013). 
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1.3.7.1.1 Helix 8 
The amphipathic H8 is a common feature of class A GPCRs (Han et al., 2001), 
and is interchangeable between certain receptors (Spomer et al., 2014). A 
conserved role of H8 has yet to be identified, although it has been implicated in ER 
exit and trafficking, membrane localisation and insertion, and as a site for G-protein 
coupling and β-arresting binding (Stadel et al., 2011; Pandey et al., 2019). 
Disruption of H8 helicity and hydrophobicity impairs the trafficking of CB1R, 
causing it to accumulate in the ER (Ahn et al., 2010). 
Interestingly, H8 has been reported to undergo a dynamic conformational switch, 
unravelling during receptor activation to allow for new interactions, potentially 
controlled by palmitoylation or de-palmitoylation of a conserved cysteine residue 
usually located close to H8 (Sensoy and Weinstein, 2015; Gopala Krishna et al., 
2002).  
1.3.7.1.2 Helix 9 
H9 is also proposed to be an amphipathic and likely associates with the plasma 
membrane along its polar face (Stadel et al., 2011; Ahn et al., 2009b). Analogous 
domains have only been reported in squid rhodopsin and the bradykinin receptor 
(Piserchio et al., 2005; Murakami and Kouyama, 2008). Squid rhodopsin H9 
interacts with H8 and transmembrane domain 6 (TM6) and other intracellular loops, 
suppressing its rotational freedom (Stadel et al., 2011; Shimamura et al., 2008). 
Little is known about the functional relevance of H9, although, interestingly, the 
analogous regions in squid rhodopsin and bradykinin receptor constitute a Gαq 
binding site (Piserchio et al., 2005; Murakami and Kouyama, 2008). 
1.3.7.2 Post-translational modifications  
1.3.7.2.1 Phosphorylation 
During ligand activation, phosphorylation of S426 and S430 (Figure 1-18) is 
required for desensitisation of CB1R (Jin et al., 1999; Kouznetsova et al., 2002; 
Daigle et al., 2008a; Morgan et al., 2014), but is not sufficient for internalisation. 
Further phosphorylation of T461, S463, S465, T466, T468, and S469 is required 
for internalisation (Straiker et al., 2012b; Daigle et al., 2008b). See 1.3.4.2.1 
Desensitisation for more details. 




The presence of a palmitoylation site just C-terminally of Helix 8 is conserved 
amongst class A GPCRs (Sensoy and Weinstein, 2015; Gopala Krishna et al., 
2002). Computational modelling of CB1R, as well as the dopamine D2 receptor 
and the β2-adrenergic receptor, suggests that palmitoylation of this conserved 
residue enhances the stability and membrane/lipid raft association of the 
amphipathic H8 (Sensoy and Weinstein, 2015; Oddi et al., 2017). When this 
residue is de-palmitoylated, membrane association of H8 is no longer energetically 
favourable, so the helix unravels, causing some interaction sites to be lost and 
exposing other interaction sites to the aqueous domain (Sensoy and Weinstein, 
2015). 
Palmitoylation of C415 (C416 in rat CB1R) affects the trafficking, localisation, and 
signalling of CB1R (Oddi et al., 2012, 2017, 2018). Specifically, mutation of this 
residue to an alanine reduced plasma membrane expression due to a decreased 
association of CB1R with lipid rafts and caveolin-1(Figure 1-13; (Oddi et al., 2012, 
2017)). Consistent with its lack of lipid raft association, the mutant displayed higher 
diffusional mobility and lacked agonist-induced internalisation (Oddi et al., 2017). 
CB1R signalling was also diminished in the C416A mutant due to the instability of 
H8 which prevented the interaction of CB1R with G-proteins (which themselves are 
palmitoylated; Figure 1-11 black zigzag line) and β-arrestins (Oddi et al., 2012, 
2017, 2018). 
1.3.7.3 Interacting proteins  
1.3.7.3.1 G-protein coupled receptor associate protein 1 (GASP1) 
GASP1 has been linked to the intracellular sorting of CB1R to lysosomes following 
chronic exposure of agonist. GASP proteins (GASP1-10) bind the C-termini of 
several GPCRs, including the D4 dopaminergic receptor, the β2 adrenergic 
receptor, and the δ opioid receptor, for post-endocytic sorting to lysosomes for 
degradation (Whistler et al., 2002; Heydorn et al., 2004; Simonin et al., 2004; 
Moser et al., 2010). GASP1/CB1R interaction was confirmed by co-
immunoprecipitations of exogenously expressed GASP1 with full-length CB1R 
exogenously expressed in HEK293 cells (Tappe-Theodor et al., 2007; Martini et 
al., 2007). However, the exact binding site of GASP1 is unclear: GASP1 co-
immunoprecipitated with the very distal 14 amino acids of ctCB1R (Martini et al., 
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2007), but also co-immunoprecipitated with CB1R lacking this section (Tappe-
Theodor et al., 2007), suggesting that there may be multiple binding sites for 
GASP1 (Stadel et al., 2011). 
Consistent with its known function, expression of a dominant negative GASP1 
attenuates downregulation of surface CB1R induced by chronic (24 hours) 
WIN55,212-2 treatment in both expressed cells and primary neurons (Tappe-
Theodor et al., 2007; Martini et al., 2007). Importantly, this process has been 
implicated in the development of tolerance to cannabinoids in habitual cannabis 
users since GASP1 knockout mice do not develop tolerance to repeated 
administration of WIN55,212-2 unlike wild-type mice (Martini et al., 2010). 
1.3.7.3.2 Cannabinoid Receptor Interacting Protein 1a and 1b (CRIP1a/b) 
1.3.7.3.2.1 Identification and binding 
Cannabinoid receptor interacting protein 1a (CRIP1a), and its primate-specific 
isoform CRIP1b, were identified as CB1R interacting proteins by yeast-two hybrid 
screens against a human cDNA library and validated by GST-pulldowns between 
purified CRIP1a/b protein and ctCB1R (Niehaus et al., 2007). Furthermore, 
CRIP1a co-localises with CB1R at presynaptic boutons (Guggenhuber et al., 
2016). 
Five amino acids in the very distal carboxy terminus of CB1R control CRIP1a 
binding: D467, T468, S469, A472, and L473 (Figure 1-18; (Mascia et al., 2017). A 
similar motif present in mGlu8aR also binds CRIP1a (Mascia et al., 2017). In mice, 
CRIP1a co-expresses with CB1R in both pyramidal neurons and interneurons of 
the hippocampus (Guggenhuber et al., 2016). CRIP1a affects CB1R internalisation 
and modulates its signalling (Mascia et al., 2017; Blume et al., 2017; Guggenhuber 
et al., 2016; Blume et al., 2016; Smith et al., 2015; Blume et al., 2015; Niehaus et 
al., 2007) 
1.3.7.3.2.2 CRIP1a prevents CB1R internalisation 
CRIP1a overexpression supresses agonist-induced downregulation of CB1R but 
not desensitisation (Smith et al., 2015; Blume et al., 2016) by competing with β-
arrestin 2 for binding of ctCB1R (Blume et al., 2017). Phosphorylation of ctCB1R 
residue T468 reduced binding efficiency of CRIP1a, allowing for β-arrestin2 binding 
(Blume et al., 2017). This is consistent with the fact that phosphorylation of central 
ctCB1R residues is necessary for desensitization but not internalisation, which 
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requires phosphorylation of the distal tail (Jin et al., 1999; Kouznetsova et al., 2002; 
Daigle et al., 2008a; Morgan et al., 2014; Straiker et al., 2012b). 
1.3.7.3.2.3 CRIP1a modulates CB1R signalling 
Overexpression of CRIP1a attenuates CB1R G-protein signalling in HEK293 cells, 
N18TG2 cells, and autaptic neuronal cultures, affecting the inhibition of N-type 
VGCCs and ERK phosphorylation (Smith et al., 2015; Niehaus et al., 2007; Blume 
et al., 2015). 
1.3.7.3.2.4 CRIP1a and disease 
Cannabis use, especially in adolescence, is associated with development of 
psychosis and schizophrenia in those who already have an underlying genetic 
predisposition for the disease (Arseneault et al., 2002; Andréasson et al., 1989; 
Henquet et al., 2005). Furthermore, individuals with schizophrenia display 
aberrations in CB1R expression and ligand binding (Zavitsanou et al., 2004; Dalton 
et al., 2011). 
Genome-wide methylation analysis of human patients with schizophrenia revealed 
aberrant methylation of the CRIP1a DNA promoter (Wockner et al., 2014). 
Moreover, overexpression of CRIP1a in the hippocampus of Sprague Dawley rats 
induced schizophrenia-like symptoms and changes in dopamine activity (Perez et 
al., 2019) These data suggest that modulation CRIP1a-mediated regulation of 
CB1R  could be a therapeutic target for treatment of schizophrenia. 
1.3.7.3.3 Src homology 3-domain growth factor receptor-bound 2-like (endophilin) 
interacting protein 1 (SGIP1)  
1.3.7.3.3.1 Identification 
Src homology 3-domain growth factor receptor-bound 2-like (endophilin) 
interacting protein 1 (SGIP1) was first identified as a novel transcript in 2005 in a 
screen of hypothalamic mRNA in the obesity model of Psammomys obesus, also 
called the fat sand rat (Trevaskis et al., 2005). SGIP1 mRNA was upregulated in 
the hypothalamus in obese fat sand rats compared to lean ones and siRNA-
mediated reduction of hypothalamic SGIP1 inhibited food intake, suggesting that 
SGIP1 in the hypothalamus plays a role in energy expenditure (Trevaskis et al., 
2005). In humans, genetics studies indicate that single nucleotide polymorphisms 
(SNPs) in SGIP1 associate with fat mass (Cummings et al., 2012; Yako et al., 
2015). 
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1.3.7.3.3.2 SGIP1 domains and function 
As its name implies, SGIP1 interacts strongly with endophilins, important 
regulators of clathrin-mediated endocytosis (CME), specifically with endophilin 3 
(Trevaskis et al., 2005). SGIP1 is an orthologue of Fer/Cip4 homology domain-only 
proteins (FCHo1/2), members of the muniscin family of cargo adaptors (Figure 
1-20) (Hollopeter et al., 2014). It contains an N-terminal membrane phospholipid 
binding (MP) domain (although not an F-BAR domain like the rest of the muniscin 
family) capable of binding liposomes containing PS, PI 3-phosphate, PI 4-
phosphate, PI 3,4-bisphosphate, PI 3,5-bisphosphate, or PI(4,5)P2 (Uezu et al., 
2007). Next is an AP-2 activator motif (APA) that directly binds to AP-2 (Hollopeter 
et al., 2014). A proline rich domain (PRD) likely contains several SH3-domain 
binding sites. SH3-domain containing proteins is binds to include endophilin 
(Trevaskis et al., 2005), intersectin 1 (ITSN1), a plasma membrane-associated 
scaffolding protein important for recruitment of components of the endocytic 
complex, and amphiphysin, an important membrane-deforming protein that 
regulates dynamin oligomerisation (Dergai et al., 2010). Lastly, the C-terminal µ 
homology domain (µHD), highly conserved in the muniscin family, mediates the 
interaction with Eps15, an important adaptor protein of CME (Uezu et al., 2007) 
and binds to cargo such as synaptotagmin (Lee et al., 2019) and CB1R (Hájková 
et al., 2016).  
 
Figure 1-20 Domains of SGIP1 and SGIP1α. 
Domains of the 827 aa long SGIP1 (Uniprot sequence) and the 854 aa long SGIP1α. The brain-
specific splicing variant SGIP1α contains an extra sequence in the MP domain. The last 99 residues 
(crosshatching) binds ctCB1R. 
Key: MP = membrane phospholipids binding domain; APA = AP-2 Activator motif; PRD = Proline-
Rich Domain; µHD = µ Homology Domain. 
 
Apart from its domain structure and interacting partners, SGIP1 is also functionally 
connected to CME. SGIP1 overexpression in Cos7 cells reduces transferrin (Tfn) 
and epidermal growth factor (EGF) uptake (Uezu et al., 2007). Knockdown of 
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SGIP1 in N1E115 cells (mouse neuroblastoma cells) reduces Tfn uptake, but not 
EGF uptake, potentially due to compensatory pathways (Uezu et al., 2007). 
1.3.7.3.3.3 SGIP1 and CB1R 
SGIP1, including the brain-specific isoform SGIP1α, is enriched in presynaptic 
boutons (Wilhelm et al., 2014) and co-localises with CB1R, bassoon, and 
synaptotagmin (Hájková et al., 2016; Lee et al., 2019). Furthermore, SGIP1 
selectively promotes the internalisation of synaptotagmin, but not synaptophysin 
or VAMP2 at presynaptic boutons (Lee et al., 2019). 
A yeast two-hybrid screen using ctCB1R C-terminally of H8 as bait detected the 
last 99 amino acids of SGIP1 as prey (Hájková et al., 2016) (Figure 1-20). The 
association between CB1R and SGIP1 was verified using co-immunoprecipitation, 
bioluminescence resonance energy transfer (BRET) assays (Hájková et al., 2016). 
Interestingly, co-expression of SGIP1 with CB1R in HEK293 cells interfered with 
agonist-induced internalisation of CB1R compared to HEK293 cells expressing 
CB1R alone (Hájková et al., 2016). This reduction in agonist-induced 
internalisation was almost the same the reduction in internalisation that occurs 
when blocking CME using expression of a dominant negative dynamin (Dyn K44A). 
Furthermore, a smaller, but significant, reduction in constitutive internalisation was 
observed in CB1R/SGIP1 co-expressing cells with exogenous agonised applied 
compared to HEK293 cells expressing CB1R alone. Furthermore, SGIP1 affected 
the signalling of activated CB1R: it enhanced β-arrestin2 – but not β-arrestin1 – 
association with activated CB1R and reduced downstream ERK1/2 activation. 
However, Gi/o-protein activation and downstream Ca2+ mobilisation were 
unaffected (Hájková et al., 2016). The reported effects of SGIP1 on CB1R 
signalling and internalisation is summarised in Figure 1-21. 
1.4 THERAPEUTIC POTENTIAL OF THE ECS 
There has been a lot of interest in recent decades in the use of cannabis, or 
cannabis constituents (specifically, Δ9-THC and/or cannabidiol), to treat a wide 
range of diseases. There has been some success: e.g. Sativex (a combination of 
THC and CBD) is legal in both the USA and the UK as an effective treatment for 
chronic pain and multiple sclerosis and treatment of epileptic patients with CBD 
can reduce seizure frequency by up to 50% (Freeman et al., 2019). However, there 
have also been a few failures. Rimonabant, a CB1R antagonist, was launched in  




Figure 1-21 Schematic of SGIP1 effect on CB1R signalling and internalisation 
A) Without SGIP1, CB1R undergoes β-arrestin mediated agonist-induced internalisation. β-arrestin 
signalling activates ERK1/2. 
B) With SGIP1, CB1R activation still recruits β-arrestin. However, internalisation does not occur, and 
ERK1/2 activation is attenuated. 
Figure from (Hájková et al., 2016). 
 
2006 as a weight-loss treatment. However, it was pulled off the market in 2008 due 
to adverse side effects, including the development of serious mood disorders 
including suicidal ideation (Johansson et al., 2009). More recently, a clinical trial of 
a FAAH inhibitor (degradative enzyme for anandamide) was stopped at phase I as 
a result of the development of serious side effects, tragically resulting in the death 
of one subject (Kaur et al., 2016b; a). 
It is not entirely surprising that drugs that target the ECS as a whole would have a 
multitude of unwanted side effects given the ubiquity, complexity, and pleiotropic 
nature of the CB1R. Therefore, in recent years, studies have focussed on a more 
targeted approach. One approach is to target drugs to specific tissues and tightly 
control the dosage (Kaur et al., 2016a). Furthermore, there has been a huge push 
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to identify new allosteric modulators of CB1R because they have the potential for 
subtype- and pathway-specificity (Khurana et al., 2017).  
This push draws on the amassed wealth of knowledge of CB1R physiology and 
pharmacology. However, comparatively little is understood about the basic cellular 
mechanisms underpinning ECS trafficking and distribution. Thus, better 
understanding of how cannabinoid receptors and eCBs are synthesized, trafficked, 
and degraded holds massive promise for therapeutic intervention for a wide range 
of diseases. 
1.5 AIMS 
The overarching aim of my work was to characterise the mechanisms that establish 
the stringent axonal polarisation of CB1R and determine the underpinning cell 
biological mechanisms. This is important because defining the trafficking pathways 
and protein interactions that mediate axonal CB1R localisation could provide novel 
targets to enhance or reduce ECS signalling without the need to directly activate 
or block the receptor.  
More specifically, the objective of each series of experiments were: 
1.5.1 Chapter 3: 
• To examine how the axonally polarised surface distribution of CB1R is both 
(1) established and (2) maintained. 
• To define the contribution of forward trafficking to the polarised surface 
distribution of CB1R. 
1.5.2 Chapter 4: 
• To determine whether the C-terminus of CB1R plays a role (1) selective 
delivery and/or (2) selective retention of axonal CB1R. 
• To determine the role of the C-terminal motif Helix 9 (H9) in CB1R 
trafficking and surface polarisation. 
1.5.3 Chapter 5: 
• To determine the mechanism by which H9 increases membrane retention. 
• To screen for interacting partners of H9 that may play a role in 1) 
preferential axonal delivery and/or 2) membrane retention. 
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Chapter 2 –   MATERIALS & METHODS        
2.1 MATERIALS 
2.1.1 Chemicals 
All chemicals were purchased from Sigma-Aldrich (Merck) unless otherwise stated. 
Non-fat milk powder was own-brand from The Co-operative. Acids and solvents 
were purchased from Fisher Scientific unless otherwise stated. 
2.1.2 Consumables and equipment 
2.1.2.1 Glass- and plastic-ware 
Gilson-style basic and sterile filter pipette tips (10 µL, 20 µL, 200 µL, 1000 µL, and 
1250 µL) were purchased from STARLAB. 0.2 mL and 0.5 mL thin-walled PCR 
tubes were also purchased from STARLAB, and 1.5 mL microcentrifuge tubes 
were purchased from Eppendorf. 15 mL and 50 mL Falcon tubes, 5 mL Bijou tubes, 
and 30 mL Universal tubes were from Greiner. 5 mL, 10 mL, and 25 mL serological 
pipettes were purchased from Greiner as well. Cell culture plates (12-well and 6-
well), dishes (35 mm, 60 mm, 10 cm), and flasks (T25, T75, and T175) were also 
bought from Greiner. Glass coverslips (24 mm and 25 mm) were from VWR. 
Syringes and needles were from Terumo. 0.2 µm syringe filters were from 
Sartorius. 
2.1.2.2 Electrical equipment 
Laminar flow hoods were from Holten LaminAir. Cell culture incubators were from 
RS Biotech and were serviced every 6 months. Gel electrophoresis power packs 
were from Bio-Rad Laboratories. Centrifuges were from Bechman-Coulter and 
Jouan. Benchtop microcentrifuges were from Eppendorf. The PCR Thermocycler 
was a MJ Research PTC-2000 Peltier Thermal Cycler. DNA and RNA 
concentrations were quantified using the NanoDrop™ ND-1000 (LabTech).  The 
X-ray film developer (SRX-101A) was from Konica and the Odyssey Fc detection 
system was from LI-COR. 
2.1.2.3 Confocal microscope specifications 
A Leica SPE single channel, a Leica SP8, and a Leica SP5II confocal laser 
scanning microscope (Wolfson Bioimaging Facility, University of Bristol), or a Zeiss 
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LSM510 UV META Axiovert 200M laser scanning microscope was used for fixed 
confocal microscopy. 40x or 63x oil immersion objectives were used. 
2.1.3 Cell culture reagents 
2.1.3.1 Cell lines and primary cultures 
Human Embryonic Kidney (HEK293T) cells, HeLa cells, and Baby Hamster Kidney 
(BHK-21) cells were obtained from the European Collection of Authenticated Cell 
Cultures (ECACC). Stocks were aliquoted in 1% DMSO, frozen slowly to −70°C in 
a Mr. FrostyTM freezing container (Thermo) and stored in liquid nitrogen. 
Primary hippocampal and cortical neurons were cultured from E17-E18 Wistar Han 
rats housed in the University of Bristol Animal Services Unit in accordance with 
Home Office guidelines. 
2.1.3.2 Media reagents 
Table 2-1 contains a list of components of different cell culture media. 
Table 2-1 Media Reagents 
REAGENT SUPPLIER CELL TYPE CAT. NO. 
Neurobasal 
Thermo Fisher Scientific 
(Gibco) 
Neuronal 21103049 
Horse Serum  Merck (Sigma-Aldrich) Neuronal H1270 
B27 
Thermo Fisher Scientific 
(Gibco) 
Neuronal A3582801 
GS21 MTI GlobalStem Neuronal 3100 
GlutaMAX 









DMEM Lonza HEK293T/ HeLa 12-614F 
L-Glutamine Merck (Sigma-Aldrich) Cell lines G7513 
FBS Merck (Sigma-Aldrich) Cell lines F7524 
Alpha MEM 
medium 
Merck (Sigma-Aldrich) BHK cells M8042 
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2.1.4 Molecular biology reagents 
2.1.4.1 Kits and enzymes 
RNA was extracted from cells with the RNeasy Mini Kit (QIAGEN). cDNA was 
synthesized with the RevertAid First Strand cDNA Synthesis kit (Thermo). DNA 
fragments were purified using the GeneJET Gel Extraction kit (Thermo). Amplified 
plasmid DNA was isolated from E. coli using the GeneJET Plasmid Miniprep or 
Midiprep kits (Thermo). 
Restriction enzymes, Calf Intestinal Alkaline Phosphatase (CIP), and 10x 
CutSmart buffer were from New England BioLabs (NEB) and T4 DNA Ligase was 
from TaKaRa.  
2.1.4.2 E. coli competent cells and bacterial reagents 
Home grown and commercially bought DH5α and XL1-blue competent cells were 
used to amplify plasmid DNA (Table 2-2). XL1-blue competent cells were 
exclusively used for amplification of viral plasmids due to their reduced tendency 
to recombine long terminal repeats (LTRs) present in viral vectors. 
Table 2-2 Competent E. coli strains 
STRAIN CHROMOSOMAL GENOTYPE SUPPLIER 
DH5α 
F- Φ80lacZΔM15 Δ(lacZYA-argF) U169 recA1 endA1 
hsdR17 (rk-, mk+) phoA supE44 λ-thi-1 gyrA96 relA1 
Thermo Fisher 
XL1-Blue 
recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac 
[F´ proAB lacIqZ∆M15 Tn10 (Tetr)] 
Agilent 
 
2.1.4.3 Plasmid Vectors 
Table 2-3 contains a list of plasmid vector backbones used. 
Table 2-3 Plasmid vector backbones 
BACKBONE NOTES 
pcDNA3.1(+) CMV promoter 
pFLAG 
pcDNA3.1(+) with N-terminal FLAG tag;                         
Made by Dr Kevin Wilkinson 
pEGFP-C2 To tag protein of interest N-terminally with EGFP 
pmCherry To tag protein of interest N-terminally with mCherry 




H1 RNA promoter + shRNA cassette; PGK protein promoter 
+ mCherry; Based on pSUPER.neo+GFP (Oligogene); 
Made by Dr Kevin Wilkinson 
pXlg3 
Lentiviral vector; Modified to contain a PacI/XhoI restriction 
sites where H1 promoter + shRNA can be cloned in for 
knockdown of protein of interest; protein expression driven 
under an SFFV promoter; contains a WPRE sequence to 
enhance expression; made by Dr Kevin Wilkinson 
pSinRep5 Sindbis viral vector 
pIRESneo3 
RUSH construct; expression of an ER localised streptavidin-
KDEL is driven under a CMV promoter; expression of the 
receptor of interest is driven under an IRES element 
 
2.1.4.4 Oligonucleotides 
All primers were bought as oligonucleotides from Sigma-Aldrich (now Merck). 
2.1.4.4.1 Primers for overexpression constructs 
A list of primers for overexpression constructs can be found in Table 2-4.  
Table 2-4 Primers for overexpression constructs 
PRIMER SEQUENCE (5’-3’) 
RESTRICTION 
SITE 




SPIl-2 For CACGGATCCACGCCACCATGTACAGGATGC BamHI 




EGFP For CACGCTAGCGCCACCATGGTGAGCAAGG NheI 
CB1R Rev GTGTTAATTAATCACAGAGCCTCGGCGGACGT PacI 
CB1R Rev GTGGCGGCCGCATCACAGAGCCTCGGCGGA NotI 
CB1R Rev CTCGGATCCTCACAGAGCCTCGGCGGACGT BamHI 
CB1R Rev CTCGGGCCCTCACAGAGCCTCGGCGGACGT ApaI 
SGIP1 For CACGGTACCGAAGGACTGAAAAAACGTACAAGA KpnI 
SGIP1 Rev GTGGGATCCTTAGTTATCTGCCAAGTATTTTCCTGCAGC BamHI 
Key: green, underlined – restriction site; blue – complementary to template; blue, 
bold, italics – start codon; orange – Kozak consensus sequence. 
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2.1.4.4.2 Primers for site-directed mutagenesis  
In order to generate point mutations by site-directed mutagenesis (SDM), primers 
were designed to incorporate the desired point mutation flanked by 21-30 base 
pairs on either side that were entirely complementary to the template. In order to 
delete a part of a construct (in this case, SBP), primers were designed to be 
complementary to 30 base pairs on either side of the area that needed to be 
deleted. Sense and antisense primers were ordered from Sigma. A list of SDM 
primers can be found in Table 2-5. 
Table 2-5 Primers for site-directed mutagenesis 
PROTEIN MUTATION PRIMER SEQUENCE (5’-3’) 
CB1R C450A Sense  
CACAGGGCCGCGGAGAGCGCCATCAAGAGCA
CCGTTAAG 
















Rab5 S34N (DN) Sense 
GGAGAGTCCGCTGTTGGCAAAAATAGCCTAGT
GCTTCGTTTTGTG 
  Antisense 
CACAAAACGAAGCACTAGGCTATTTTTGCCAAC
AGCGGACTCTCC 
Rab5 Q79L (DA) Sense 
GAAATATGGGATACAGCTGGTCTAGAACGATAC
CATAGCCTAGCA 









  Antisense 
CCCGGTGAACAGCTCCTCGCCTTTGCTCACGG
AATTCGTGACAAGTGCAAGACTTAGTGC 
Key: Blue – complementary to template; red – point mutation change 
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2.1.4.4.3 Primers for knockdown constructs 
Table 2-6 is a list of oligos for the generation of shRNA knockdown constructs.  
Table 2-6 Knock-down oligos 
PROTEIN NAME   PRIMER SEQUENCE (5’-3’) 
AP3D1 KD#1 21mer Sense 
GATCCCCAGCTGCTCACCAAGATCATTGTTCAA 
GAGACAATGATCTTGGTGAGCAGCTTTTTTC 
   Antisense 
TCGAGAAAAAAGCTGCTCACCAAGATCATTGTC
TC TTGAACAATGATCTTGGTGAGCAGCTGGG 
 KD#2 20mer Sense 
GATCCCCACCGCATGTTCGACAAGAACTTCAA 
GAGAGTTCTTGTCGAACATGCGGTTTTTTC 
   Antisense 
TCGAGAAAAAACCGCATGTTCGACAAGAACTCT
C TTGAAGTTCTTGTCGAACATGCGGTGGG 








Key: green – restriction site (BamHI/XhoI); green, underlined – overhang; yellow – target 
sequence 
 
A list of non-targeting control shRNA oligos is found in Table 2-7. 
Table 2-7 Non-targeting oligos 
NAME PRIMER SEQUENCE 
19mer  Sense 
GATCCCCAATTCTCCGAACGTGTCACTTCAA 
GAGAGTGACACGTTCGGAGAATTTTTTTC 
  Antisense 
TCGAGAAAAAAATTCTCCGAACGTGTCACTCTC 
TTGAAGTGACACGTTCGGAGAATTGGG 













Key: green – restriction site (BamHI/XhoI); green, underlined – overhang; yellow – target 
sequence 
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2.1.4.5 Mammalian overexpression and shRNA plasmids 
A list of overexpression constructs can be found in Table 2-8. CB1R, CRIP1a, and 
SGIP1 correspond to Rattus norvegicus sequences. Rab5 is a Homo sapiens 
sequence.  
All CB1R constructs lack the first 25 N-terminal amino acids to avoid possible 
cleavage of the SBP-EGFP tag (McDonald et al., 2007b; Nordström and 
Andersson, 2006). A full full-length construct (FFL) was also generated. SGIP1 
was cloned out of a cDNA library made from RNA extracted from DIV 21 cortical 
cultures. The SGIP1 transcript variant corresponds to the predicted Rattus 
norvegicus SH3-domain GRB2-like (endophilin) interacting protein 1 (Sgip1), 
transcript variant X21, mRNA. 
A list of shRNA knockdown constructs and their sources can be found in Table 
2-9. Targeting sequences were designed either according to previously published 
targeting sequences (Uezu et al., 2007) or from verified sequences found in 
Sigma’s online shRNA tool. 19mer (Choy et al., 2014; Carmichael et al., 2018; Zhu 
et al., 2018) and 21mer (Haar et al., 2007) non-targeting sequences have been 
previously published as scrambled controls. The 29mer non-targeting control 
sequence is from the Origene HuSH-29 kit. 
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Table 2-8 Overexpression plasmids 




pcDNA1- SPHgH-SEP-CB1RWT N/A N/A N/A Andrew Irving 
pcDNA3.1- SPHgH-SEP-CB1RWT N/A N/A N/A Keri Hildick 
pcDNA3.1- SPHgH-SEP-CB1RΔH9 N/A N/A N/A Keri Hildick 
pIRESneo3_Str-
KDEL_IRES- 
SPIl-2-SBP-mCherry-Ecadherin N/A N/A N/A Perez 
pIRESneo3_Str-
KDEL_IRES- 






































pcDNA3.1- SPIl-2-SBP-EGFP-CB1R C450A pcDNA3.1-SPIl-2-SBP-EGFP-CB1RWT C450A N/A This thesis 
pcDNA3.1- SPIl-2-SBP-EGFP-CB1R 2P pcDNA3.1-SPIl-2-SBP-EGFP-CB1RWT  2P N/A This thesis 
pcDNA3.1- SPIl-2-EGFP-CB1RWT  pcDNA3.1-SPIl-2-SBP-EGFP-CB1RWT  Minus SBP N/A This thesis 
pcDNA3.1- SPIl-2-EGFP-CB1RΔH9   pcDNA3.1-SPIl-2-SBP-EGFP-CB1RΔH9   Minus SBP N/A This thesis 
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pXlg3- SPIl-2-EGFP-CB1RFFL pcDNA3.1-HA-CB1R (including N-terminus) 

















pSinRep5- EGFP N/A N/A N/A Kevin Wilkinson 












pCB6- CD4Δct N/A N/A N/A B Dargent 
pCB6- CD4Δct-ctCB1RWT  N/A N/A N/A Keri Hildick 
pCB6- CD4Δct-ctCB1RΔH9  N/A N/A N/A Keri Hildick 






pmCherry- Rab5 WT N/A N/A N/A 
Pete Cullen, Chris 
Danson 
pmCherry- Rab5 S34N (DN) pmCherry-Rab5 WT S34N N/A This thesis 
pmCherry- Rab5 Q79L (DA) pmCherry-Rab5 WT Q79L N/A This thesis 
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Table 2-9 shRNA knockdown plasmids 
VECTOR TARGET PROTEIN TARGET SEQUENCE NAME SOURCE OVEREXPRESSION 
pSUPER.neo AP3D1 5’ AGCTGCTCACCAAGATCATTG 3’  AP3D1 KD#1 Sigma mCherry 
pSUPER.neo AP3D1 5’ ACCGCATGTTCGACAAGAAC 3’  AP3D1 KD#2 Sigma mCherry 




pSUPER.neo SGIP1 5’ GCTGAGCAGACCTTCATTAAA 3’  SGIP1 KD#2 Sigma mCherry 








pSUPER.neo Non-targeting 29mer 5’ GCACTACCAGAGCTAACTCAGATAGTACT 3’ Nt29 Origene mCherry 
pXlg3 AP3D1  5’ AGCTGCTCACCAAGATCATTG 3’  AP3D1 KD#1 Sigma SPIl-2-EGFP-CB1RWT  
pXlg3 AP3D1 5’ ACCGCATGTTCGACAAGAAC 3’  AP3D1 KD#2 Sigma SPIl-2-EGFP-CB1RWT  




pXlg3 SGIP1 5’ GCTGAGCAGACCTTCATTAAA 3’  SGIP1 KD#2 Sigma SPIl-2-EGFP-CB1RWT  
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pXlg3 Non-targeting 29mer 5’ GCACTACCAGAGCTAACTCAGATAGTACT 3’ Nt29 Origene SPIl-2-EGFP-CB1RWT  
pXlg3 AP3D1 (KD#1) 5’ AGCTGCTCACCAAGATCATTG 3’  AP3D1 KD#1 Sigma SPIl-2-EGFP-CB1RΔH9  
pXlg3 AP3D1 (KD#2) 5’ ACCGCATGTTCGACAAGAAC 3’  AP3D1 KD#2 Sigma SPIl-2-EGFP-CB1RΔH9  




pXlg3 SGIP1 (KD#2) 5’ GCTGAGCAGACCTTCATTAAA 3’  SGIP1 KD#2 Sigma SPIl-2-EGFP-CB1RΔH9  








pXlg3 Non-targeting 29mer 5’ GCACTACCAGAGCTAACTCAGATAGTACT 3’ Nt29 Origene SPIl-2-EGFP-CB1RΔH9  




2.1.5.1 Primary antibodies used for ICC and WB 
Table 2-10 lists all primary antibodies used for immunocytochemistry and Western 
blotting. 
Table 2-10 Primary antibodies 
ANTIBODY SPECIES CLONE SUPPLIER CAT. NO.  USE DILUTION 




AP-3 delta subunit Mouse SA4 DSHB AB_2056641 WB 1:5,000 





























































SBP-tag Mouse 20 
Sigma-
Aldrich 
MAB10764 ICC 1:500 
Key: DSHB – Developmental Studies Hybridoma Bank;  
ICC –Immunocytochemistry; WB – Western Blotting. 
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2.1.5.2 Secondary antibodies used for ICC and WB 
Table 2-11 lists all secondary antibodies used for immunocytochemistry and 
Western blotting. 
Table 2-11 Secondary antibodies 

























































Key: JIR – Jackson ImmunoResearch; ICC – Immunocytochemistry;  
WB – Western Blotting; NB. JIR secondary antibodies are distributed by Stratech. 
 
2.2 MOLECULAR BIOLOGY METHODS 
2.2.1 RNA extraction from cells 
RNA extraction was performed using the RNeasy Mini Kit using RNAse free tubes 
and filter tips. The workspace, pipettes, and gloves were sprayed down with 
RNAseZap (Thermo Fisher Scientific) prior to RNA extraction.  
To generate rat SGIP1, RNA was extracted from a 10 cm dish of DIV 21 cortical 
neurons according to the manufacturer’s instructions. 
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2.2.2 cDNA synthesis 
cDNA was synthesized from 1 µg of RNA using the RevertAid First Strand cDNA 
synthesis kit according to the manufacturer’s instructions. The oligo(dT)18 primer, 
which selectively binds poly(A) tails of mRNA, was used reverse transcribe only 
mRNA and generate a cDNA library. ‘No RT’ and ‘no template’ controls were 
included. 
2.2.3 Polymerase Chain Reaction (PCR) 
Polymerase Chain Reactions (PCRs) were performed using the KOD Hot Start 
DNA Polymerase Kit and a PCR Thermocyler as indicated in Table 2-12 and Table 
2-13 Template DNA consisted of synthesized 2-3 µL of cDNA for SGIP1. For all 
other constructs, template DNA consisted of 10 ng plasmid DNA as indicated in 
Table 2-4. 




10x Buffer for KOD Hot Start DNA 
Polymerase 
5 µL 1x 
25 mM MgSO4 3 µL 1.5 mM 
dNTPs (2 mM each) 5 µL 0.2 mM each 
Milli-Q water 20.5 µL  
DMSO 2.5 µL 5% 
Sense (5’) Primer (10 µM) 1.5 µL 0.3 µM 
Anti-Sense (3’) Primer (10 µM) 1.5 µL 0.3 µM 
Template DNA (plasmid: 1 ng/µL; cDNA: 2-3µL) 10 µL 0.2 ng/µL 
KOD Hot Start DNA Polymerase (1 U/µL) 1 µL 0.02 U/µL 
TOTAL REACTION VOLUME 50 µL  
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> 3000 bp 
1. Polymerase 
activation 
95°C for 2 min 
2. Denature 95°C for 20 s 
3. Annealing 55°C for 10 s 
4. Extension 
70°C for 10 
s/kb 
70°C for 15 
s/kb 
70°C for 20 s/kb 
70°C for 25 
s/kb 
5. Repeat  
steps 2-4 
20-35 cycles 
6. Hold At 10°C 
  
2.2.4 Agarose Gel Electrophoresis 
PCR products were resolved using 0.8% or 1.5% (w/v) agarose gels containing 0.5 
µg/mL of ethidium bromide. 6x gel loading dye (NEB) was added 5 µL of the sample 
and the sample was loaded into the gel alongside 10 µL of HyperLadder™ 1kb 
molecular weight marker. The samples were run at 135V in 0.5x TAE buffer (20mM 
Tris acetate, 0.5mM EDTA) using a Mupid-exU electrophoresis system (Mupid Co. 
Ltd) for 20 minutes, then visualised on a UV transilluminator (Ultra-Violet Products 
Ltd.). 
2.2.5 DNA fragment purification 
Once the presence of a PCR product of the right size was confirmed, the PCR 
product was purified using the GeneJET gel extraction kit according to the 
manufacturer’s instructions with some slight modifications. 5x volume of binding 
buffer was added to the PCR product before adding it to the column. The product 
was eluted in 43 µL of ddH2O.  
2.2.6 Restriction digest 
The cleaned PCR product and 2-3 µg of vector plasmid DNA were incubated with 
20 U of each restriction enzyme in the appropriate NEB buffer (total volume 50 µL) 
at 37°C for 2 hours. 10 U of calf intestinal alkaline phosphatase (CIP; NEB) was 
also added to the vector DNA.  
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5 µL of each digest was resolved on an agarose gel to check that the vector had 
linearised, and the DNA was purified with the GeneJET gel extraction kit. The PCR 
product was eluted in 50 µL of ddH2O and the vector was eluted in 25 µL of ddH2O 
and the concentration of DNA was determined using a nanodrop.  
2.2.7 Sticky end ligation 
1:1 and 3:1 insert:vector molar ratios were calculated using the online NEBio 
ligation calculator, and the PCR product was diluted accordingly. 1 µL of insert and 
1 µL of vector were then added to 2 µL of TaKaRa T4 DNA ligase solution. The 
ligation mix was mixed by pipetting and incubated at RT for 30 minutes. A control 
of 1 µL vector, 1 µL ddH2O, and 2 µL ligase solution was also included. 
2.2.8 Transformation of competent E. coli 
40 µL of DH5α or XL1-Blue competent cells was added to the ligation mixture on 
ice and flicked to mix. XL1-Blue competent cells were used for viral vectors (Xlg3 
and pSinRep5) to prevent recombination of the long terminal repeats (LTRs). 
Following a 30-minute incubation on ice, the competent E. coli were heat shocked 
at 42°C for 45-90 seconds and returned to ice for 2 minutes. 100 µL plain LB broth 
or SOC media was added to the transformed cells. For ampicillin resistant vectors, 
the transformed cells were immediately plated onto LB-Agar plates containing 100 
µg/mL ampicillin. For kanamycin resistant vectors, the transformed cells were 
incubated at 37°C for 1 hour before plating onto LB-Agar plates containing 25 
µg/mL kanamycin. The plates were incubated overnight at 37°C. 
2.2.9 DNA miniprep and PCR screen  
Single colonies were picked from the plate and added to culture tubes containing 
3 µL LB broth with the appropriate selection antibiotic. They were incubated 
overnight at 37°C in a shaking incubator. Plasmid DNA was isolated using the 
GeneJET Miniprep kit according to the manufacturer’s instructions. The presence 
of an insert was determined with by a mini PCR (1/5 of PCR mix in Table 2-12) 
amplification and running on a DNA agarose gel.  
2.2.10 Plasmid DNA sequencing 
1-2 mini preps containing an insert were sent for sequencing by Eurofins 
Genomics. Sequences were checked for accuracy using the NCBI blast/alignment 
tools and SnapGene. Mini preps of the correct sequence were either used in 
experiments or midi prepped, depending on the quantity of plasmid DNA needed. 
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2.2.11 DNA Midi Preps 
1 µL of validated mini preps was used to transform 10 µL of DH5α or XL1-Blue E. 
coli competent cells. The transformed E. coli were added to 100 µL of LB broth 
containing the appropriate selection antibiotic and incubated overnight at 37°C in 
a shaking incubator. Plasmid DNA was isolated using the GeneJET Midiprep kit 
according to the manufacturer’s instructions (high speed spin). 
2.2.12 Site-directed mutagenesis 
The protocol above was slightly modified for site-directed mutagenesis. 50 ng of 
plasmid DNA was used as the PCR template. The number of cycles was kept as 
low as possible (20-25) in order to minimize errors. The extension time was 
calculated for the full length of the plasmid.  
To remove the template DNA, 20 units of DpnI, which only cleaves methylated 
DNA, and not the PCR product, was added to the PCR mix, which was then 
incubated at 37°C for 1-2 hours. The DNA was purified using the GeneJET gel 
extraction kit and eluted in 10 µL of ddH2O twice. 5 µL of the purified product used 
to transform 50 µL of DH5α. Single colonies were picked for screening by 
sequencing. 
2.2.13 shRNA synthesis 
shRNA vectors were designed according to the pSUPER.neo RNAi system 
(Oligoengine).  Sense and antisense oligos were designed to target a particular 
region (19-29 bp) of the gene of interest as well as non-targeting controls. The 
oligos included sense and antisense target sequences, a hairpin loop, and 
overhangs corresponding to BamHI/BglII and XhoI sites as shown in Table 2-14. 
Table 2-14 shRNA oligo design 
 
The oligos were dissolved to 100 µM in TE buffer (1M Tris pH8.0, 100mM). 2 µL 
each of sense and antisense oligos were mixed, heated to 95°C to denature 
secondary structures for 5 minutes, then cooled and incubated at RT for 30 minutes 
to anneal. The annealed primers were diluted in 250 µL of ddH2O. 1 µg of vector 
(pSUPER.neo+mCherry) was digested with BglII (which produces an overhang 
complementary to BamHI overhang in the primers) and XhoI (without CIP) in 








 XhoI  
5' GATC C CC TTCAAGAGA TTTTT C  3' 
3'  G GG AAGTTCTCT AAAAA G AGCT 5' 
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NEB3.1 buffer and purified using the GeneJET gel extraction kit. 1 µL of vector and 
1 µL of annealed primers were added to 2 µL of TaKara I ligation mix and left at 
RT for 30 minutes, before being transformed into competent cells as above. Since 
the HindIII site is located between the BglII and XhoI site, mini preps were screened 
for the presence of an insert by digestion with HindIII. 
In order to make shRNA virus, or to allow for the co-expression of shRNA and an 
overexpressed protein, the entire H1 promotor and target sequence was inserted 
Xlg3 using PacI and XhoI sites located upstream of the SFFV protein promoter in 
Xlg3 using standard primers. 
2.3 CELL CULTURE METHODS 
All cell culture was carried out using aseptic techniques in a laminar flow hood. 
Cells were grown in incubators kept at 37°C, 90% humidity, 5% CO2, and 95% O2. 
2.3.1 Primary Neuronal Cultures 
2.3.1.1 Plastic or glass preparation 
2.3.1.1.1 Glass coverslips treatment 
Glass coverslips (24-25mm) were washed overnight at RT in nitric acid with gentle 
agitation. They were then washed three times in cell culture grade water and 
sterilized overnight in 70% ethanol with gentle agitation. After several washes in 
cell culture grade water, coverslips were stored in cell culture grade water in a 140 
mm cell culture dish. 
2.3.1.1.2 Coating 
Treated glass coverslips were added to 35mm dishes and coated with Poly-D-
Lysine (1mg/mL; Sigma) or Poly-L-Lysine (1mg/mL; Sigma) in sterile borate buffer 
(10mM borax, 50mM boric acid) or cell culture grade water. Plastic 6 well plates, 
35mm dishes, or 10 cm dishes were coated in Poly-L-Lysine (0.5mg/mL; Sigma) 
in borate buffer or cell culture grade water. Following an overnight incubation at 
37°C, dishes and coverslips were washed 3 times in cell culture grade water and 
then incubated in 1.5mL plating medium (Neurobasal, Gibco supplemented with 
10% horse serum, Sigma; 2 mM GlutaMAX, Gibco; and either GS21, GlobalStem, 
or B27, Thermo Fisher) overnight at 37°C or until required. 
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2.3.1.2 Rat embryonic dissection  
All animal care and procedures were carried out in accordance with UK Home 
Office and University of Bristol guidelines. All dissection tools were sterilised with 
70% EtOH, although the dissection occurred outside a laminar flow hood. Pregnant 
E17-E18 Wister rats were sacrificed under Home Office Schedule 1 regulations by 
overdose of isoflurane followed by cervical dislocation by a trained individual. The 
skin of the abdomen was sterilised 70% EtOH and embryos were extracted from 
womb and placed in RT Hank’s Buffered Salt Solution (without Ca2+ or Mg2+; 
HBSS) where they were immediately removed from their amniotic sac and 
decapitated. Severed heads were placed into fresh RT HBSS and the brains were 
removed using forceps under a dissection microscope at RT and outside a laminar 
flow hood. The brains were moved into fresh HBSS and the hemispheres were 
divided in two. The olfactory bulbs, hind brain, midbrain, and meninges were 
removed. The hippocampus was dissected from the cortex and hippocampi and 
cortices were pooled separately in RT HBSS.  
2.3.1.3 Cortical and hippocampal dissociation 
Cortical and hippocampal dissociation was carried out in a laminar flow hood using 
aseptic technique. HBSS (without Ca2+ or Mg2+) and plating media were used at 
RT. For hippocampal dissociation, dissected hippocampi were placed in a 15 mL 
Falcon tube and washed 3x in 10 mL HBSS. Hippocampi were then incubated in 
10 mL 0.005% Trypsin-EDTA (Thermo) in HBSS for 9 minutes in a 37°C water 
bath. Trypsinised hippocampi were then washed 3x in 10 mL HBSS and 1x in 1 
mL plating media in order to remove residual trypsin. Hippocampal tissue was then 
dissociated in 1 mL plating media by trituration using a P1000 pipette and then 
diluted with an additional 4 mL of plating media. The number of cells in a 1:10 
dilution mixed with 0.4% Trypan blue (Thermo) was counted using a 
haemocytometer and the dissociated cells were diluted to a concentration of 1 
million per mL. 
Dissected cortices were dissociated similarly, but with a few extra steps due to the 
size of the tissue and with larger volume of reagents due to the greater number of 
cells. Specifically, dissected cortices were cut into smaller pieces using a sterile 
scalpel blade before being added to a 50 mL Falcon. The HBSS washes and 
trypsinisation occurred as above, but in a volume of 30 mL and a trypsin incubation 
time of 15 min. After washing in 5mL plating media, cortical tissue was dissociated 
in 5 mL plating media by trituration with a 5 mL serological pipette. The dissociated 
Chapter 2 –   Materials & Methods 
60 
 
cells were then strained through a sterile 70 µm cell strainer into a fresh 50 mL 
Falcon tube to remove any debris before being counted and diluted to 5 million per 
mL. 
2.3.1.4 Plating and Feeding 
Cells were then plated at various densities according to the experimental design. 
Generally, between 150,000 and 400,000 hippocampal cells were plated per 25 
mm coverslip and 500,000-700,000 hippocampal or cortical cells were plated per 
6-well dish. For proteomics, 5 million cortical cells were plated per 10 cm dish. The 
following day, the plating media was replaced with 3 mL feeding medium 
(Neurobasal supplemented with 1.2 mM GlutaMAX and either GS21 or B27). 
Neurons were incubated at 37°C and 5% CO2 for up to 2 weeks. 
2.3.2 Mammalian cell line culture  
2.3.2.1 Cell lines used 
Human embryonic kidney (HEK293T) cells were used for protein biochemistry 
experiments. Due to their flatter shape and greater ability to stick to glass, HeLa 
cells were used for imaging experiments. Baby hamster kidney (BHK-21) cells 
were used to produce Sindbis virus. All cell lines were obtained from the European 
Collection of Cell Cultures (ECACC). 
2.3.2.2 Cell culture media components 
HEK293T cells and HeLa cells were grown in complete DMEM medium 
supplemented with 10% FBS and 1% L-glutamine. BHK-21 cells were grown in 
complete Alpha MEM medium supplemented with 5% FBS and 1% 
Penicillin/Streptomycin (Thermo). 
2.3.2.3 Long-term storage and thawing of cell lines 
Aliquots of HEK293T, HeLa, and BHK-21 cells mixed with 1% DMSO were stored 
in liquid nitrogen. An aliquot was removed from storage and quickly thawed in a 
37°C water bath and then transferred to a 15 mL Falcon tube with 10 mL complete 
medium. To remove the DMSO, the cells were pelleted at 1000 g for 2 min at RT 
and the medium was aspirated and replaced with 1 mL of fresh medium. The cells 
were then gently resuspended and transferred to a T25 flask containing 5 mL 
complete medium and incubated overnight. The next day, the cells were 
dissociated and re-plated into a T75 flask. Cell lines were treated with Ciprofloxacin 
(10 µg/mL) for several passages after thawing to prevent mycoplasma infection. 
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2.3.2.4 Passaging of cell lines 
HEK293T and HeLa cells were grown in T75 flasks until they were 70-90% 
confluent and then passaged 1/10 (about 2 times a week) as below. HEK293T cells 
were not kept beyond P25. BHK-21 cells were more carefully monitored because 
they are more sensitive to overgrowth – they were passaged about every 2 days 
and 1x106 cells were added to a new T75 flask in order to prevent overgrowth and 
to not split them too harshly. 
HEK293T, HeLa, and BHK-21 cells were gently washed with 10 mL pre-warmed 
PBS (no Ca2+ or Mg2+) and dissociated with 1 mL 0.05% trypsin-EDTA incubated 
at 37°C for 2-5 minutes. Cells were then triturated in 4-9 mL of medium with a 
serological pipette. To remove the trypsin, cells were pelleted by centrifugation at 
1700 g for 2 minutes at RT, the supernatant was removed, and the pellet was 
resuspended in 10 mL of medium. For stock maintenance, 1 mL of cells was added 
to a T75 flask with 11 mL of fresh medium.  
2.3.2.5 Plating HEK293T and HeLa cells 
2.3.2.5.1 Plastic or glass preparation 
The wells of a 6 well plate were coated in 0.1 mg/mL PLL in cell culture grade water 
and left to incubate at 37°C for at least 1 hour. The wells were then washed 3x in 
cell culture grade water. 2 mL of complete DMEM was added to each well. 
For imaging experiments, 25 mm coverslips were sterilised and stored in 70% 
EtOH. A coverslip was added to each well of a 6 well plate and washed 3x in cell 
culture grade water. The coverslips were then coated in PLL and washed as above.  
2.4 IMMUNOCYTOCHEMISTRY METHODS 
2.4.1 Lipofectamine transfection 
2.4.1.1 Cell line transfection 
HeLa cells or HEK293T cells were transfected the day after plating with 
Lipofectamine2000 (Thermo). Per transfection, 1-2 µg of plasmid DNA and 3-5 µL 
of Lipofectamine2000 were added to 200 µL plain DMEM. The transfection mix 
was vortexed, spun down, and incubated at RT for 30 minutes. The transfection 
mix was then added dropwise to the cells and the cells were returned to the 
incubator for 20-72 hours. 
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2.4.1.2 Neuronal transfection 
Hippocampal cultures were usually transfected at DIV 12 with Lipofectamine2000. 
For knockdown constructs, neurons were transfected at DIV 9 to allow extra time 
for the knockdown to work. Amounts of plasmid DNA and Lipofectamine2000 were 
optimised for each plasmid, but, generally, 2-5 µL of Lipofectamine per well was 
added to 200 µL per well of plain neurobasal and vortexed. 1-2.5 µg of DNA per 
well was added to the lipofectamine/neurobasal mix and the tubes were vortexed, 
spun down, and incubated at RT for about 30 minutes. Neuronal cultures on 
coverslips were prepared for transfection during the incubation. Two (of three) mL 
of media were withdrawn from each well and added to a 50 mL Falcon tube labelled 
“Conditioned Media.” An additional mL per well of fresh feeding medium was added 
to the tube, and the tube was kept warm in a 37°C water bath during transfection. 
The neurons were then usually transfected in the remaining mL of conditioned 
medium. Because B27 reduces the efficiency of transfection, neurons kept in B27 
media were sometimes transfected in plain neurobasal media, depending on how 
well the plasmid expressed. After the 30-minute incubation, the DNA/ 
Lipofectamine mix was added dropwise to the neurons and the neurons were 
returned to their incubator for 45 minutes to 1.5 hours. The transfection mixture 
was then removed, and the neurons were washed in 1 mL of fed conditioned 
media. The remaining 2 mL of fed conditioned media was added to the neurons, 
and the neurons were placed back in the incubator and immunostained at DIV 13 
or DIV 14.  
2.4.2 Live surface staining 
To measure surface expression, DIV 13 or DIV 14 hippocampal neurons 
transfected with the construct of interest were cooled at room temperature for 5-10 
min (to  reduce further internalisation), then incubated with the appropriate 
antibody (chicken anti-GFP or mouse anti-CD4) in 100 µL conditioned media for 
10-20 min at RT. The antibody mix was dotted onto parafilm, and the coverslip was 
incubated upside down to ensure even coating. 
For agonist and inverse agonist experiments, the neurons were treated with either 
5 μM ACEA (in EtOH), 10 μM AM281 (in DMSO), or vehicle control (0.1% EtOH or 
DMSO) for 3 hours at 37°C and 5% CO2, and then subsequently surface stained 
as above. 
The neurons were washed multiple times in PBS before fixation.  
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2.4.3 Staining of endocytosed receptors 
To measure endocytosed receptors, DIV 14 hippocampal neurons transfected with 
the construct of interest were fed with the appropriate antibody (chicken anti-GFP 
or mouse anti-CD4) for 2 hours in 200 µL of conditioned media at 37°C and 5% 
CO2. Neurons were washed several times in PBS and cooled to 4°C to prevent 
further internalisation. Anti-GFP surface antibody was stripped by two quick 
washes with ice-cold pH 2.5 PBS. Because two acid washed did not completely 
remove surface fluorescence, anti-CD4 surface antibody was stripped using a 
harsher condition – a 4 min incubation with 0.5 M NaCl and 0.2 M acetic acid (pH 
3.5). Neurons were washed several times in PBS before fixation. 
2.4.4 Fixation 
Cultured neurons were fixed in pre-warmed (37°C) 4% formaldehyde in PBS for 
12 minutes. Following three washes in PBS, excess formaldehyde was quenched 
with one wash in 100 mM Glycine in PBS. The cells were then washed three more 
times in PBS and either blocked immediately or left in PBS at 4°C overnight. 
2.4.5 Blocking and permeabilisation 
Neurons were blocked and permeabilised in 1 mL 3% BSA + 0.1% Triton-X 100 in 
1x PBS for 20 minutes at RT.  
2.4.6 Fixed immunostaining  
In general, for fixed immunostaining, the antibodies were diluted in 100 µL 3% BSA 
in PBS per coverslip. 90 µL antibody mix was dotted onto parafilm, and the 
coverslip was incubated upside down at room temperature for 45 minutes to one 
hour. The cells were washed at least three times in 1x PBS between incubations. 
Primary concentrations can be found in (Table 2-10). All secondaries were used 
at 1:400 (Table 2-11) 
Fixed, blocked, and permeabilised neurons that had been live stained for surface 
or endocytosed receptors were incubated in secondary antibody at (Alexa Fluor 
647 donkey anti-chicken IgY for GFP primary antibody or Cy5-labelled donkey anti-
mouse IgG for CD4 primary antibody) to label surface or endocytosed primary. The 
neurons were then re-stained with primary antibody (chicken anti-GFP or mouse 
anti-CD4) to label total receptor of interest. At the same time, they were labelled 
with mouse anti-AnkyrinG antibody and/or rabbit anti-MAP2 antibody in order to 
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mark the axon initial segment or the dendrites, respectively, and then incubated in 
the appropriate secondary.  
2.4.7 Retention Using Selective Hooks (RUSH) 
2.4.7.1 HeLa RUSH 
HeLa cells grown on 25mm glass coverslips were transfected with the mCherry 
RUSH CB1RWT construct for no longer than 24 hours to prevent ER stress resulting 
from accumulation of retained receptors. Receptors were released with the 
addition of 40 μM D-biotin (Merck) for different lengths of time. At the end of the 
timepoint, the cells were washed three times in PBS and fixed in pre-warmed 4% 
formaldehyde in PBS for 10 minutes. They were then washed three times in PBS, 
one time in 100 mM glycine, and three times in PBS.  
Cells were then blocked in a non-permeabilising buffer (3% BSA in 1x PBS) for 20 
minutes at RT and subsequently incubated in mouse anti-SBP antibody (in 3% 
BSA in 1x PBS) for 45 minutes at RT in order to stain surface receptors. After 3 
washes in PBS, the cells were then incubated in Cy5-labelled anti-mouse IgG for 
45 minutes at RT. Following 3 washes in PBS, coverslips were mounted in 
Fluoromount-G with DAPI onto glass slides. 
2.4.7.2 Neuronal RUSH 
Hippocampal neurons were transfected with RUSH constructs at DIV 12 for no 
longer than 24 hours to prevent ER stress resulting from accumulation of 
unreleased receptors. To release the receptor, neurons were incubated in 200 µL 
conditioned media containing D-biotin (40 μM) for different lengths of time at 37°C 
and 5% CO2. Chicken anti-GFP antibody (1:1,000) was also added to the media to 
label receptors reaching the surface. The 0 min timepoint was only incubated with 
chicken anti-GFP antibody without biotin for 60 min. For the O/N timepoint, neurons 
were incubated in 40 μM D-biotin immediately following transfection and then left 
overnight at 37°C and 5% CO2 before being incubated with biotin and chicken anti-
GFP for 60 min to label surface CB1R. Every independent experiment included a 
60 min timepoint to which values were normalised and a 0 min control to make 
sure that the receptors had been retained prior to release.  
Following biotin treatment, neurons were washed several times in PBS and cooled 
to 4°C to prevent further internalisation. They were then live labelled with 647-
labelled anti-chicken IgY (1:400) in conditioned media for 15 min at 4°C before 
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being fixed and permeabilised and stained with Cy3-labelled anti-chicken IgY. 
Therefore, in the text, “surface” thus refers to 647 fluorescence acquisition. 
Because the 647-labelled secondary was unlikely to saturate the primary antibody, 
especially with a 15 min incubation at 4°C, Cy3 fluorescence acquisition is referred 
to as “surface+endocytosed”. 
The neurons were then re-stained with chicken anti-GFP antibody, followed by 
Cy2-labelled anti-chicken IgY antibody, to boost the GFP signal and to measure 
the total amount of receptor present. Concurrently, they were stained with mouse 
anti-AnkyrinG antibody, followed by DyLight 405 anti-mouse IgG antibody to label 
the axon initial segment.  
2.4.8 Image acquisition and analysis 
2.4.8.1 Image acquisition 
Images were acquired using either a Leica SPE single channel, a Leica SP8, or a 
Leica SP5II confocal laser scanning microscope (Wolfson Bioimaging Facility, 
University of Bristol), or a Zeiss LSM510 UV META Axiovert 200M laser scanning 
microscope. All settings were kept the same within experiments. To avoid bias, 
neurons were selected for data acquisition based only on their total staining and 
surface/endocytosed was stained in far red. Based on previous experiments, 4-10 
cells were acquired per experiment per condition, and at least three independent 
experiments (i.e. on different neuronal cultures from different dams on different 
days) were performed. 
2.4.8.2 Image analysis 
2.4.8.2.1 Surface and endocytosed normalisation 
All quantification was performed using FIJI (ImageJ) software. Images were max 
projected, and regions of interest (ROIs) of approximately similar lengths were 
drawn around axons and 3–4 proximal and secondary dendrites based on the total 
channel only. Axons were defined either as processes whose initial segment was 
positive for Ankyrin-G or as processes negative for MAP2. The mean fluorescence 
was measured for each channel and the dendritic values were averaged. ‘Surface’ 
or ‘endocytosed’ mean fluorescence values were normalised to the ‘total’ mean 
fluorescence value for each ROI to account for varying levels of expression of 
transfected constructs. These values were then normalised to the axon value of 
the control (WT or CD4). For drug treatments, surface values were normalised to 
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their respective vehicle treated controls and sampled at the same time-point (i.e. 
WT + drug was normalised to WT + vehicle and ΔH9 + drug was normalised to 
ΔH9 + vehicle) to account for possible differences in steady-state surface 
expression between the constructs and/or constitutive internalisation. 
2.4.8.2.2 RUSH 
Because of the change in total mean fluorescence in axons throughout the different 
conditions, the above image analysis was slightly modified for RUSH experiments. 
In these experiments, neurites were traced using NeuronJ so that only the mean 
fluorescence of exactly the first 50 μm of the axons and 30–40 μm of 2–4 primary 
dendrites for each channel was measured. All ‘surface’ and ‘surface + 
endocytosed’ values (of both axons and dendrites) were normalised to the average 
total dendritic value for each neuron. Axon total mean fluorescence was also 
normalised to the average total dendritic value within each cell. All values were 
then normalised to the WT 60 min axon value within each experiment. In a slightly 
smaller subset of RUSHed neurons, axons were traced for ~100 µm using 
NeuronJ. Line plots were generated, and the mean fluorescence was averaged in 
10 µm segments. The averages for each 10 µm segment from each cell were 
normalised first to the dendritic total value, then to the axonal 60 min value of the 
first 50 µm. 
2.4.8.2.3 Polarity indices 
Polarity indices (A/D ratio) were calculated by dividing the axonal mean 
fluorescence value by the average dendritic mean fluorescence value. 
2.5 SINDBIS METHODS 
2.5.1 Preparation of BHK-21 cells for electroporation 
BHK-21 cells were cultured and maintained in T75 flasks as described in “2.3.2 
Mammalian cell line culture”. Two days before electroporation, 1x106 cells were 
plated into T175 flasks. To ensure that there would be enough cells, two T175 
flasks were plated for every virus.  
During in vitro transcription, the BHK cells were prepared for electroporation. Per 
T175 flask, the cells were washed twice in 5mL PBS, then dissociated in 3 mL 
0.05% trypsin-EDTA for 5 min at 37°C. The cells were then triturated and pooled 
together in 10 mL growth medium, pelleted by centrifugation at 1700rpm for 4 min 
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at RT, and resuspended in 10 mL PBS. Following another round of centrifugation 
and resuspension in PBS to wash the cells, 100 µL of cells were mixed with 100 
µL and were counted using a haemocytometer. The cells were then recentrifuged 
and resuspended in the volume needed to make a suspension of 1x107 cells/mL. 
2.5.2 Preparation of viral RNA 
Tagged genes of interest (goi) were cloned into the pSinRep5 plasmid which 
contains the non-structural genes (Replicase) for Sindbis. These constructs, as 
well as the defective helper plasmid, pDH-BB (tRNA; TE12), which provides the 
structural proteins for Sindbis, were midiprepped. In this thesis, Sindbis virus was 
made to overexpress EGFP-tagged c-terminus of CB1R (ctCB1R) – specifically 
EGFP-ctCB1WT and EGFP-ctCB1ΔH9 – as well as an empty EGFP control.  
2.5.2.1 Linearising templates  
30-50 µg of pSinRep5 plasmid with gene of interest (goi) and 50 µg of pDH-BB 
were linearised by restriction enzyme digest overnight at 37°C (Table 2-15). 
Table 2-15 Template linearisation reactions 




pSinRep5-goi 30-50 µg  pDH-BB 50 µg 
10xCutSmart buffer 10 µL  
10xCutSmart 
buffer 10 µL 
NotI-HF (20 
units/µL) 2 µL  XhoI (20 units/µL) 2 µL 




1 µL of the digest was run on an agarose gel to check for the presence of a single 
band. The linearised DNA was then purified using a Gel Extraction Purification Kit 
on 2 columns so as not to overload the columns.  
2.5.2.2 Ethanol precipitation 
The purified DNA was then ethanol precipitated in order to obtain a concentration 
of 0.5 µg/µL. 0.1x (of volume of DNA) 3M sodium acetate was added first. Then 
2.5x 100% EtOH (pre-chilled to -20°C) was added and mixed well. To pellet the 
DNA, the tube was centrifuged for at 13.2K rpm for 15 min at RT. The supernatant 
was removed, and the pellet was washed in 500 µL 70% EtOH by inverting 3 times. 
The DNA was re-pelleted by centrifugation at 13.2K rpm for 5 minutes at RT, the 
Chapter 2 –   Materials & Methods 
68 
 
supernatant was removed thoroughly, and the pellet was left to air-dry. The DNA 
was resuspended in 5 µL DEPC-treated water, the concentration was measured 
using a nanodrop, and the DNA was diluted to 0.5 µg/µL 
2.5.2.3 In vitro transcription of viral RNA 
RNA was transcribed from the linearised DNA in vitro using the mMessage 
mMachine SP6 transcription kit (Ambion) and SUPERaseIn (Ambion) RNAse 
inhibitor in a work area cleaned with RNaseZap and with RNase-free tubes and 
pipette tips (Table 2-16). For the defective helper plasmid, one reaction per virus 
being made plus one was set up. 
Table 2-16 In vitro transcription reaction 
FOR ONE REACTION: 
 
DEPC-treated water  0.55 µL 
Linearised DNA (0.5 µg/µL) 0.6 µL 
2x ribonucleotide mix (NTP/CAP) 2.5 µL 
20mM GTP 0.25 µL 
10x Reaction Mix 0.5 µL 
SUPERaseIn 0.1 µL 
10x SP6 enzyme mix 0.5 µL 
TOTAL REACTION VOLUME 5 µL 
 
The reaction was incubated at 37°C for 2 hours. Then, 5 µL of defective helper 
RNA was mixed with 5 µL of goi RNA and the mixture was kept on ice. 
2.5.3 Electroporation 
0.5 mL of suspended cells were added with the RNA mix a gene pulse cuvette (0.2 
cm gap) and quickly pulsed twice at 1.5kV and 20 µF. Cells were allowed to recover 
on ice for 5-10 minutes and then plated into a T25 flask containing 3.5 mL of growth 
medium. 
2.5.4 Harvesting pseudovirion 
24 hours after electroporation, the expression of EGFP was confirmed using a 
fluorescent microscope. Between 36 and 48 hours after electroporation, the 
supernatant was collected in a 15 mL centrifuge tube which was centrifuged at 
2000rcf for 10 minutes to pellet any cell debris. The supernatant was then 
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transferred to a fresh 15 mL Falcon tube, aliquoted, and either used right away or 
stored at -80°C.  
2.5.5 Viral transduction of primary neurons with Sindbis virus 
Aliquots of Sindbis virus were thawed on ice and added to cultured cortical neurons 
for no longer than 24 hours to prevent toxicity. 
2.6 PROTEIN BIOCHEMISTRY METHODS 
2.6.1 Cell lysis 
To prevent protein degradation, all steps were carried out on ice or at 4°C. In 
general, transfected HEK293T cells or virally transduced primary neurons were 
lysed in the appropriate lysis buffer (as outlined in Table 2-17), scraped with a cell 
scraper, pipetted into an Eppendorf tube, vortexed, and sonicated. 
Table 2-17 Types of lysis buffer 
APPLICATION LYSIS BUFFER 
GFP Traps 
50 mM Tris HCl pH 7.4 
150 mM NaCl 
0.5% Triton X 
1 x protease inhibitors 
Mass Spec/GFP Traps 
50 mM Tris HCl pH 7.4 
0.5% NP40 
1 x protease inhibitors 
200 μM sodium orthovanadate 
Surface biotinylations; 
Solubilizing full length 
CB1 
50 mM Tris HCl pH 7.4 
150 mM NaCl 
1% CHAPS 
1 x protease inhibitors 
Phospho-ERK assay 
50 mM Tris HCl pH 7.4 
150 mM NaCl 
1% CHAPS 
1 x protease inhibitors 
1 x phosphatase inhibitors 
Knockdown validation 1 x Laemmli Sample Buffer 
 
Samples lysed in lysis buffers were incubated on ice for 20-30 minutes then 
centrifuged at 13.2k rpm at 4°C for 20 minutes. The supernatant was pipetted to a 
new tube. An equal volume of 2x Laemmli sample buffer (4% SDS, 20% glycerol, 
0.004% bromophenol blue, 0.125M Tris-HCl pH 6.8, 10% 2-mercaptoethanol) was 
added to the lysate which and it was boiled at 95°C for 10 minutes. To avoid 
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aggregation of CB1R, samples that needed to be blotted for CB1R were not boiled, 
but left overnight at RT.  
Samples lysed in 1x sample buffer were heated to 95°C for 10 minutes while 
shaking, spun down, and kept at room temperature or on the freezer (long term 
storage).  
2.6.2 GFP-Trap 
Cortical cells transduced with Sindbis virus were lysed in lysis buffer as above and 
the around 40 µL of the supernatant was added to an Eppendorf tube to act as a 
total/input. 500 µL of lysis buffer was added to 13 µL of washed GFP-Trap beads 
and incubated on a rotating wheel at 4°C for 1 hour. The beads were pelleted for 
2 minutes at 6.6k rpm, and the supernatant was removed. The beads were washed 
in 500 µL of lysis buffer, inverted and flicked gently to mix. This washing was 
repeated 3 times. 40 µL of 2x Laemmli sample buffer was added to the beads and 
the inputs and the samples were incubated at 75°C – 95°C for 5-10 minutes. 
2.6.2.1 GFP-Trap for proteomics 
Sindbis virus was added to cortical neurons 24 hours prior to starting the GFP trap 
protocol. HEK293T cells were transfected 48 hours prior to starting the GFP trap. 
The cells were washed twice in ice-cold PBS and lysed in 500 μL of lysis buffer (50 
mM Tris HCl pH 7.4, 0.5% NP40, 1xprotease inhibitors, 200 μM sodium 
orthovanadate), inverted, and left on ice for 20 minutes. Cell debris was spun out 
at 13.2k rpm for 20 minutes and the supernatant was added to 35 μL of washed 
GFP-trap (ChromoTek) beads and incubated on a rotating wheel at 4°C for 1 hour. 
The beads were then washed four times in lysis buffer and brought to the University 
of Bristol Proteomics facility. 
2.6.3 Proteomics 
Tandem Mass Tagging (TMT) quantitative mass spectrometry analysis was 
performed by Dr Kate Heesom at the University of Bristol Proteomics facility. Data 
was analysed using Perseus with help from Dr Lea Hampton-O’Neil. 
2.6.4 Surface biotinylation assay 
2.6.4.1 Surface biotinylations 
All solutions were pre-chilled to 4°C and steps were carried out on ice. HEK293T 
cells expressing GFP- (but not SBP-) tagged CB1R constructs were chilled on ice 
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for a few minutes before being washed 3x in 2 mL PBS. The cells were then 
incubated in 1.5 mL 0.3 mg/mL of EZ-link Sulfo-NHS-SS-Biotin dissolved in 1xPBS 
for 10 minutes. Unreacted biotin was washed off with 3 washes in 2 mL PBS and 
quenched in 1.5 mL of 50 mM NH4Cl in PBS for 2 minutes. The cells were washed 
3 more times in PBS and lysed in 200 µL lysis buffer (Table 2-17). Cells were 
scraped into a labelled Eppendorf tube, vortexed, sonicated, and left on ice for 30 
minutes. The lysate was centrifuged at 13.2k rpm for 20 minutes. 40 µL of lysate 
was removed to a new tube to act as the total. 
2.6.4.2 Streptavidin pulldown 
Biotinylated surface proteins were isolated using streptavidin-coated agarose 
beads. The beads were washed 2 times in lysis buffer by centrifugation at low 
speed (<3k rpm). 100 µL of centrifuged lysate was added to 30 µL of beads along 
with 250 µL of lysis buffer. The beads were incubated on a rotating wheel at 4°C 
for 1.5 hours, then washed in wash buffer (lysis buffer without protease inhibitors) 
3 times, pelleting the beads for 2 minutes at 6.6k rpm between washes. 40 µL of 
2x Laemmli sample buffer was added to both the surface and total fractions. The 
samples were vortexed, spun down, and incubated overnight at RT.   
2.6.5 SDS-PAGE 
2.6.5.1 Gel preparation 
Separation of proteins by molecular weight was performed by sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) using the Bio-Rad Mini-
PROTEAN system. 8-12% acrylamide gels were cast in 1.5 mm glass plates using 
a Bio-Rad gel stand. Resolving gel (375 mM Tris-HCl pH 8.8, 8-12% acrylamide, 
0.1% SDS, 0.1% APS, and 0.01 % TEMED) was added to the glass plates and 
overlayed with ethanol to ensure an even surface. Once the resolving gel 
polymerised, the ethanol was washed off with ddH2O. A 5% stacking gel (125 mM 
Tris-HCl pH 6.8, 5% acrylamide, 0.1% SDS, 0.1% APS, 0.01% TEMED) was added 
on top of the resolving gel, and a 15-well comb was inserted. Once polymerised, 
the gel was either used straight away or stored at 4°C in paper towel soaked in 1 
x SDS-PAGE running buffer.  
2.6.5.2 SDS-PAGE 
Acrylamide gels were mounted into electrophoresis tanks and which were filled 
with running buffer (25 mM Tris base, 250 mM glycine, 0.1% (w/v) SDS). Samples 
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were loaded into the wells along with 5 µL of molecular weight marker (PageRuler 
Prestained Protein Ladder, Thermo). The gel was run at 80V until the samples 
cleared the stacking gel, then at 120-180V until the dye front ran off the bottom of 
the gel. 
2.6.6 Wet transfer 
Following SDS-PAGE, resolved proteins were transferred onto methanol-activated 
PVDF (0.45 µm, Millipore). The gel was removed from the glass plates and the 
PVDF membrane was activated in methanol then equilibrated in transfer buffer (50 
mM Tris base, 40 mM glycine, 20% methanol). The PVDF was then layered on top 
of the gel, and both were sandwiched in a cassette with three pieces of filter paper 
and one sponge on either side. The cassette was added to an electrophoresis tank 
with the membrane facing the cathode (red) and the gel facing the anode (black). 
An ice pack and a magnetic flea were added to the tank and the tank was filled 
with transfer buffer. The proteins were transferred at 400mA for 70-90 minutes with 
constant stirring. 
2.6.7 Immunoblotting 
Following transfer, membranes were removed from the cassette and blocked in 
6% (w/v) non-fat milk (the Cooperative) or 4% (w/v) bovine serum albumin (BSA) 
dissolved in PBST (1x PBS + 0.1% Tween-20) for 1 hour with gentle shaking. 
Primary antibody was then added at an appropriate concentration (Table 2-10) 
diluted in either 6% milk or 4% BSA according to the manufacturer’s 
recommendation. Full blots or cut parts of blots were incubated in primary antibody 
either overnight at 4°C or for 1.5 hours at RT with gentle shaking. Primary antibody 
was removed from the blot (and kept in order to be re-used, with sodium azide) 
and the blot was washed 3x quickly in PBST and 3x 5 minutes in PBST. The blot 
was then incubated with the appropriate secondary antibody conjugated to 
horseradish peroxidase (HRP) and diluted 1:10,000 in 6% milk or 4% BSA for 1 
hour at RT. The blot was washed 3x quickly in PBST and 3x 5 minutes in PBST. 
2.6.8 Chemiluminescence detection 
Protein bands were visualised by incubation of an enhanced chemiluminescence 
(ECL) HRP substrate of different sensitivity depending on the antibody used ( 
Table 2-18). Excess PBST was blotted off on tissue paper, and membranes were 
incubated for 1-2 minutes in the appropriate substrate (Table 2-18). 
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Table 2-18 ECL HRP Substrates 
SUBSTRATE SUPPLIER SENSITIVITY 
Pierce™ ECL Western Blotting Substrate Thermo Low 
Immobilon Classico Western HRP substrate Merck  
Immobilon Crescendo Western HRP substrate Merck  
Immobilon Forte Western HRP substrate Merck  




Excess ECL was blotted off on tissue paper, and the membrane was transferred 
to either a film cassette or tray and covered with a thin sheet of overhead projector 
plastic smoothed to remove any bubbles so that the membrane did not dry out. 
Protein bands were visualised either by X-ray film exposure or by image 
acquisition. CL-Xposure X-ray film (Thermo) was exposed to the bands in a light-
tight cassette for varying lengths of time. The film was developed using an 
automated X-ray film developer (Konica SRX-101A). Images of the bands were 
acquired using an Odyssey Fc imaging system (LI-COR). 
2.6.9 Stripping and re-probing 
To re-probe the blot with another antibody, the blots were stripped of bound 
antibody with Restore PLUS Western Blot Stripping Buffer (Thermo) at 60°C for 15 
minutes. The blots were washed 5 x in PBST and re-blocked in milk or BSA for 1 
hour before being incubated with the relevant antibody. 
2.6.10 Quantification of chemiluminescence 
Blots on film were scanned and the density of the bands was analysed using the 
ImageJ Gel Analysis Tool. Rectangles of equal size were drawn around each band 
and profile plots were drawn for each band. The background was removed by 
drawing a straight line under the peak, and the area under the peak was calculated 
for each band. The values were copied over to an Excel spreadsheet for further 
analysis. 
Blots acquired on the LI-COR were analysed using Image Studio. Rectangles were 
drawn around each band. A border 3 pixels wide around each rectangle was used 
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to calculate the background. If the bands were too close together, the background 
was calculated only from the top/bottom borders. The “signal” (“total” – 
“background”) was copied over into an Excel spreadsheet for further analysis.  
2.6.11 Normalisation 
Values for proteins of interest were normalised to the values of the sample’s 
loading control – usually beta Actin. For surface biotinylations, surface values were 
normalised to total values instead. 
To control for variations in exposure/acquisition, values for each condition within 
an experiment were normalised to the average value for the experiment. Each 
value in the whole data set were then normalised to the average control value so 
that the control value was set to 1 and each condition represented a proportion of 
the control.  
2.7 STATISTICAL METHODS 
All statistics were performed using GraphPad Prism.  
For imaging experiments, the ROUT method was used to identify outliers for all 
parameters measured before normalising to control. Neurons were removed from 
analysis if any one parameter was found to be an outlier. As is the convention in 
the field (Leterrier et al., 2006; Coutts et al., 2001; Simon et al., 2013; Evans et al., 
2017; McDonald et al., 2007a; Leterrier et al., 2004, 2017), ‘N’ denotes the number 
of separate neuronal cultures prepared from litters of pups from separate dams 
and ‘n’ denotes the total number of neurons across the separate cultures 
assessed.  
To determine statistical significance between two groups, a D’Agostino and 
Pearson normality test was performed. Unpaired t-tests were performed on data 
that passed the normality test whereas the Mann-Whitney test was used if it did 
not. One- or Two-way ANOVAs with Tukey’s or Sidak’s post hoc test were used to 
determine statistical significance between more than two groups depending on the 
comparisons required. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001. All data 
are presented as mean ± SEM. 
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Chapter 3 –   NEWLY SYNTHESISED CB1R IS 
PREFERENTIALLY TRAFFICKED TO THE AXON 
3.1 AIMS 
• To examine how the axonally polarised surface distribution of CB1R is both 
(1) established and (2) maintained. 
• To apply retention using selective hooks (RUSH) to examine the 
contribution of forward trafficking to the polarised surface distribution of 
CB1R. 
3.2 INTRODUCTION 
3.2.1 Surface polarity of CB1R 
CB1R has a highly polarised axonal surface expression (Irving et al., 2000; Coutts 
et al., 2001; Leterrier et al., 2006; Thibault et al., 2013; Rozenfeld and Devi, 2008; 
McDonald et al., 2007a), where it acts to attenuate neurotransmitter release 
(Katona, 2009) and modulate synaptic plasticity (Lu and Mackie, 2016). Although 
CB1R is not stably surface expressed on somatodendritic plasma membrane, ~80% 
of total CB1R is present in intracellular vesicular clusters in the soma and dendrites 
(Leterrier et al., 2006).  
How this near exclusive axonal surface expression of CB1R is established remains 
the subject of debate (see 1.3.6 Three currently proposed models of CB1R polarity). 
One suggestion is that high rates of endocytosis due to constitutive activity 
selectively remove CB1Rs from the somatodendritic plasma membrane, resulting 
in an accumulation at the axonal surface; (Leterrier et al., 2006). These internalised 
somatodendritic CB1Rs may then be either sorted for degradation or recycled to 
axons via a transcytotic sorting pathway (Simon et al., 2013). Alternatively, newly 
synthesized CB1Rs may be constitutively targeted to lysosomes, but under 
appropriate circumstances the CB1Rs destined for degradation are retrieved and 
rerouted to axons (Rozenfeld, 2011; Rozenfeld and Devi, 2008). 
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3.2.1.1 The role of the secretory pathway 
Surprisingly little is known about the contribution of the secretory pathway to CB1R 
surface polarisation. Since siRNA knockdown of adaptor protein 3 subunit δ (AP-
3δ) increases surface expression of CB1R in Neuro2A cells and primary 
hippocampal neurons, (Rozenfeld and Devi, 2008) suggest that at the TGN, CB1R 
is constitutively sorted by AP-3 for lysosomal degradation. By an unknown 
mechanism, a small proportion may be rescued and rerouted to axons.  
(Leterrier et al., 2006) examined the forward trafficking of CB1R using a Brefeldin 
A (BFA) block and release protocol (Figure 1-14). Blocking the secretory pathway 
with BFA caused newly synthesized cargo to accumulate. By washing out the BFA, 
they were able to pulse-chase exogenously expressed CB1R. They found that 
CB1R is non-discriminately delivered to the membrane, and then retrieved in the 
somatodendritic compartment and rerouted to axons.  
However, both of these experiments are limited by the fact that they block the 
secretory pathway as a whole – BFA blocks any cargo from trafficking, and 
furthermore has been shown to also affect endocytosis and recycling (Wood et al., 
1991; Hunziker et al., 1991; Damke et al., 1991; Miller et al., 1992; Hunziker et al., 
1992; Graham et al., 1993), and AP-3δ knockdown affects any cargo sorted by 
AP3.  
In this chapter, I present a more targeted, genetic approach to examine CB1R 
forward trafficking by applying retention using selective hooks (RUSH) and show 
that CB1R is preferentially delivered to the axonal membrane by the secretory 
pathway. 
3.2.2 Non-canonical secretory pathway trafficking in neurons 
3.2.2.1 Local synthesis 
Because of the unique architecture of neurons, cargo must often travel long 
distances. In order to accommodate for this, neurons have a local secretory 
pathway system in place. mRNA can be sent to dendrites for local synthesis and 
the machinery required for translation, assembly, and trafficking – the rough 
endoplasmic reticulum (rER), ER Exit Sites (ERES), and Golgi outposts are all 
present in dendrites (Horton and Ehlers, 2003, 2004; Holt and Schuman, 2013; 
Valenzuela and Perez, 2015; Quassollo et al., 2015; Evans et al., 2017).   
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It is conventionally thought that local synthesis of transmembrane proteins is 
impossible in axons because axons contain neither rER nor a traditional stacked 
Golgi. However, recent, somewhat controversial, evidence, especially from the 
Couve lab, suggests that local synthesis may indeed occur, through local smooth 
ER (sER) and a Golgi-independent pathway (see (González et al., 2018) for 
review).  
3.2.2.2 Golgi bypass 
Another recent, and also somewhat controversial, study reported that cargo can 
reach the surface with immature glycosylation profiles (Hanus et al., 2016). This 
suggests that certain cargo may bypass the Golgi and go straight from the ER to 
the plasma membrane. Furthermore, it has been reported that Kv2.1, a voltage-
gated K+ channel present in both the somatodendritic compartment and the axon 
initial segment (AIS) traffics to the two compartments by different mechanisms – 
Kv2.1 reaches the somatodendritic membrane through the conventional secretory 
pathway, but appears to bypass the Golgi in order to go to the AIS (Jensen et al., 
2017).  
I present below some preliminary data suggesting that CB1R traffics through the 
conventional secretory pathway. 
3.2.3 Axonal morphology 
In the canonical representation of a neuron, excitatory and inhibitory inputs 
received throughout the dendritic arbour are summed up and integrated in the 
soma. Under the right conditions, depolarisation of the soma may then initiate an 
all-or-nothing action potential, which travels down the axon and passes the signal 
on. This action potential is triggered by the axon initial segment (AIS), a dense 
cluster of voltage-gated Na+ channels and anchoring proteins that emanates 
directly from the soma. 
However, a body of evidence collected over the past couple of decades suggests 
that axons can emanate from dendrites rather than the soma in a variety of cell 
types (Figure 3-1), including neuroendocrine cells (Herde et al., 2013), 
dopaminergic neurons (Häusser et al., 1995), interneurons (Martina et al., 2000), 
cortical neurons (Sloper and Powell, 1979; Peters et al., 1968), and hippocampal 
neurons (Lorincz and Nusser, 2010; Thome et al., 2014). In the hippocampus, as 
many as 50% of CA1 pyramidal neurons and 25% of CA3 pyramidal neurons have 
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axons of dendritic origin (DO) rather than axons of somatic origin (SO; (Thome et 
al., 2014)). The majority of these DO axons emanate from a basal dendrite (Thome 
et al., 2014), although ones originating from apical dendrites have also been 
observed (Lorincz and Nusser, 2010). In these neurons, the axon carrying dendrite 
(AcD) holds a privileged position – it is more likely to generate dendritic spikes and 
input into the AcD elicits an action potential at a lower threshold compared to 
normal basal dendrites.   
Apart from the privileged electrical properties of the dendrite carrying them, little 
else is known about the properties of the DO axons themselves. Trafficking of 
axonally polarised cargo to the DO axons is conceivably even more complex since 
cargo must travel along a portion of dendrite before entering the axon rather than 
traveling directly from the soma.  
In preliminary data outlined below, I show that less CB1R traffics to DO axons than 
SO axons. 
 
Figure 3-1 Somatic origin and dendritic origin axons in CA1 pyramidal neurons. 
Schematic of example morphologies of CA1 pyramidal neurons of transgenic mice. Axons (red, white 
arrows) can emanate either from the soma (left) or an axon-carrying dendrite (AcD; right). In this 
example, the authors determined the whole cell morphology by DsRed expression whereas axon 
origin was identified by ankyrin-G labelling indicating the AIS. 
Figure adapted from (Thome et al., 2014) 
 




3.3.1 Exogenous expression of an N-terminally tagged CB1R construct 
in primary hippocampal neurons 
In order to examine the trafficking of CB1R, it was necessary to exogenously 
express a tagged construct of CB1R that faithfully recapitulates the properties of 
endogenous CB1R as closely as possible. Therefore, several aspects needed to 
be considered. Since we are particularly interested in the role that the C-terminus 
plays in the trafficking of CB1R, we used an N-terminally tagged construct rather 
than a C-terminally tagged one to prevent the C-terminal tag from occluding 
potential localisatiosn motifs and/or interfering with potential protein-protein 
interactions important for CB1R trafficking. Indeed, comparisons between C- and 
N-terminally tagged versions of CB1R expressed in HEK293 cells or Neuro2A cells 
indicate that C-terminal tagging interfered with CB1R trafficking, causing a 2-3-fold 
increase in surface expression (Rozenfeld and Devi, 2008). 
However, the N-terminal tail of CB1R is exceptionally long, and its large size, even 
without a tag, impedes its ability to translocate across the ER membrane 
(Nordström and Andersson, 2006; Andersson et al., 2003). Therefore, the addition 
of a 27kDa fluorescent protein might further impede its translocation. For these 
reasons, it is necessary to add an exogenous signal peptide before the fluorescent 
tag in order to achieve stable surface expression (Nordström and Andersson, 
2006; McDonald et al., 2007b; Andersson et al., 2003). 
Moreover, the N-terminal tail of CB1R, like those of other GPCRs, does not contain 
a canonical, cleavable signal peptide. However, CB1R has been reported to 
undergo N-terminal truncation, removing the N-terminal tag (Nordström and 
Andersson, 2006). Therefore, the first 25 amino acids of the N-terminus have 
previously been removed in order to prevent cleavage of the N-terminal tag 
(McDonald et al., 2007b). Interestingly, the first 22 amino acids of the N-terminus 
have subsequently been reported to constitute a mitochondrial targeting motif 
(Hebert-Chatelain et al., 2016). Importantly, while constructs with this type of N-
terminal truncation display impaired trafficking to mitochondria, the trafficking to 
plasma membrane is unaffected (McDonald et al., 2007b; Hebert-Chatelain et al., 
2016). Since this thesis focuses on the plasma membrane trafficking and 
localisation of CB1R, the N-terminal truncation adds the advantage that it 
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circumvents potential complications due to mitochondrial targeting which, although 
of interest, are not the focus of our study. 
A SPHgH-SEP-CB1R (rat) construct, containing a human growth hormone signal 
peptide (SPHgH), a 25 amino acid N-terminal truncation, and an N-terminal 
superecliptic pHluorin (SEP) tag was kindly donated by Dr Andrew Irving (Dundee) 
(McDonald et al., 2007b; a). This construct was subcloned by a previous PhD 
student (Dr Keri Hildick) in the Henley lab into pcDNA3.1 or pSinRep5 for either 
transfection or Sindbis viral transduction of hippocampal neurons, respectively 
(Figure 3-2 A-B). Transfected cells displayed a polarised surface distribution 
analogous to that of endogenous CB1R which was stained using the N-terminal 
rabbit FP1A antibody kindly provided by Professor Ken Mackie (Indiana University; 
Figure 3-2 A upper and middle panels, B). However, the method of transduction 
has an effect on surface localisation – the vast majority of the surface expression 
of Sindbis virally transduced CB1R was non-polarised, presumably due to 
excessive CB1R expression, which might saturate the polarising mechanisms 
(Figure 3-2 A lower panel, B). Therefore, throughout this thesis, primary 
hippocampal neurons were transfected with tagged CB1R, not virally transduced.  
To confirm that the N-terminal truncation does not affect surface localisation, the 
surface expression of a construct lacking the first 25 amino acids (CB1RWT) was 
compared to that of a full, full length CB1R construct (CB1RFFL; Figure 3-3 A). No 
significant difference in surface polarity (axon/dendrite ratio) between EGFP-
CB1RWT and EGFP-CB1RFFL was found (Figure 3-3 B). Indeed, there was no 
significant difference in the surface-to-total expression of axons and dendrites 
between EGFP-CB1RWT and EGFP-CB1RFFL (Figure 3-3 C). Nevertheless, there 
was a non-significant trend towards decreased surface expression of EGFP-
CB1RFFL, especially in axons. However, it cannot be ruled out that this might have 
been due to N-terminal cleavage removing the tag.  
Thus, because it showed a highly similar surface distribution, to avoid loss of the 
tag, and to avoid complications with potential mitochondrial targeting, the N-
terminally truncated form of CB1R was used (named as CB1RWT) to examine the 
trafficking of CB1R throughout this thesis. Any additional deletions/mutations used 
CB1RWT as a template meaning that the changes in trafficking observed were due 
to the additional deletions/mutations, not due to the N-terminal tagging, presence 
of an exogenous signal peptide, or deletion of the first 25 amino acids.  




Figure 3-2 Comparison of endogenous CB1R surface distribution with transfected (SEP-
CB1RTRANSFECT) or virally overexpressed (SEP-CB1RVIRUS) SEP-CB1R in primary hippocampal 
neurons. 
(A) Representative DIV 15 hippocampal neurons analysed by immunocytochemistry to compare 
surface and total receptor distributions for neurons endogenously expressing CB1Rs (top panels; 
FP1A) with neurons expressing SEP-CB1R either by transfection (middle panels) or viral transduction 
(lower panels). SEP-CB1R expressing neurons were either transfected on DIV 12 or virally 
transduced 15 h prior to surface immunostaining with anti-GFP antibody (Roche). Acquisition 
parameters were maintained constant across SEP-CB1RTRANSFECT and SEP-CB1RVIRUS, for direct 
comparison of total expression levels.  
 (B) Quantification of relative percentage of polarize (green) to non-polarized (yellow) SEP-CB1R 
surface distributions observed across experiments (SEP-CB1RTRANSFECT n = 25 neurons; SEP-
CB1RVIRUS n = 30 neurons; n = 4 independent experiments). 
Experiments, figure, and figure legend by Dr Keri Hildick (Hildick, 2013). 




Figure 3-3 Indistinguishable axonal surface polarisation of EGFP-tagged full-length CB1R 
(CB1RFFL) and CB1R lacking the first 25 N-terminal residues (CB1RWT). 
(A) Representative confocal images of surface stained DIV 14 hippocampal neurons expressing 
EGFP-CB1RWT or EGFP-CB1RFFL. Merge: surface to total seen as white. Scale bar = 20 µm. 
(B) Quantification of data shown in (A) presented as surface polarity index (A/D). There was no 
significant difference in surface polarity between EGFP-CB1RWT and EGFP-CB1RFFL. Unpaired t test. 
N = three independent experiments; n = 11 neurons per condition. nsp < 0.05.  
(C) Quantification of data shown in (A). Surface expression of CB1RWT in both axons and dendrites 
was not significantly different to that of CB1RFFL.  Two-way ANOVA with Tukey’s post hoc test. N = 
three independent experiments; n = 11 neurons per condition. nsp < 0.05.  
 
3.3.2 Synchronous forward trafficking of plasma membrane receptors 
using the retention using selective hooks (RUSH) system 
3.3.2.1 Retention using selective hooks (RUSH) 
To investigate how CB1R surface polarity is established we used the retention 
using selective hooks (RUSH) system (Figure 3-4; Figure 3-5) and antibody 
feeding (Figure 3-9) techniques to examine its examine its secretory pathway 
trafficking and surface expression (Boncompain et al., 2012; Evans et al., 2017). 
The layout of the RUSH cloning cassette is shown in (Figure 3-4). Streptavidin is 
expressed and translocated to the endoplasmic reticulum (ER) due to the presence 
of a stromal interaction molecule 1 (STIM-1) signal peptide (SPSTIM-1). It is 
prevented from being secreted due to the addition of a KDEL ER retention peptide 
sequence at the C-terminal end of the protein (Munro and Pelham, 1987; 
Stornaiuolo et al., 2003). The expression of this ER ‘hook’ is driven under a CMV 
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promoter. An IRES insert allows for the expression of the reporter, in this case 
CB1R. The membrane topology of CB1R means that the N-terminus is in the lumen 
of ER. Thus, the reporter is translocated to the ER due to the presence of an 
exogenous interleukin-2 signal peptide (SPIl-2) and an N-terminally located 
streptavidin binding peptide (SBP) tag binds to the ER-located streptavidin, thus 
anchoring it to the ER. Because translation under an IRES sequence is about a 
tenth as efficient as under a CMV promoter (Kaufman et al., 1991; Bouabe et al., 
2008), this ensures a saturating amount of hook and prevents leakage of the 
reporter. The receptor of interest is also N-terminally tagged with a fluorescent 




Figure 3-4 Schematic of the RUSH cloning cassette structure. 
The expression of an ER localised streptavidin-KDEL hook is driven under a CMV promoter. An IRES 
sequence drives expression of the receptor of interest, in this case CB1R, N-terminally tagged with 
SBP, which binds to the streptavidin, thus causing it to be retained in the ER. A fluorescent protein 
tag (here EGFP) allows for detection of the localisation of the reporter. Each section of the reporter 
is flanked by restriction sites, thus allowing flexibility in changes of signal peptides, fluorescent 
proteins, and reporters. Arrows indicate signal peptide cleavage sites. 
 
Thus, in biotin-free media, the SBP-tagged reporter is anchored in the ER by the 
streptavidin-KDEL hook (Figure 3-5 left). The addition of biotin, which has a 
greater affinity for streptavidin than SBP (Keefe et al., 2001), outcompetes the 
hook-reporter interaction and the reporter is synchronously released and trafficked 
by bulk flow through the secretory system to the plasma membrane (Figure 3-5 
right). The progress of the reporter can be monitored by live imaging of the 
fluorescent protein or by fixed immunostaining for SBP and/or EGFP (Evans et al., 
2017).  
3.3.2.2 Validation of RUSH SBP-EGFP-CB1R in HeLa cells 
The N-terminally truncated rat CB1R was cloned into the RUSH cassette by Dr 
Ash Evans (Figure 3-4). Versions with two different fluorescent reporters were 
generated (EGFP or mCherry), depending on the specifications of the confocal 
microscopes used.  
 




Figure 3-5 Schematic of RUSH protocol.  
(1) Before the addition of biotin, SBP-EGFP-CB1R is retained in the ER by a streptavidin-KDEL hook 
(0 min).  
(2) Addition of biotin (orange triangles), which has a higher affinity for streptavidin than SBP, releases 
the receptor from the ER, causing it to traffic through the Golgi Apparatus and accumulate at the 
plasma membrane.  
 
To validate that the RUSH assay was working as expected, RUSH SBP-mCherry-
CB1R was transfected into HeLa cells (Figure 3-6). Biotin was added for 
incrementally longer times before the cells were fixed in 4% formaldehyde in non-
permeabilising conditions and immunostained for SBP present at the surface. 
In the no-biotin condition (0 min), there was generally no SBP detected on the 
surface, indicating that the SBP-mCherry-CB1R was successfully retained in the 
ER. Rarely, the occasional cell that expressed the construct very highly did show 
SBP staining – therefore moderately-expressing cells were chosen for analysis for 
all timepoints. After 25 minutes of biotin-mediated release, SBP staining began to 
be detectable at the surface. Surface SBP-mCherry-CB1R continued to 
accumulate at the surface until 60 minutes, when the accumulation began to 
plateau (Figure 3-6 B). 




Figure 3-6 Validation of RUSH CB1R in HeLa cells. 
(A) Representative confocal images of RUSH SBP-mCherry-CB1R total (red) and surface (magenta) 
localisation in HeLa cells following the addition of biotin for 0 (no biotin), 15, 20, 25, 30, 35, 40, 45, 
60, and 75 minutes. HeLa cells were fixed in non-permeabilizing conditions then surface stained with 
anti-SBP antibody (magenta). At 0 minutes (no biotin), SBP-mCherry-CB1R was retained in the ER. 
Surface labelling began to appear 25 minutes following biotin-mediated release and continued to 
accumulate until it plateaus after about 60 minutes. Scale bar = 20 µm.  
(B) Quantification of data represented in (A). Surface CB1R was normalised to total CB1R. N = 1-4 
independent experiments; n = 40-120 cells per timepoint. One-way ANOVA with Tukey’s post hoc 
test. *p ≤ 0.05, ****p ≤ 0.0001 compared to no biotin control (0 min). 
 
These data indicate that RUSH CB1R is successfully hooked in the ER by the 
streptavidin-KDEL, and that the addition of biotin successfully releases it, allowing 
it to go through the secretory pathway and be delivered to the surface. 
3.3.2.3 CB1R is directly trafficked to the axon by the secretory pathway 
Next, I transfected primary hippocampal neurons with RUSH SBP-EGFP-CB1R 
and added biotin incrementally longer times. At 0 minutes, SBP-EGFP-CB1R was 
retained in the ER and displayed a diffuse somatic localisation. After addition of 
biotin, SBP-EGFP-CB1R trafficked through the secretory pathway and by 15 
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minutes, it was located in bright clusters in the soma, indicating that it was most 
likely located in the somatic Golgi, although co-staining with a Golgi marker would 
be needed to definitively confirm this (Figure 3-7). These bright clusters were still 
present after 25 minutes but were gone by 45 minutes (Figure 3-7). 
 
Figure 3-7 Once released, SBP-EGFR-CB1R progresses through the secretory pathway. 
Representative confocal images of the somatic localisation of SBP-EGFP-CB1R as it goes through 
the secretory pathway. Images are lower exposures of representative neurons and are enlarged post 
acquisition to examine the soma. At 0 min, SBP-EGFP-CB1R was retained in the somatodendritic 
ER. After 15 min, bright clustering of SBP-EGFP-CB1R suggestive of cargo progression to the Golgi. 
This clustering was gone by 45 min. However, co-staining with a Golgi marker such as Giantin would 
be needed to fully confirm that these clusters do, indeed, represent Golgi-based cargo. Scale bar = 
20 µm. 
 
Next, I examined the synchronous trafficking of total SBP-EGFP-CB1R in the 
somatodendritic and axonal compartments of primary hippocampal neurons 
(Figure 3-8). Since the secretory pathway components are only present in the 
soma and proximal dendrites, and axons contain very little, if any, rough ER (rER), 
I first examined the total distribution of CB1R during retention and biotin-mediated 
release between the somatodendritic and axonal compartments. Prior to biotin-
mediated release, SBP-EGFP-CB1R was retained in the ER in the soma and 
proximal dendrites but was absent from the axonal compartment (0 min; Figure 
3-7, Figure 3-8 A, left). Between the different the retention and release timepoints, 
the expression levels of SBP-EGFP-CB1R was identical, as indicated by mean 
total dendritic fluorescence (Figure 3-8 B). In the unretained control (O/N), SBP-
EGFP-CB1R expressed at slightly lower levels, most likely due to the normal 
turnover of the protein when not retained in the ER (Figure 3-8 B).  
 
After 25 minutes, SBP-EGFP-CB1R began to enter the proximal segment of the 
axonal compartment, where it continued to accumulate until 45 minutes when it 
reached its peak. By 30 minutes, the level of SBP-EGFP-CB1R was not 
significantly different from and unretained control (O/N) (Figure 3-8 C) and 
exceeded the average amount of total CB1R present in an average dendrite, 
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indicating a polarised total distribution towards the axons. These data suggest that 
once released from the ER, CB1R was immediately trafficked towards the axonal 
compartment, and passed through the axon initial segment (AIS), which constitutes 
an exclusion and diffusion barrier to separate the axonal from the somatodendritic 
compartments (Leterrier and Dargent, 2014), via the intracellular secretory 
pathway.  
3.3.2.4 De novo CB1R is more rapidly surface expressed in axons than in 
dendrites 
Having established that SBP-EGFP-CB1R released from the ER trafficked directly 
to axons, I next investigated where and when the newly synthesised SBP-EGFP-
CB1R first reaches the plasma membrane. I determined how much SBP-EGFP-
CB1R was surface expressed during a given time period using an antibody feeding 
assay (Figure 3-9). Antibody feeding was performed concurrent with the addition 
of biotin to release ER-retained SBP-EGFP-CB1R. This protocol labels both 
surface expressed CB1Rs and those that have been surface expressed and 
subsequently endocytosed (surface+endocytosed), giving a measure of total 
amount of surface expression irrespective of internalisation. SBP-EGFP-CB1R 
was surface expressed in the proximal segment of axons 40 min after release from 
the ER, whereas in dendrites, CB1R was not surface expressed until 60 min after 
release (Figure 3-10 B; hash signs). Moreover, significantly more SBP-EGFP-
CB1R reached the surface of axons than the surface of dendrites 45, 60, and 90 
min after release from the ER (Figure 3-10 B; asterisks). These data demonstrate 
that the secretory pathway delivers a greater amount of CB1R more rapidly to the 
axonal membrane than to the dendritic membrane. 
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Figure 3-8 Rapid trafficking of newly synthesized CB1R to the axon. 
The trafficking of SBP-EGFP-CB1R following release with biotin was monitored after 0 (no biotin), 
15, 25, 30, 35, 40, 45, 60, 90 min, and overnight (O/N; non-retained control) in DIV 13 hippocampal 
neurons.  
(A) Representative images of hippocampal neurons expressing the RUSH SBP-EGFP-CB1R 
construct without biotin (0 min), 25 min, and 45 min after biotin-mediated release. Without biotin, 
SBP-EGFP-CB1R is anchored in the ER of the somatodendritic compartment and is not detected in 
the proximal 50 µm of axons. 25 min after biotin-mediated release, SBP-EGFP-CB1R entered the 
axon. Upper panels for each condition show whole cell field of view and lower panels are 
enlargements of axonal (a) and dendritic (d) ROIs. Merge: green = total; blue = Ankyrin G. In all 
images the scale bar = 20 µm. 
(B) Quantification of data represented in (A). Analysis of the normalised total dendritic fluorescence 
(average of 2-3 dendrites) indicates that SBP-EGFP-CB1R was expressed equally amongst the 
retained and released timepoints. There is a trend to a decrease in the unretained O/N control that is 
significantly different only from the 0, 60, and 90 timepoints, but not the other timepoints. This is most 
likely due to normal turnover in the unretained control that would not be possible in the retained and 
released timepoints. One-way ANOVA with Tukey’s post hoc test. N = three to six independent 
experiments, n = 19–45 neurons per condition.   
(C) Quantification of data represented in (A). SBP-EGFP-CB1R was initially absent from the axon 
but entered after 25 min and by 30 min, the amount of SBP-EGFP-CB1R in the axon was not 
significantly different from the unretained control (O/N) and had surpassed the amount present in 
dendrites (>1; dotted line). The amount of SBP-EGFP-CB1R in the axon peaked after 45 minutes. 
To measure axonal entry of SBP-EGFP-CB1R, the average fluorescence of the first 50 m of the 
axon was normalised to the average fluorescence of 2-3 dendrites (so that a value of 1 is equal 
amounts in both). One-way ANOVA with Tukey’s post hoc test. N = three to six independent 
experiments, n = 19–45 neurons per condition. **p ≤ 0.01 compared to 0 min; nsp > 0.05 compared 
to O/N. 
 
3.3.2.5 De novo CB1R is retained longer at the surface of axons than of 
dendrites 
It has been suggested CB1R polarity is maintained by differential rates of 
endocytosis in the somatodendritic and axonal compartments (Leterrier et al., 
2006; McDonald et al., 2007a). To test this, we also stained for retained surface 
SBP-EGFP-CB1R at the end of the timepoint by live incubation with Alexa 647-
conjugated chicken anti-GFP (Figure 3-9) and compared the amount of surface 
expressed SBP-EGFP-CB1R to the amount of surface+endocytosed SBP-EGFP-
CB1R in axons (Figure 3-11 A, B) and in dendrites (Figure 3-11 A, C). In the 
proximal segment of axons, the normalised surface and surface+endocytosed 
curves were identical, suggesting that most surface expressed SBP-EGFP-CB1R 
is stable and retained at the axonal membrane (Figure 3-11 B). This may be due 
either to minimal endocytosis or to the efficient recycling of endocytosed receptors. 
In stark contrast, however, in dendrites there is significantly less surface than 
surface+endocytosed SBP-EGFP-CB1R 90 min after addition of biotin, indicating 
that surface expressed CB1R is more rapidly endocytosed from and/or not 
recycled back to the dendritic membrane (Figure 3-11 C). 
 




Figure 3-9 Antibody feeding protocol. 
Numbering is continued from Figure 3-5.  
(3) Antibody feeding with anti-GFP antibodies during biotin-mediated release labels newly delivered, 
surface expressed SBP-EGFP-CB1R.  
(4) A proportion of receptors internalise, still bound to primary antibody.  
(5) Cells are cooled to 4°C to prevent further internalisation. Live secondary antibody incubation 
labels retained surface receptors (indicated by magenta star).  
(6) Cells are then fixed and permeabilised (dotted lines). Incubation with a different secondary 
antibody labels all receptors delivered to the surface during the time course of the experiment (red 








Figure 3-10 Newly synthesized CB1R is preferentially delivered to the axonal surface. 
The trafficking of SBP-EGFP-CB1R following release with biotin was monitored after 0 (no biotin), 
15, 25, 30, 35, 40, 45, 60, 90 min, and overnight (O/N; non-retained control) in DIV 13 hippocampal 
neurons.  
(A) Representative confocal images of total and surface expressed SBP-EGFP-CB1R in DIV 13 
hippocampal neurons 0 min, 40 min, and 90 min after biotin-mediated release showing that SBP-
EGFP-CB1R is preferentially delivered to the axonal surface. Merge: surface+endocytosed to total 
seen as yellow.  
(B) Quantification of data represented in (A). SBP-EGFP-CB1R reached the proximal surface of the 
axon 40 min after release and the surface of dendrites 60 min after release. Furthermore, significantly 
more SBP-EGFP-CB1R reached the axonal versus dendritic surface at 45, 60, and 90 min. Asterisks 
represent **p ≤ 0.01, ****p ≤ 0.0001 comparing axons vs. dendrites. Coloured hash signs represent 
#p ≤ 0.05, ####p ≤ 0.0001 compared to respective 0 min. 
Statistical analyses in (B and Figure 3-11 B-C); Two-way ANOVA with Tukey’s post hoc test (all 
analysed and corrected for multiple comparisons together). N = three to six independent experiments, 
n = 19–45 neurons per condition. 




Figure 3-11 Newly delivered CB1R is preferentially retained at the surface of axons. 
The trafficking of SBP-EGFP-CB1R following release with biotin was monitored after 0 (no biotin), 
15, 25, 30, 35, 40, 45, 60, 90 min, and overnight (O/N; non-retained control) in DIV 13 hippocampal 
neurons.  
(A) Representative confocal images of total and surface expressed SBP-EGFP-CB1R in DIV 13 
hippocampal neurons 60 min and 90 min after biotin-mediated release showing that SBP-EGFP-
CB1R is preferentially retained at the axonal surface, but not at the dendritic surface. Merge: retained 
surface (overlap between surface and surface+endocytosed) is seen as magenta; endocytosed only 
is seen as red. 
(B) Quantification of data represented in (A). Comparison between surface+endocytosed (red; see 
Figure 3-10 B) and surface (magenta) curves show that SBP-EGFP-CB1R was retained on the 
surface of axons. For all p > 0.9999.  
(C) Quantification of data represented in (A). Comparison between surface+endocytosed (pale red; 
see Figure 3-10) and surface (pale magenta) curves show that SBP-EGFP-CB1R was internalised 
from the surface of dendrites. **p ≤ 0.01 comparing 90 min surface+endocytosed and surface. 
Statistical analyses in (Figure 3-10 B and B-C); Two-way ANOVA with Tukey’s post hoc test (all 
analysed and corrected for multiple comparisons together). N = three to six independent experiments, 
n = 19–45 neurons per condition. 
 
 




Figure 3-12 Intracellular trafficking and lateral diffusion to more distal parts of the axon. 
(A) Distribution of total CB1R along the first 100 µm of the axon indicates that CB1R is trafficked 
within the axon. By 30 min after release from the ER, and before CB1R reaches the surface, CB1R 
is present at least 100 µm away from the soma at levels comparable to an unretained control (O/N). 
The blue shaded portion indicates the location of the AIS (defined by Ankyrin-G immunostaining). 
Two-way ANOVA with Sidak’s post hoc test. N = four to six independent experiments, n = 12–18 
neurons per condition. 90–100 µm: *p ≤ 0.05. 90–100 µm comparing 30 min to 0 min, nsp > 0.05 
comparing 30 min to O/N.  
(B) Distribution of surface expressed CB1R along the first 100 µm of the axon shows an accumulation 
of CB1R at the distal region of the AIS 90 min after release from the ER. This accumulation in the 
AIS is reduced in the O/N unretained control consistent with lateral diffusion within the membrane. 
Two-way ANOVA with Sidak’s post hoc test. N = four to six independent experiments, n = 12–18 
neurons per condition. 0–50 µm, 90 min vs. O/N: All points p ≤ 0.05. 50–100 µm, 90 min vs. O/N: All 
points nsp ≥ 0.05. 
 
3.3.2.6 CB1R may be trafficked to more distal parts of the axon via both 
intracellular mechanisms and lateral diffusion. 
Analysis of CB1R total fluorescence along the axon indicates that by 30 min after 
release from the ER, and before CB1R appears on the surface, intracellular CB1R 
has progressed through the AIS and is already present at least 100 µm along the 
axon at levels similar to the unretained control (O/N; Figure 3-12 A). These data 
indicate that CB1R-containing secretory vesicles can rapidly travel to more distal 
areas of the axon. Furthermore, surface CB1Rs delivered from the secretory 
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pathway accumulate at the final portion of the AIS, before then progressing further 
along the axon (Figure 3-12 B). Interestingly, 100 µm along the axon CB1R levels 
reach a steady state 90 min after release, at levels similar to when receptors are 
released overnight. However, following overnight release, fewer receptors remain 
in the most proximal region of the axon. These results suggest that additional 
mechanisms contribute to the delivery of CB1R receptors the distal axon and 
presynaptic boutons. This process occurs over a time-course of several hours and 
could involve lateral surface diffusion and trapping analogous to the accumulation 
of AMPARs at the postsynaptic membrane (Borgdorff and Choquet, 2002). More 
studies would need to be done to elucidate the mechanisms by which CB1R is 
delivered to distal areas of the axon and the presynapse.  
3.3.2.7 SBP-EGFP-CB1R traffics through the canonical secretory pathway 
Since SBP-CB1R-EGFP trafficked very rapidly to the axon, extending to at least 
100 m down the axon and appearing at the axonal surface long before appearing 
at the dendritic surface (Figure 3-12), I wondered whether the faster trafficking to 
the axon was due to axonal CB1R bypassing the Golgi, such as it has been 
reported for Kv2.1 (Jensen et al., 2017). I tested this by adding 10 M Golgicide A 
(Figure 1-14) concurrent to biotin release for 60 minutes (Figure 3-10 B; Figure 
3-13). However, inhibition of the Golgi prevented visible axonal entry of CB1R and 
prevented accumulation of CB1R at the surface of any compartment (Figure 3-13; 
unquantified observation), suggesting that CB1R traffics through the canonical 
secretory pathway to both the somatodendritic and axonal compartments. 
3.3.2.8 Less SBP-EGFP-CB1R is delivered to axons of dendritic origin than 
axons of somatic origin 
Previously, Dr Ash Evans in the lab noticed that when RUSHing SBP-EGFP-GluK2 
significantly less cargo would enter axons of dendritic origin (DO) than those of 
somatic origin (SO). In order to determine whether this might be a generic trend or 
something specific to GluK2, I also compared CB1R axonal delivery between SO 
and DO axons (Figure 3-14). 
Less SBP-EGFP-CB1R entered DO axons than SO axons after both 30 minutes 
and 60 minutes of trafficking (Figure 3-14 A-B). This could, perhaps, be simply 
due to the fact that in order to enter DO axons, cargo has farther to go – along an 
additional section of dendrite – before it reaches the axon and thus simply takes 
more time to get there. However, intriguingly, this difference in axonal entry/polarity 
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is also present in the unretained control (O/N; Figure 3-14 B). This may indicate 
that DO axons have different properties to SO axons. 
Importantly, in all the above and subsequent RUSH experiments, only SO axons 
were analysed to prevent false positive differences due to the number of SO or DO 
axons analysed.  
 
Figure 3-13 SBP-EGFP-CB1R traffics through the canonical secretory pathway. 
Representative images of DIV 13 hippocampal neurons expressing SBP-EGFP-CB1R released for 
60 minutes. Golgicide A was added concurrent to biotin (right-hand panels). In the presence of 
Golgicide A, SBP-EGFP-CB1R does not enter the axon, nor does it reach the surface in any 
compartment. Merge: surface+endocytosed to total seen as yellow.  




Figure 3-14 Less SBP-EGFP-CB1R is delivered to axons of dendritic origin than axons of 
somatic origin. 
The trafficking of SBP-EGFP-CB1R following release with biotin was monitored after 0 (no biotin), 
15, 25, 30, 35, 40, 45, 60, 90 min, and overnight (O/N; non-retained control) in DIV 13 hippocampal 
neurons.  
(A) Representative images hippocampal neurons expressing RUSH SBP-EGFP-CB1R after 60 min 
of biotin-mediated release. Left panels show an axon of somatic origin and right panels show an axon 
of dendritic origin Upper panels for each condition show whole cell field of view and lower panels are 
enlargements of the axon initial segment (AIS) and from where it originates. Merge: green = total; 
blue = Ankyrin G. In all images the scale bar = 20 µm. 
(B) Quantification of data shown in (A). Significantly less SBP-EGFP-CB1R entered the axon 30 and 
60 min after biotin-mediated release. This difference was maintained in the unretained overnight 
control. Two-way ANOVA with Sidak’s post hoc test. N = four to nine independent experiments, n = 
13-41 neurons per condition. *p ≤ 0.05, ***p ≤ 0.001, ****p ≤ 0.0001. 




3.4.1 A two-part model of CB1R polarity 
Our results using RUSH time-resolved analysis show that CB1R surface polarity is 
initially established and maintained by two distinct but complementary mechanisms 
(see Figure 3-15 for summary schematic). Firstly, I show the novel finding that the 
secretory pathway preferentially delivers CB1R to the axonal surface, with 
significantly less going to the dendritic surface. Secondly, by distinguishing 
between surface and surface+endocytosed receptors, the antibody feeding 
experiments show that newly delivered CB1R is preferentially retained/stabilised 
at the axonal membrane and internalised from the dendritic membrane. Previous 
literature proposes that this differential internalisation is due to the presence of 
agonist in the dendritic membrane and absence of agonist on axonal membrane 
(Leterrier et al., 2006; Ladarre and Lenkei, 2017), although a potential role for 
constitutive internalisation distinct to agonist-induced internalisation has also been 
proposed (McDonald et al., 2007a). Taken together, I propose that preferential 
delivery to the proximal segment of the axon and less rapid internalisation of 
axonally surface expressed CB1Rs are major contributors to the axonal surface 
polarisation of CB1R in hippocampal neurons. 
3.4.2 Preferential axonal trafficking 
The Lenkei group has previously reported that CB1R is delivered in a non-polarised 
manner to plasma membrane and is then transcytosed from somatodendritic 
endosomes to distal axon to generate a polarised surface distribution. In particular, 
they presented data from a BFA block showing that 2-4 hours after release from 
the BFA block, the majority of cells examine display either a non-polarised or even 
somatodendritically polarised CB1R surface distribution, with the axonal polarity 
only arising 24 hours post release once transcytosis has occurred (Leterrier et al., 
2006). 
While the data presented above do not exclude the possibility of transcytosis as a 
secondary mechanism to boost axonal polarisation, our results strongly suggest 
that axonal polarisation occurs much earlier than previously described by the 
Lenkei group due to preferential delivery of CB1R by the secretory pathway to 
axons. The discrepancy between my data and data from the Lenkei group may be 
the result of several differences in methods. The genetically targeted RUSH 
approach is a much more precise method than the BFA block which targets the  




Figure 3-15 Schematic summarising the two-part model of CB1R polarity. 
Polarised surface distribution of CB1R is established and maintained by two complementary 
mechanisms: (A) selective delivery of newly synthesized CB1R to the axon (or restricted delivery to 
dendrites) and (B) selective retention in axons and/or selective retrieval from dendrites. 
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secretory system as a whole. The difference in results from the targeted and whole 
block methods may hint at the possibility that the axonal preference of CB1R 
surface expression may require some kind of “chaperone” that needs to have 
passed the secretory pathway already, so that blocking the secretory pathway as 
a whole also interferes with this process, while the more specific CB1R retention 
does not. Furthermore, BFA has been found to affect several other trafficking 
pathways including endocytosis and recycling (Wood et al., 1991; Hunziker et al., 
1991; Damke et al., 1991; Miller et al., 1992; Hunziker et al., 1992; Graham et al., 
1993), which may present other confounding issues. Moreover, the Lenkei group 
used a C-terminally tagged CB1R, thus potentially occluding C-terminal motifs 
required for axonal sorting. 
The microfluidic chamber experiments from the Lenkei group suggests that 
transcytosis is more important for getting CB1R to distal parts of axons (Simon et 
al., 2013). Since I have only examined the initiation of polarisation as measured by 
fluorescence at the first 50 m, it would be intriguing to repeat the microfluidics 
transcytosis experiments in combination with my RUSH experiments in order to 
examine whether transcytosis or direct secretory pathway delivery accounts for the 
majority or the minority of distal axonal CB1R. 
3.4.3 Possible mechanisms behind preferential delivery 
The mechanism behind polarised membrane trafficking in neurons is a 
fundamental question and our data suggest a sorting mechanism at the level of the 
secretory pathway that preferentially targets CB1R to the axon. Since dendritic and 
axonal cargo are synthesized in the somatodendritic compartment, selective 
sorting to the correct domain is crucial. While several sorting signals and adaptors 
have been described for dendritic cargo, the mechanisms behind selective sorting 
to axons are less well known (Lasiecka and Winckler, 2011; Bentley and Banker, 
2016). However, a recent study in C. elegans has suggested that sorting of cargos 
to axons or dendrites depends on binding to different types of clathrin-associated 
adaptor proteins (AP); axonal cargo bind to AP-3 whereas dendritic cargo bind to 
AP-1 (Li et al., 2016). Interestingly, AP-3 has been shown to bind CB1R and an 
siRNA knockdown of AP-3 caused the accumulation of CB1R at the dendritic 
surface of primary hippocampal neurons (Rozenfeld and Devi, 2008). The authors 
attribute this to the canonical role of AP-3 of trafficking from the TGN to the 
lysosome in the dendritic compartment, but also note that neuronal isoforms of AP-
3 are associated with axonal cargo (Rozenfeld and Devi, 2008). 
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One possibility is that CB1R may be sorted by AP-3 to produce the preferential 
delivery to axons. Further studies using RUSH to examine the trafficking of CB1R 
in AP-3 KD hippocampal neurons may shed light on the exact role AP-3 plays in 
CB1R trafficking.  
3.4.4 Trafficking and surface localisation within the axon 
My RUSH experiments measured the transit through the secretory pathway and 
incorporation into, and passage through, the highly organised axon initial segment 
(AIS) that acts as a ‘gate-keeper’ for proteins entering the axonal compartment. 
Our data show that CB1R polarisation was initiated in the first 90 min since they 
were directly targeted to, and surface expressed within, proximal axonal regions. 
Immunocytochemistry in brain sections using immunogold electron microscopy 
(Katona et al., 1999; Nyíri et al., 2005), or STORM super-resolution imaging 
(Dudok et al., 2015) detect CB1R predominantly at the presynaptic terminal, 
consistent with a disto-proximal gradient of expression at the axonal plasma 
membrane (Simon et al., 2013). Therefore, given the highly branched morphology 
of typical CB1R expressing neurons, correct axonal polarisation likely requires 
specific distal targeting mechanisms in addition to the processes we describe using 
time-resolved RUSH experiments. 
CB1Rs are highly mobile and diffuse rapidly in the plasma membrane (Mikasova 
et al., 2008; Oddi et al., 2012), so the accumulation of surface CB1R I observe may 
be followed by lateral diffusion and ‘capture’ of surface CB1R at presynaptic sites, 
analogous to the diffusion and retention models proposed for AMPARs and 
GABAARs at the postsynaptic membrane (Hastings and Man, 2018; Kneussel and 
Hausrat, 2016).  
On the other hand, the observation that intracellular CB1R is present at least 100 
µm along the axon before it appears at the surface (Figure 3-12) supports the 
concept of a rapid and direct trafficking of CB1R-containing secretory vesicles to 
more distal areas of the axon, although more detailed tracking of these secretory 
vesicles to presynaptic boutons would be required to confirm this. It would be 
interesting to RUSH SBP-EGFP-CB1R in hippocampal neurons grown in a 
microfluidic chamber, since the distance travelled along the axon would be slightly 
better controlled, to determine whether SBP-EGFP-CB1R reaches distal axonal 
areas internally in secretory vesicles or through surface diffusion. 
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Overall, we interpret our data to suggest that arrival at, and progression through, 
the AIS constitutes the initial phase of CB1R axonal polarisation. Once within the 
axonal compartment trafficking to more distal locations and to presynaptic sites is 
then mediated by additional mechanisms that probably include both intracellular 
transport and lateral diffusion and trapping. 
3.4.5 Local synthesis and Golgi bypass 
Recent reports suggest that synthesis and trafficking of transmembrane receptors 
can occur through other ways than the canonical somatic rER-to-Golgi stack 
pathway. Transmembrane proteins can be locally synthesized in dendrites 
(Valenzuela and Perez, 2015) and even perhaps in axons (González et al., 2016). 
A proportion of receptors can also bypass the Golgi as revealed by the fact that 
surface receptors can have immature glycosylation profiles (González et al., 2018; 
Hanus et al., 2016). Furthermore, it has been reported that Kv2.1 bypasses the 
Golgi only when proceeding to the axon – blocking the Golgi only prevented Kv2.1 
from accumulating at the somatodendritic membrane, but not at the axonal 
membrane (Jensen et al., 2017). The RUSH assay allowed me to make some 
preliminary observations as to whether CB1R traffics via these non-canonical 
methods. 
Firstly, in the ER retained condition (0 minutes), SBP-EGFP-CB1R was only 
located in the soma and some of the proximal dendrites, but not in the proximal 
segment of the axons (Figure 3-8 A, C). This suggests that CB1R is not locally 
translated in axons. However, it is possible that local translation occurs at more 
distal areas of the axon or at such low levels that it could not be detected. Distal 
areas of the axons were not examined here since, due to the way the experiment 
was set up, it was impossible to trace axons much further than the axon initial 
segment (usually around 50 m) when there was no marker in them.  
Secondly, in some very preliminary and unquantified experiments, I added the 
Golgi transport blocker GCA concurrent to biotin addition for 60 minutes. Unlike 
the 60 minute control, SBP-EGFP-CB1R did not enter the axon or go to the surface 
of the dendrites in the presence of GCA (Figure 3-13), strongly suggesting that 
CB1R does not bypass the Golgi. 
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3.4.6 Dendritic and somatic origin axons 
Previous experiments in the lab suggested that significantly less SBP-EGFP-
GluK2 entered axons of dendritic origin (DO) than those of somatic origin (SO). 
Whether this observation was specific to GluK2 or a generic trend in trafficking was 
unclear. My observation that SBP-EGFP-CB1R also traffics less to DO axons than 
SO axons suggests that this may be a generic property of DO axons.  
This observation makes intuitive sense – CB1R released from the somatic Golgi 
presumably has to travel farther to reach DO axons since it must traverse a section 
of the Golgi. Therefore, it might not be that less cargo enters DO axons, but it just 
enters it more slowly. However, I also found less SBP-EGFP-CB1R in DO axons 
compared to SO axons in the unretained control (O/N). 
Little is known about the properties of DO axons or how/why there are generated, 
apart from the fact that the dendrite carrying the DO axon has preferential effect 
on whether the axon generates an action potential or not. Our data, suggest that 
DO axons may also have different intrinsic properties than SO axons. 
3.5 CONCLUSION 
Overall, this chapter shows provides novel molecular insights into the pattern of 
forward trafficking of CB1R, an axonally polarised cargo, using RUSH.  
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Chapter 4 –   HELIX 9 (H9) REGULATES 
TRAFFICKING OF CB1R 
4.1 AIMS 
• To determine whether the C-terminus of CB1R plays a role (1) selective 
delivery and/or (2) selective retention of axonal CB1R. 
• To determine the role of the C-terminal motif Helix 9 (H9) in CB1R 
trafficking and surface polarisation. 
4.2 INTRODUCTION 
Having determined that CB1R surface polarisation is established and generated 
by (1) selective delivery of newly synthesized CB1R to the axon and (2) selective 
retention of CB1R at the axonal membrane and selective retrieval from the 
dendritic membrane, I next sought to determine by what mechanisms these two 
pathways might occur.  
4.2.1 The C-terminus of CB1R (ctCB1R) 
Surprisingly, a direct role for the 73-residue intracellular C-terminal domain of 
CB1R (ctCB1R) in axonal/somatodendritic trafficking and/or polarised surface 
expression has not been identified (Figure 4-1). It has, however, been reported 
that two serine residues (S426, S430) within ctCB1R are required for receptor 
desensitization and β-arrestin-mediated agonist-induced internalization (Daigle et 
al., 2008a; Mackie, 2008; Hsieh et al., 2002; Jin et al., 1999). Furthermore, two 
ctCB1R interacting proteins, SGIP1 and CRIP1a have been implicated in CB1R 
surface stability (Hájková et al., 2016; Smith et al., 2015; Blume et al., 2017; Mascia 
et al., 2017). Moreover, CB1R palmitoylation at C416 is required for agonist-
induced internalisation (Oddi et al., 2012, 2017, 2018). 
ctCB1 contains two amphipathic putative helical domains: Helix 8 (H8) and Helix 9 
(H9; (Ahn et al., 2009b)). H8 is common to many GPCRs and has been proposed 
to play a role in ER assembly and/or exit during biosynthesis (Stadel et al., 2011; 
Ahn et al., 2010). The role of the 21-residue H9 motif is unknown, although 
analogous regions have been reported to act as a Gαq-binding site in both squid 
rhodopsin (Murakami and Kouyama, 2008) and bradykinin receptors (Piserchio et 
al., 2005).  
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In this chapter, I examine the role of ctCB1R in general, and H9 in particular, on 
the trafficking and surface expression of CB1R. 
 
Figure 4-1 The C-terminus of rat CB1R. 
(A) Amino acid sequence of the C-terminus of rat CB1R highlighting helical motifs (Helix 8 and Helix 
9) predicted from NMR spectroscopy and computational modelling. The proposed interaction 
domains of CRIP1a, SGIP1, and β-arrestin1/2, the palmitoylated cysteine residue involved in 
membrane association and agonist-induced internalisation, and the two serine residues which are 
phosphorylated during desensitisation, are also indicated. A potentially post-translationally modified 
cysteine in H9 is highlighted.  
(B) Schematic diagram of ctCB1RWT and (C) ctCB1RΔH9.   
 
4.2.2 Using CD4 chimeras to identify polarising localisation motifs 
CD4 and CD8 are simple single transmembrane glycoproteins found on the 
surface of T cells. Because of their simplicity, the abundance of N-terminal 
antibodies against them, and the fact that they lack of any intrinsic localisation 
signals in neurons and are therefore surface expressed in a non-polarised manner, 
they have been used in several studies to investigate localisation motifs of 
polarised transmembrane proteins (see (Gu et al., 2003; Fache et al., 2004; Yap 
et al., 2008a; Biermann et al., 2010; Johnson et al., 2018; Frazier et al., 1998; 
Garrido et al., 2001; Bel et al., 2009; Sampo et al., 2003) for examples). In these 
studies, the putative localisation motif of interest is fused to the C-terminus of 
CD4/8 and the localisation of this chimera is compared to CD4/8 alone. This allows 
the putative localisation motif to be examined in isolation from any other localisation 
motifs mechanisms located in the transmembrane protein of interest. 
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I therefore used this strategy to examine the role that ctCB1R and H9 play in 
determining the polarised distribution of CB1R using CD4-ctCB1R chimeras.  
4.2.3 Agonist-induced internalisation and CB1R polarity 
The Lenkei group propose that CB1R surface polarity is due to differences in 
endocannabinoid levels between the somatodendritic and axonal compartments 
(Figure 1-15; (Ladarre and Lenkei, 2017)). This difference is generated because 
the 2-AG synthetic enzyme, DAGLα, is located in the somatondendritic 
compartment, whereas the degradative enzyme, MAGL, is located in the axonal 
compartment (Ladarre et al., 2015). Therefore, they suggest that any CB1R that 
reaches the somatodendritic membrane is immediately activated by the tonal 
presence 2-AG specifically in the somatodendritic membrane and therefore 
undergoes agonist-induced internalisation (Leterrier et al., 2006; Simon et al., 
2013). This model is supported by the fact that, in their hands, application of the 
antagonist/inverse agonist AM281 causes an increase in surface localisation of 
somatodendritic CB1R (Leterrier et al., 2006). 
4.3 RESULTS 
4.3.1 The C-terminus of CB1R, particularly Helix 9 (H9), contributes to 
CB1R surface polarisation. 
To test the role of the C-terminal domain of CB1R (ctCB1R) in CB1R polarisation 
I initially used CD4, a single-pass membrane protein that has no intrinsic 
localisation signals and is normally surface expressed in a non-polarised manner 
(Garrido et al., 2001; Fache et al., 2004). I expressed CD4 alone or chimeras of 
CD4 fused to either ctCB1RWT (Figure 4-1 B; Figure 4-2 A) or a ctCB1R lacking 
the H9 domain (ctCB1RΔH9; Figure 4-1 C; Figure 4-2 A). I expressed these in 
hippocampal neurons and examined surface and total expression distributions by 
immunostaining with an N-terminal CD4 antibody (clone OKT4; Figure 4-2 B-E). 
In this way, I could examine the contribution of the C-terminus as a whole, and H9 
in particular, to the polarised distribution of CB1R in the absence of any other 
potential localisation signals on intracellular loops and, importantly, without the 
effect that agonist activation may have on trafficking. 
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Figure 4-2 The C-terminal domain of CB1R, especially the Helix 9 motif, plays a role in axonal 
polarisation. 
(A) Schematic of the CD4-ctCB1R chimeric proteins used.  
(B) Representative confocal images of hippocampal neurons showing the distribution of expressed 
CD4 (left), CD4-ctCB1RWT (middle), or CD4-ctCB1RΔH9 (right). Upper panels for each condition show 
a whole cell field of view and lower panels are enlargements of axonal (a) and dendritic (d) ROIs. 
Green = total; magenta = surface; blue = dendrite marker (MAP2). Merge: surface to total seen as 
white. Scale bar = 20 µm.  
(C) Quantification of data represented in (B) presented as the total polarity index (A/D ratio). Total 
CD4-ctCB1RWT strongly favoured the axonal compartment compared to CD4 alone. CD4-
ctCB1RΔH9 showed no bias towards the axonal compartment and was identical to CD4 alone. 
Kruskal-Wallis test with Dunn’s post hoc test (WT was strongly non-parametric). N = six independent 
experiments; n = 52–59 neurons per condition. Pooled with data from Figure 4-3. 
(D) Quantification of data represented in (B) presented as the surface polarity index (A/D ratio). CD4-
ctCB1RWT strongly favoured the axonal compartment compared to CD4 alone. CD4-
ctCB1RΔH9 favoured the axonal compartment significantly less than CD4-ctCB1RWT. One-way 
ANOVA with Tukey’s post hoc test. N = three independent experiments; n = 28–33 neurons per 
condition.   
(E) Quantification of data represented in (B) presented normalised surface-to-total ratios (CD4 Axons 
= 1) for axons and dendrites. CD4-ctCB1RWT and CD4-ctCB1RΔH9 displayed a significantly more 
internal distribution compared to CD4 alone. This may be due to either increased internalisation or 
decreased forward trafficking. Two-way ANOVA with Tukey’s post hoc test. N = three independent 
experiments; n = 28–33 neurons per condition.  
 
Firstly, I examined the total distribution of the CD4 chimeras (the total polarity index 
= (mean fluorescence of axon)/(average mean fluorescence of 3-4 dendrites)). 
Intriguingly, CD4-ctCB1RWT was markedly more axonally polarised than CD4 alone 
(Figure 4-2 B), suggesting that ctCB1R, despite its lack of defined canonical 
localisation signals, contains some motif(s) that direct axonal sorting. Indeed, the 
CD4-ctCB1RΔH9 chimera did not show a polarised  total distribution (Figure 4-2 B), 
suggesting that H9 constitutes that sorting motif.  
Analysis of the surface polarity index (A/D ratio) revealed that CD4-ctCB1RWT was 
also markedly more axonally surface polarised than CD4 alone (Figure 4-2 C), 
further indicating that ctCB1R may play a role in polarisation. Nevertheless, this 
polarisation was not complete and there was still CD4-ctCB1RWT detectable on the 
dendritic membrane. This suggests that either other localisation motifs or agonist-
induced internalisation (Leterrier et al., 2006) is required for full polarisation. 
However, in agreement with the total polarisation results, the degree of surface 
polarisation was significantly lower for CD4-ctCB1RΔH9 than CD4-ctCB1RWT. 
Intriguingly, however, CD4-ctCB1RΔH9 was still significantly more axonally surface 
polarised than CD4 alone (Figure 4-2 C).  
Compared to CD4, both CD4-ctCB1RWT and CD4-ctCB1RΔH9 were less surface 
expressed (surface-to-total ratio) to equal degrees (Figure 4-2 D). Whether this 
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more internal distribution could be due to increased internalisation or less forward 
trafficking (the CD4 control does not have a C-terminus at all, meaning that it is 
possible it traffics very rapidly to the surface) cannot be distinguished in this 
experiment. 
Therefore, I next analysed constitutive endocytosis of CD4-ctCB1RWT and CD4-
ctCB1RΔH9 by ‘feeding’ with anti-CD4 antibody for 2 hours, followed by a harsh 
stripping of surface antibody using two washes in 0.5 M NaCl and 0.2 M acetic acid 
at pH 3.5 (Figure 4-3 A-B). My data indicate that H9 does not determine surface 
polarity by driving differential constitutive endocytosis from either the dendritic or 
axonal membrane since there was no difference between the internalisation of 
CD4-ctCB1RWT or CD4-ctCB1RΔH9. However, both CD4-ctCB1RWT and CD4-
ctCB1RΔH9 were significantly more internalised than CD4 alone in dendrites, but 
not in axons (Figure 4-3).  
These results suggest that a C-terminal domain other than H9 promotes 
constitutive, but reportedly not activity-dependent (McDonald et al., 2007a) 
internalisation in dendrites but not in axons. Moreover, it provides an explanation 
for why CD4-ctCB1RΔH9 surface polarity index does not return to the same level of 
CD4 like the total polarity index – the increased internalisation in dendrites 
increases the surface polarity index. 
Importantly, however, because this increase in internalisation in identical between 
CD4-ctCB1RWT and ctCB1RΔH9, this endocytic mechanism does not account for 
the failure of CD4-ctCB1RΔH9 to surface polarise to the level of CD4-ctCB1RWT. 
Since CD4-ctCB1RWT and CD4-ctCB1RΔH9 chimeras cannot bind agonist, these 
results are consistent with ctCB1R contributing to constitutive polarisation via a 
mechanism distinct from the proposed continuous activation of CB1R by the 
presence of the endogenous agonist 2-AG in the dendritic membrane (Ladarre and 
Lenkei, 2017). Thus, our data demonstrate that ctCB1R, particularly H9, 
contributes to the constitutive preferential delivery of CB1R to the axonal 
membrane. 




Figure 4-3 the C-terminal domain of CB1R plays a role in constitutive internalisation in 
dendrites independent of H9. 
(A) Representative confocal images of DIV 14 primary hippocampal neurons expressing CD4ΔCT (left), 
CD4-ctCB1RWT (middle), or CD4-ctCB1RΔH9 (right). Neurons were subjected to 2 hr of antibody 
feeding followed by stripping of surface antibody to reveal the endocytosed pool of receptors. Upper 
panels for each condition show a whole cell field of view and lower panels are enlargements of axonal 
(a) and dendritic (d) ROIs. Green = total; red = endocytosed; blue = dendritic marker (MAP2). Merge: 
endocytosed to total seen as yellow. Scale bar = 20 µm.  
(B) Quantification of data presented in (A). Both CD4-ctCB1RWT and -ctCB1RΔH9 were significantly 
more internalised in dendrites, but not in axons, than CD4 alone. N = three independent experiments; 
n = 24–26 neurons per condition. Two-way ANOVA with Sidak’s post hoc test.  
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4.3.2 H9 plays a role in the forward trafficking of CB1R  
The CD4 chimera experiments indicate that the H9 motif is involved in CB1R 
trafficking and axonal polarity. Therefore, I next used the RUSH assay to compare 
the dynamics of forward trafficking of SBP-EGFP-CB1RWT and SBP-EGFP-
CB1RΔH9 in a time-resolved manner (Figure 4-4).  
4.3.2.1 H9 plays contributes to, but is not essential for, axonal entry of CB1R 
Since CD4-ctCB1RΔH9 displayed a dramatic loss of total polarity compared to CD4-
ctCB1RWT (Figure 4-2), I examined the dynamics of total SBP-EGFP-CB1RΔH9 in 
to axons (Figure 4-5 A). SBP-EGFP-CB1RΔH9 entered axons at a slower rate than 
SBP-EGFP-CB1RWT – there was significantly less axonal expression after 30 
minutes and 60 minutes of biotin-mediated release (Figure 4-5 A). However, by 
90 minutes, the level of axonal CB1R was the same between the WT and mutant 
CB1R. These data suggest that while H9 may be involved in total delivery to axons, 
there other mechanisms outside of ctCB1R that can compensate when H9 is 
removed. 
It is important to note that there was no difference in total dendritic expression 
between WT and ΔH9 or between the four timepoints (Figure 4-5 B). This control 
indicates that the expression of the RUSH construct was the same for all 
conditions. Because total dendritic expression did not vary over time or mutation, 
every measure (including total axonal expression) was normalised to the dendritic 
total to control for variation in expression between neurons within conditions. 
4.3.2.2 H9 restricts delivery of CB1R to the dendritic membrane 
I next compared the delivery of SBP-EGFP-CB1RWT to that of SBP-EGFP-
CB1RΔH9 to the surface of axons and dendrites 0, 30, 60, and 90 min after biotin-
mediated release from the ER. As explained in Chapter 3, this 
surface+endocytosed parameter measures all the CB1R that had been surface 
expressed, regardless of whether it has subsequently been internalised.  
There was no difference in the amount of CB1R delivered to the surface of axons 
between SBP-EGFP-CB1RΔH9 and SBP-EGFP-CB1RWT  (Figure 4-5 C).  




Figure 4-4 The trafficking of SBP-EGFP-CB1RWT was compared to that of SBP-EGFP-CB1RΔH9 in a time resolved manner using RUSH. 
Representative confocal images of hippocampal neurons expressing SBP-EGFP-CB1RWT or SBP-EGFP-CB1RΔH9 0 (no biotin), 30, 60, and 90 min after release with biotin. Upper 
panels for each condition show whole cell field of view and lower panels are enlargements of axonal (a) and dendritic (d) ROIs. Green = total; red = surface + endocytosed; 
magenta = surface; blue = axon marker (Ankyrin-G). Merge: surface to total seen as white; endocytosed to total seen as yellow. Scale bar = 20 µm. 




Figure 4-5 H9 both restricts delivery of CB1R to the dendritic membrane and plays a role in 
surface retention of CB1R. 
Quantification of data shown in Figure 4-4. A-D, F-G: Two-way ANOVA with Sidak’s post hoc test. 
N = three to seven independent experiments, n = 26–63 neurons per condition. E, H: N = four 
independent experiments, n = 26–31 neurons per condition. Unpaired t-test. 
(A) Time-resolved analysis of total axonal CB1R fluorescence (normalised to total dendrite 
fluorescence) indicates that SBP-EGFP-CB1RΔH9 entered the axon at a slower rate than SBP-EGFP-
CB1RWT. However, by 90 min there was no significant difference in axonal total fluorescence between 
WT and ΔH9. 
(B) Quantification of the total dendritic fluorescence confirms equal expression levels of SBP-EGFP-
CB1R between timepoints and between WT vs. ΔH9. 
(C) Time-resolved analysis of surface+endocytosed receptors shows no difference between SBP-
EGFP-CB1RWT and SBP-EGFP-CB1RΔH9 in reaching the surface of the axon.  
(D) Time-resolved analysis of surface+endocytosed receptors shows significantly more SBP-EGFP-
CB1RΔH9 reached the surface of dendrites than SBP-EGFP-CB1RWT, indicating that H9 may play a 
role in restricting delivery to the dendritic surface.  
(E) Analysis of surface+endocytosed polarity index (A/D) demonstrates a defect in polarised delivery 
of SBP-EGFP-CB1RΔH9 compared to SBP-EGFP-CB1RWT. 
(F) Time-resolved analysis of surface receptors shows significantly less SBP-EGFP-CB1RΔH9 than 
SBP-EGFP-CB1RWT on the surface of axons 90 min after release, most likely due to increased 
endocytosis of the ΔH9 mutant.  
(G) Time-resolved analysis of surface receptors shows significantly less SBP-EGFP-CB1RΔH9 than 
SBP-EGFP-CB1RWT on the surface of dendrites 60 and 90 min after release, most likely due to 
increased endocytosis of the ΔH9 mutant. 
(H) Analysis of surface polarity index (A/D) revealed no difference between SBP-EGFP-CB1RWT and 
SBP-EGFP-CB1RΔH9.  
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Interestingly, however, significantly more SBP-EGFP-CB1RΔH9 than SBP-EGFP-
CB1RWT reached the surface of dendrites after 60 and 90 minutes of ER release 
(Figure 4-5 D). This altered profile of delivery resulted in a significant difference in 
the surface+endocytosed polarity index after 90 min (the latest timepoint 
measured; Figure 4-5 E) similar to the difference in surface polarity observed in 
the CD4 chimera experiment (Figure 4-2). These data indicate that H9 plays a role 
in restricting secretory pathway delivery of CB1R to the dendritic membrane. 
4.3.2.3 H9 plays a role in the surface retention of CB1R 
Surprisingly, in contrast to the total amount of CB1R that had been surface 
expressed during the time course (surface+endocytosed; Figure 4-5 E), the 
polarity of the amount of CB1R on that remained on the cell surface 90 min after 
biotin-mediated release was identical for SBP-EGFP-CB1RWT and SBP-EGFP-
CB1RΔH9 (surface; Figure 4-5 H). Closer analysis dissecting what occurs at axons 
vs. dendrites revealed identical levels of axonal surface expression of both SBP-
EGFP-CB1RWT and SBP-EGFP-CB1RΔH9 60 min after release from the ER. 
However, at 90 min there is significantly less surface expression of ΔH9 mutant 
(Figure 4-5 F) suggesting that, although similar amounts of SBP-EGFP-
CB1RWT and SBP-EGFP-CB1RΔH9 reach the surface, surface expression of SBP-
EGFP-CB1RΔH9 is less stable than that of the wild-type. Furthermore, in dendrites, 
the increased delivery and surface trafficking of the ΔH9 mutant is counteracted by 
the fact that less is retained at the surface 60 min and 90 min after ER release 
(Figure 4-5 G).  
Taken together these results suggest that, separate from its role in restricting 
delivery to the dendritic membrane, H9 also plays a role in membrane stability and 
retention at both axons and dendrites. 
The lack of effect of deleting H9 on surface CB1R polarity is inconsistent with the 
CD4 chimera data. This may indicate that other regions of CB1R may play a role 
in its localisation. It also suggests the possibility that agonist-induced activation 
may be affected by H9 deletion. 
4.3.3 H9 stabilises CB1R at the surface 
To investigate the role of H9 in membrane stability and surface polarity, I next 
compared surface expression of EGFP-CB1RWT and EGFP-CB1RΔH9 in axons and 
dendrites at steady-state. To do this, I cloned the entire SPIl-2-SBP-EGFP-
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CB1RWT/ΔH9 cassette out of the RUSH construct (Figure 3-4) and into pcDNA3.1, 
transfected the constructs into primary hippocampal neurons, and surface stained 
with anti-GFP antibody after 48 hours (Figure 4-6 A).  
EGFP-CB1RΔH9 displayed lower levels of surface expression in both axons and 
dendrites (Figure 4-6 B) resulting in no difference in either surface polarity (Figure 
4-6 C) or total polarity (Figure 4-6 D) compared to EGFP-CB1RWT.  
 
Figure 4-6 H9 stabilises CB1R at the surface. 
(A) Representative confocal images of surface stained DIV 14 hippocampal neurons expressing 
EGFP-CB1RWT or EGFP-CB1RΔH9. Green = total; magenta = surface; blue = axon marker (Ankyrin-
G). Merge: surface to total seen as white.  
(B) Quantification of data shown in (A). Surface expression of EGFP-CB1RΔH9 in both axons and 
dendrites was significantly reduced compared to EGFP-CB1RWT. Two-way ANOVA with Tukey’s post 
hoc test. N = ten independent experiments; n = 80–88 neurons per condition. Experiments include 
pooled results from Vehicle controls of Figure 4-9 and Figure 4-10. 
(C) Quantification of data shown in (A) presented as the surface polarity index. There was no 
difference in surface polarity between EGFP-CB1RWT or EGFP-CB1RΔH9. Mann-Whitney test. 
N = ten independent experiments; n = 80–88 neurons per condition. Experiments include pooled 
results from Vehicle controls of Figure 4-9 and Figure 4-10. 
(D) Quantification of data shown in (A) presented as the total polarity index. There was no difference 
in total polarity between EGFP-CB1RWT or EGFP-CB1RΔH9. Mann-Whitney test. N = fourteen 
independent experiments; n = 107-117 neurons per condition. Experiments include pooled data from 
Vehicle controls of Figure 4-7, Figure 4-9, and Figure 4-10. 
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4.3.4 H9 prevents CB1R internalisation 
To investigate the role of H9 in membrane stability, I next compared internalisation  
of EGFP-CB1RWT and EGFP-CB1RΔH9 in axons and dendrites at steady-state (i.e. 
non-RUSH; Figure 4-7). To do this, I fed with anti-GFP antibody for 2 hours, then 
stripped off surface antibody to only label the endocytosed pools.  
EGFP-CB1RΔH9  displayed increased endocytosis in both axons and dendrites 
compared to EGFP-CB1RWT (Figure 4-7 A-B), consistent with the decrease of 
surface expression observed in both axons and dendrites (Figure 4-6). These data 
suggest H9 plays a role in stabilising CB1R at the surface of both axons and 
dendrites.  
 
Figure 4-7 H9 prevents internalisation in both axons and dendrites. 
(A) Representative confocal images of DIV 14 primary hippocampal neurons expressing EGFP-
CB1RWT or EGFP-CB1RΔH9. Neurons were subjected to 2 hr of antibody feeding with anti-GFP 
antibody followed by stripping off of surface antibody to reveal the endocytosed pool of receptors. 
Green = total; red = endocytosed; blue = axon marker (Ankyrin-G). Merge: endocytosed to total seen 
as yellow.  
(B) Quantification of data shown in (A). Endocytosis of EGFP-CB1RΔH9 is significantly increased 
compared to EGFP-CB1RWT in both axons and dendrites. Two-way ANOVA with Tukey’s post 
hoc test. N = seven independent experiments; n = 49 neurons per condition.  
 




Figure 4-8 CB1RΔH9 is less efficient at activating the downstream signalling pathways. 
(A) Representative blots showing ERK1/2 phosphorylation in HEK293T cells expressing EGFP-
CB1RWT or EGFP-CB1RΔH9 following vehicle (0.1% EtOH) or ACEA (1 μM) treatment for 5 min after 
overnight serum starvation.  
(B) Quantification of data shown in (A). Following treatment with ACEA, ERK1/2 was significantly 
more phosphorylated in EGFP-CB1RWT- and EGFP-CB1RΔH9-transfected cells compared to 
untransfected cells. However, ERK1/2 activation was significantly reduced in EGFP-CB1RΔH9-
expressing cells compared to EGFP-CB1RWT-expressing cells. There was no significant difference 
in ERK1/2 phosphorylation in vehicle-treated cells. Two-way ANOVA with Tukey’s post hoc test. 
N = three independent experiments.  
(C) Quantification of data shown in (A). EGFP-CB1RWT and EGFP-CB1RΔH9 expressed equally in 
HEK293T cells. Two-way ANOVA with Sidak’s post hoc test. Three independent experiments.  
(D) Representative immunoblots from surface biotinylation experiments showing surface and total 
fractions of EGFP-CB1RWT and EGFP-CB1RΔH9 in HEK293T cells.  
(E) Quantification of data shown in (D). EGFP-CB1RWT and EGFP-CB1RΔH9 were surface expressed 
at equivalent levels in HEK293T cells. Unpaired t-test. Eight independent experiments.  
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4.3.5 CB1RΔH9 is less efficient at activating downstream signalling 
pathways  
Because CB1R surface expression and polarisation has been linked to its activity 
(Leterrier et al., 2006; Ladarre et al., 2015), I investigated if deleting H9 affects 
CB1R downstream signalling pathways. Measuring the signalling efficiency of 
EGFP-CB1RΔH9 in neurons would require the complete removal of endogenous 
CB1R. However, HEK293T do not express endogenous CB1R (Atwood et al., 
2011) and are routinely used to measure activation of the ERK pathway. I 
expressed EGFP-CB1RWT, EGFP-CB1RΔH9, or empty vector in HEK293T cells and 
treated with vehicle (EtOH) or stimulated with the selective CB1R agonist ACEA 
(arachidonyl-2'-chloroethylamide) (Hillard et al., 1999) and blotted for ERK1/2 
phosphorylation as a measure of downstream signalling of CB1R (Daigle et al., 
2008a).  
There was no significant difference in ERK1/2 phosphorylation in cells expressing 
EGFP-CB1RWT, EGFP-CB1RΔH9, or empty vector under basal conditions in the 
absence of ACEA. Upon ACEA stimulation, ERK1/2 phosphorylation increased 
significantly in both EGFP-CB1RWT and -CB1RΔH9 transfected cells (Figure 4-8 A-
C). However, the level of ERK1/2 activation were significantly less in EGFP-
CB1RΔH9-transfected cells compared to EGFP-CB1RWT-transfected cells 
expressing equivalent amounts of receptor (Figure 4-8 A-C).  
Because the ΔH9 mutant is more internalised than the wild-type in neurons, I 
examined whether the deficiency in ERK1/2 phosphorylation was due to a similarly 
reduced surface expression in HEK283T cells. However, EGFP-CB1RWT and 
EGFP-CB1RΔH9 were surface expressed at equivalent levels in HEK293T cells, as 
determined by surface biotinylation experiments (Figure 4-8 D-E), suggesting the 
ΔH9 mutant is deficient in its ability to activate this downstream signalling pathway. 
4.3.6 CB1RΔH9 is more susceptible to agonist-induced internalisation 
I next monitored ACEA-induced internalisation of EGFP-CB1RWT and EGFP-
CB1RΔH9 in axons of hippocampal neurons (Figure 4-9 A). ACEA-induced 
internalisation of EGFP-CB1RΔH9 was significantly greater than that observed for 
EGFP-CB1RWT in axons (Figure 4-9 B). Taken together, these data indicate that 
CB1RΔH9 is less stable at the axonal surface under basal conditions and that it is 
more susceptible to agonist-induced internalisation. 




Figure 4-9 Role of H9 in resisting agonist-induced endocytosis. 
(A) Representative confocal images of DIV 14 hippocampal neurons expressing EGFP-CB1RWT or 
EGFP-CB1RΔH9 and treated with vehicle (0.1% EtOH) or CB1R agonist (5 μM ACEA) for 3 hrs. Upper 
panels for each condition show whole cell field of view and lower panels are enlargements of axonal 
(a) and dendritic (d) ROIs. Green = total; magenta = surface; blue = axon marker (Ankyrin-G). Merge: 
surface to total seen as white.  
(B) Quantification of data represented in (A). Significantly less EGFP-CB1RΔH9 than EGFP-CB1RWT 
remained on the surface of axons after agonist application, indicating greater sensitivity to agonist-
induced internalisation. The surface mean fluorescence was first normalised to the total mean 
fluorescence for each ROI, then to the average axonal EtOH value within a condition (set to 100%). 
Unpaired t-test. N = three independent experiments; n = 23–24 neurons per condition. 
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4.3.7 The role of H9 in polarity is revealed in the presence of inverse 
agonist 
My data indicate that ctCB1R, and the H9 domain in particular, can determine the 
surface and total polarity of a CD4 chimera (Figure 4-2), and promote polarised 
surface delivery of CB1R (Figure 4-5). In contrast, deletion of H9 has no effect on 
CB1R surface polarity at steady state (Figure 4-6). However, deletion of H9 does 
have a striking effect on the surface stability of CB1R with CB1RΔH9 being less 
surface expressed in both axons and dendrites and displaying increased 
endocytosis (Figure 4-6, Figure 4-7). Furthermore, CB1R ΔH9 is more responsive 
to agonist-induced internalisation (Figure 4-9). 
I therefore wondered whether the difference between the CD4 chimeras and the 
full-length receptor and between surface+endocytosed and surface polarity may 
be attributable to the agonist binding capability of the full-length receptor. To test 
this, I used the CB1R-specific inverse agonist AM281 to prevent the receptor 
entering an active conformation and which has previously been shown to increase 
somatodendritic surface expression similar to treatment with an endocytosis 
inhibitor (Leterrier et al., 2006). I reasoned that AM281 might reveal a difference in 
surface polarity between EGFP-CB1RWT and EGFP-CB1RΔH9, like that observed 
with the CD4 chimeras and in surface+endocytosed polarity. 
In hippocampal neurons treated with the DMSO control both EGFP-CB1RWT and 
EGFP-CB1RΔH9 displayed similar levels of surface polarity (Figure 4-10 A-B). In 
the presence of AM281, however, EGFP-CB1RΔH9 had significantly reduced 
surface polarity compared EGFP-CB1RWT (Figure 4-10 B). This was due to a 
significantly increased dendritic surface expression (Figure 4-10 C). These data 
indicate that the increased dendritic delivery that occurs in EGFP-CB1RΔH9 is offset 
and ‘masked’ by the increase in agonist-induced endocytosis. 
Next, I examined more closely what happens in axons and dendrites during AM281 
application. Axons: Consistent with the above results, with Vehicle treatment 
(DMSO), the ΔH9 mutant was less surface expressed than WT in axons (Figure 
4-10 D black asterisks). This difference was reversed upon AM281 incubation, 
where there was no significant difference in axonal surface expression between 
WT and ΔH9 after AM281 incubation (Figure 4-10 D black asterisks). This 
increase was due to significantly enhanced surface expression during AM281 
treatment for ΔH9 that did not occur in WT (Figure 4-10 D coloured asterisks). 
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Figure 4-10 The role of H9 in polarity is revealed in the presence of inverse agonist. 
(A) Representative confocal images of DIV 14 hippocampal neurons expressing EGFP-CB1RWT or 
EGFP-CB1RΔH9 and treated with vehicle (0.2% DMSO) or CB1R inverse agonist (10 µM AM281) for 
3 hr. Upper panels for each condition show whole cell field of view and lower panels are enlargements 
of axonal (a) and dendritic (d) ROIs. Green = total; magenta = surface; blue = axon marker (Ankyrin-
G). Merge: surface to total seen as white.  
(B) Quantification of data shown in (A) presented as the surface polarity index (A/D ratio). In the 
presence of inverse agonist, but not vehicle, EGFP-CB1RΔH9 was significantly less axonally polarised 
than EGFP-CB1RWT. Two-way ANOVA with Sidak’s post hoc test.  
(C) Quantification of data represented in (A). Significantly more EGFP-CB1RΔH9 than EGFP-
CB1RWT relocated to the surface of dendrites after inverse agonist application. The surface mean 
fluorescence was first normalised to the total mean fluorescence for each ROI, then to the average 
DMSO value within a condition (set to 100%). Unpaired t-test. N = three independent experiments; 
n = 18–19 neurons per condition. 
(D) Quantification of data represented in (A). In axons, inverse agonist application reversed the 
reduced surface expression phenotype of EGFP-CB1RΔH9 compared to EGFP-CB1RWT. There is no 
significant increase in surface expression with inverse agonist application in to EGFP-CB1RWT. The 
surface mean fluorescence was normalised to the total dendritic mean fluorescence for each neuron. 
Two-way ANOVA with Sidak’s post hoc test. Coloured asterisks = DMSO vs. AM281; black asterisks 
= WT vs. ΔH9. 
(E) Quantification of data represented in (A). In dendrites, inverse agonist application reversed the 
reduced surface expression phenotype of EGFP-CB1RΔH9 compared to EGFP-CB1RWT (non-
significant trend). There is a non-significant trend to increased surface expression in dendrites for 
ΔH9 compared to WT after inverse agonist treatment. There is no significant increase in surface 
expression with inverse agonist application in to EGFP-CB1RWT. The surface mean fluorescence was 
normalised to the total dendritic mean fluorescence for each neuron. Two-way ANOVA with Sidak’s 
post hoc test. Coloured asterisks = DMSO vs. AM281; black asterisks = WT vs. ΔH9. 
(F) Quantification of data represented in (A). In axons, inverse agonist application increased the total 
amount of receptor for both EGFP-CB1RWT and EGFP-CB1RΔH9. The total mean fluorescence was 
normalised to the total dendritic mean fluorescence for each neuron. Two-way ANOVA with Sidak’s 
post hoc test. Coloured asterisks = DMSO vs. AM281; black asterisks = WT vs. ΔH9. 
(G) Quantification of data represented in (A). No difference in total dendritic fluorescence confirms 
equal expression levels of SBP-EGFP-CB1R between WT vs. ΔH9 and DMSO vs. AM281. Because 
it was the only measure that stayed constant, all the above parameters were normalised to total 
dendritic fluorescence. Two-way ANOVA with Sidak’s post hoc test.  
 
These data indicate that the phenotype of reduced surface expression (Figure 4-6) 
and increased internalisation (Figure 4-7) in axons in the ΔH9 mutant is due to an 
increased sensitivity to, and thus increased levels of, agonist-induced endocytosis 
(Figure 4-9). 
Dendrites: Interestingly, a similar profile also occurs in the dendrites. In this case, 
with vehicle treatment, the reduced surface expression of ΔH9 was a non-
significant trend (Figure 4-10 E). AM281 treatment significantly increased dendritic 
surface expression of ΔH9, but not of WT (Figure 4-10 E coloured asterisks) so 
that under AM281 treatment, the non-significant trend went the other way – there 
was a trend to more dendritic surface CB1R for ΔH9 than for WT.  
These data indicate that the phenotype of reduced surface expression (Figure 4-6) 
and increased internalisation (Figure 4-7) in dendrites of the ΔH9 mutant is due to 
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an increased amount of agonist-induced endocytosis. Furthermore, the trend 
towards an increased dendritic surface expression after AM281 treatment reveals 
the increased delivery of EGFP-CB1RΔH9 to the dendritic surface as seen in 
(Figure 4-5). 
Lastly, AM281 treatment increased the amount of total CB1R in axons in both WT 
and ΔH9 conditions (normalised to dendrite total; Figure 4-10 F coloured 
asterisks).  
Importantly, total levels of CB1R in dendrites remained the same over all conditions 
(Figure 4-10 G). Because this was the only parameter that remained constant 
throughout all of the conditions, the data in C-F were all normalised to dendrite 
total for each cell to control for within-condition variation in expression (rather than 
surface expression being normalised to total expression for each ROI).  
These results indicate that in the absence of constitutive activity of the receptor, H9 
plays a role in mediating CB1R surface polarity, because H9 restricts delivery of 
CB1R to the dendritic surface. Furthermore, these data suggest that the increased 
internalisation observed both dendrites and in axons with H9 deletion may be 
mediated by the presence of endogenous agonist and reaffirm the importance of 
the neuronal milieu on CB1R trafficking. 
4.4 DISCUSSION 
4.4.1 Summary of results 
The data presented in this chapter demonstrate that ctCB1R in general, and 
especially the H9 motif, is important for generating and maintaining axonal surface 
polarity (summarised in Figure 4-11). In Chapter 3, I identified a two-part model of 
CB1R polarisation (Figure 3-15). In the present chapter, I show that H9 plays a 
role in both the 1) preferential delivery and 2) selective retention of CB1R at the 
axonal membrane. I show that deleting H9 (CB1RΔH9) causes 1) an increase in 
secretory pathway delivery to dendrites, and 2) a reduction surface retention in 
both the dendrites and axons (Figure 4-4; Figure 4-5), resulting, at steady-state, 
in decreased surface expression (Figure 4-6) and increased internalisation 
(Figure 4-7) of the mutant compared to WT. In both dendrites and axons, the 
reduced surface retention is due to increased susceptibility to agonist-induced 
internalisation (Figure 4-9) as revealed by the fact that incubation with AM281, an 
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inverse agonist, reverses the reduced surface retention phenotype of EGFP-
CB1RΔH9 compared to EGFP-CB1RWT (Figure 4-10). 
 
Figure 4-11 Schematic summarising main findings. 
Polarised surface distribution of CB1R is established and maintained by two complementary 
mechanisms: (Ai) selective delivery of newly synthesized CB1R to the axon (or restricted delivery to 
dendrites) and (Aii) selective retention in axons and retrieval from dendrites. The C-terminal motif 
Helix 9 plays a role in both of these mechanisms because deletion of H9 leads to: (Bi) a loss of axon-
selective delivery and (Bii) reduced retention in both axons and dendrites that can be reversed in 
dendrites by inverse agonist application, suggesting that CB1RΔH9 is more susceptible to activity-
driven internalisation. 
 
4.4.2 Total CB1R preference 
Although intracellular CB1R is apparently non-polarised and present throughout 
the neuron surface expressed CB1R displays a characteristic highly polarised 
surface distribution. However, in this chapter I show that total CB1R does, in fact, 
display a slight axonal polarisation. The total polarity index (A/D ratio) of the 
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completely non-polarised CD4 transmembrane protein was around 0.8 (Figure 4-2 
C). This value is less than 1 most likely due to the larger volume of dendrites 
compared to axons.  
Therefore, if we define a total polarity index of 0.8 as being “non-polarised,” the 
total distribution of CB1R, which is ~1 (Figure 4-6 D) indicates an axonal 
polarisation compared to completely non-polarised CD4. This axonal preference is 
mediated by ctCB1R, since addition of ctCB1R to CD4 was sufficient to shift CD4 
from a non-polarised distribution of ~0.8 to ~1.2 (Figure 4-2 C).  
Our initial hypothesis was that this polarity shift is mediated by H9 because the 
distribution of CD4-CB1RΔH9 chimera was non-polarised (0.76; Figure 4-2 C). 
However, while the full length SBP-EGFP-CB1RΔH9 mutant was impaired in its 
ability to enter the axon when newly synthesised (Figure 4-5 A), at steady state, 
SBP-EGFP-CB1RΔH9 total polarity is identical to that of SBP-EGFP-CB1RWT 
(Figure 4-6 D). These data indicate that, in addition to H9, other as yet undefined 
motifs are present outside the ct (e.g. in the intracellular loops) that contribute to 
the polarity of CB1R.  
4.4.3 Surface CB1R polarity 
The surface polarity index (A/D ratio) of the completely non-polarised CD4 
transmembrane protein was also around 0.8 (defined as “non-polarised”; Figure 
4-2 D). Addition of ctCB1RWT (CD4-ctCB1RWT) shifted the surface polarity index to 
around 1.5 (Figure 4-2 D). This shift in surface polarity index is slightly larger than 
the shift in total polarity (0.8 to 1.2) indicating that the difference in surface polarity 
is not solely attributable directed axonal targeting of intracellular CB1R (total 
polarity).  
Indeed, analysis of internalisation reveals a small, but significant, increase in 
internalisation of CD4-ctCB1RWT in dendrites but not in axons compared to CD4 
(Figure 4-3 B) which accounts for the greater level of surface polarity than total 
polarity. This internalisation is, however, H9-independent since it occurs in both 
CD4-ctCB1RΔH9 and CD4-ctCB1RWT chimeras (Figure 4-3 B). Furthermore, since 
CD4-ctCB1RWT and CD4-ctCB1RΔH9 chimeras cannot bind CB1R agonist, this 
internalisation must be constitutive, not agonist-induced.  
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Nevertheless, CD4-ctCB1RWT surface polarity is not complete – the surface 
polarity of full length CB1RWT is around 3.3 (Figure 4-6 C), indicating that other 
motifs in CB1R and/or agonist-induced internalisation due to the tonal level of 2-
AG in the dendritic membrane are required for complete CB1R surface polarity 
(Ladarre and Lenkei, 2017). 
4.4.4 H9 plays a role in preferential delivery of de novo CB1R to axons 
In Chapter 3, I found that de novo CB1R is preferentially trafficked to the axonal 
membrane compared to the dendritic membrane. In this chapter, I found that 
deletion H9 results in increased delivery to dendrites (Figure 4-5 D), suggesting 
that H9 plays a role in restricting delivery to dendrites. 
One possibility is that H9 may modulate CB1R binding to AP-3, allowing for 
preferential delivery to axons and sorting to dendritic lysosomes, causing a 
decrease in dendritic membrane CB1R. More studies are needed to examine the 
possibility of H9 influencing AP-3 and CB1R interaction. 
It would be interesting to co-RUSH SBP-EGFP-CB1RWT and -CB1RΔH9 to 
determine at what point in the secretory pathway the diversion occurs. For 
example, are WT and ΔH9 receptors sorted into different Golgi compartments? 
Would some secretory vesicles only contain ΔH9 because they are destined to the 
dendritic membrane? These experiments would provide more insight not only into 
CB1R polarised secretory pathway trafficking, but into polarised trafficking in 
general. 
4.4.5 H9 resists agonist-induced endocytosis 
The most consistent phenotype that I observed for CB1RΔH9 was a reduced 
membrane retention – less surface expression (Figure 4-6 B) and more 
internalisation (Figure 4-7) in both axons and dendrites. The lack of an effect of 
deleting H9 on CD4-CB1R chimera internalisation (Figure 4-3), the increased rate 
of agonist-induced internalisation of CB1RΔH9 in axons (Figure 4-9), and the 
reversal of reduced surface expression upon AM281 treatment (Figure 4-10), 
suggest that this phenotype is due to increased agonist-induced endocytosis in the 
ΔH9 mutant. These data strongly suggest that H9 functions to resist agonist-
induced internalisation. 
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4.4.5.1 CB1R agonist-induced endocytosis 
4.4.5.1.1 β-arrestin recruitment 
GPCRs such as CB1R are subject to dynamic regulation by ligand stimulation. 
Following activation by extracellular cannabinoids, CB1R is desensitised by 
phosphorylation of two serine residues (S426 and S430) by GCR kinase 3 (GRK3) 
and β-arrestin recruitment (Jin et al., 1999; Daigle et al., 2008a; Delgado-Peraza 
et al., 2016). How CB1R is then internalised is not entirely clear, but reports 
indicate that internalisation may be a result of binding of β-arrestin2 over β-
arrestin1 (Ahn et al., 2013; Delgado-Peraza et al., 2016) and that further 
phosphorylation of six serines and threonines in the distal C-terminal tail is required 
(Straiker et al., 2012b). H9 sits right between these two major sites of 
phosphorylation. Therefore, it is possible that deletion of H9 favours β-arrestin2 
recruitment rather than β-arrestin1 recruitment. Standard assays measuring β-
arrestin recruitment to GPCR such as the Pathhunter and Tango assays would 
shed light on the role of H9 on β-arrestin recruitment and subsequent 
internalisation. 
4.4.5.1.2 ctCB1R interacting proteins 
Other ctCB1R interacting proteins affect agonist-induced internalisation of CB1R. 
Cannabinoid receptor interacting protein (CRIP1a) binds to the distal C-terminal 
tail of CB1R (Niehaus et al., 2007; Mascia et al., 2017). CRIP1a prevents agonist-
induced internalisation of CB1R by competing with β-arrestin1/2 for binding of 
ctCB1R (Blume et al., 2016; Mascia et al., 2017; Blume et al., 2017). H9 sits right 
between the serine residues important for desensitisation and CRIP1a binding site 
(Figure 4-1). Therefore, H9 may mediate the interactions between β-arrestin1/2 
and CRIP1a binding, and its loss favours β-arrestin2 recruitment over β-arrestin1 
or CRIP1a binding, causing an increased amount of agonist-induced 
internalisation. 
Src homology 3-domain growth factor receptor-bound 2-like (endophilin) 
interacting protein 1 (SGIP1) binds ctCB1R C-terminally of H8 and prevents 
agonist-induced internalisation of CB1R (Hájková et al., 2016). SGIP1 is discussed 
in detail in the next chapter. 
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4.4.5.2 H9 and AM281 
There have previously been conflicting reports on the effect of inverse agonist 
incubation on CB1R surface expression. In (Leterrier et al., 2006), incubation with 
AM281 for 3 hours significantly increased the surface expression of both 
endogenous and exogenously expressed CB1R in dendrites – although the 
increase was less dramatic in endogenous CB1R compared to exogenously 
expressed CB1R, requiring EM. This increase was equivalent to the increased 
surface expression observed with treatment with an endocytosis blocker methyl-β-
cyclodextrin (MβCD; (Leterrier et al., 2006)). This result led them to believe that 
the dendritic internalisation of CB1R in dendrites is dependent on agonist. 
However, (McDonald et al., 2007a) found no such dendritic increase in surface 
expression with AM281 in both endogenous and exogenously expressed CB1R. 
However, co-expression with a dominant-negative dynamin to prevent endocytosis 
did result in translocation to the dendritic plasma membrane. 
One main methodological difference between these two experiments was the 
tagging of CB1R – in (Leterrier et al., 2006), the CB1R construct was Myc tagged 
N-terminally (with the full N-terminus) and tagged with EGFP C-terminally. In 
(McDonald et al., 2007a), a SEP tag was added to the truncated N-terminus. My 
construct is derived from (McDonald et al., 2007a) – it is N-terminally tagged with 
SBP and EGFP and the N-terminus is truncated. 
In this chapter, I found that EGFP-CB1RΔH9 strongly translocated to the dendritic 
membrane with AM281 incubation (Figure 4-10).  While there was a small increase 
in dendritic surface expression for EGFP-CB1RWT (around 122%), it is not quite 
significant (p = 0.086; one-sample t-test, and no multiple comparisons corrections). 
This leads me to wonder whether, while there is some effect of AM281, the 
exaggerated effect seen by (Leterrier et al., 2006) is due to the C-terminal tagging 
of CB1R preventing an unknown protein-protein interaction and having a similar 
effect as deleting H9.  
It is unlikely that the N-terminal truncation could be the cause of the discrepancy 
since there was no difference in surface expression of the N-terminally tagged full, 
full length CB1R compared to the truncated version (Figure 3-3) and this truncation 
does not affect signalling (McDonald et al., 2007a; b). Further studies repeating 
this experiment with comparing different versions of exogenously expressed, 
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tagged, and truncated CB1R vs. an untagged CB1R, or preferentially further 
studies with endogenous CB1R, are needed to fully resolve this discrepancy. 
4.4.5.3 What happens next? 
While I have shown that CB1RH9 displays increased internalisation compared to 
WT, further studies are also needed to determine the fate of the internalised WT 
and H9 receptors in both dendrites and axons. Are they sent for degradation via 
GASP1 or re-sensitised and recycled back to the surface? Is the fate the same in 
axons vs. dendrites? Are dendritic endosomal CB1Rs rerouted to the axonal 
surface (transcytosis)?  
The degradation of internalised CB1R can be examined by adding lysosomal 
inhibitors such as bafilomycin or leupeptin to constitutive or agonist-induced 
endocytosis experiments, staining for a lysosomal marker such as LAMP1, and 
screening for colocalization with LAMP1 in axons vs. dendrites.  
4.4.6 ctCB1R and constitutive internalisation  
While the data presented in this chapter mainly focused on the role of H9 in 
agonist-induced internalisation, the CD4 internalisation experiment also provided 
evidence for the presence of dendrite-specific internalisation controlled by ctCB1R 
independently of H9 (Figure 4-3). This internalisation may be due to a motif that 
either interacts either with a dendritically polarised pro-endocytic factor or with an 
axonally polarised surface stabilising factor. 
The ΔH9 mutant retains the final 13 residues. Within this section, 5 amino acids 
have been shown to be important for binding of cannabinoid receptor interacting 
protein (CRIP1a; Figure 4-1) (Mascia et al., 2017). Because CRIP1a co-localises 
with CB1R at presynaptic boutons (Guggenhuber et al., 2016)  and binding of 
CRIP1a negatively regulates constitutive endocytosis of CB1R (Mascia et al., 
2017), it is possible that CRIP1a binding to the CD4-ctCB1R chimeras in axons but 
not in dendrites is the source of the differential endocytosis patterns seen in this 
experiment. Repeating the experiment with a CD4-ctCB1R chimera lacking these 
5 residues and/or knocking down CRIP1a would be needed to confirm this 
possibility. 
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4.4.7 H9 affects downstream signalling 
4.4.7.1 Kinetics of ERK1/2 activation 
My data indicate that deletion of H9 decreases downstream signalling (Figure 4-8) 
and increases agonist-induced internalisation (Figure 4-9). However, more 
experiments are needed to fully characterise the effect of H9 deletion on 
downstream signalling in terms of kinetics and signalling pathways.  
A time course of agonist application would provide information regarding the 
kinetics of ERK1/2 activation. I chose 5 minutes because of a report that the 
maximum ERK1/2 signal occurs at 5 minutes of 100 nM CP 55,940 treatment in 
HEK293 cells expressing CB1RWT (Daigle et al., 2008a). This peak is then followed 
by a rapid decrease which stabilises after around 15 minutes of agonist treatment. 
This is due to desensitization by phosphorylation of two serine residues (S426, 
S430) since a mutant where these two serine residues are replaced by alanine 
residues (phospho-null) does not show the rapid peak and decrease, but rather a 
stable activation for at least 45 minutes (Daigle et al., 2008a). Since the peak of for 
ERK1/2 activation occurs so rapidly and so transiently, if the kinetics for ERK1/2 
activation are different for the H9 mutant, it is possible that I missed the peak 
because it did not occur at 5 minutes, but before or afterwards.  
4.4.7.2 Desensitisation 
This single snapshot approach also provides no insight into the ability of the ΔH9 
mutant to desensitise. Therefore, a time course would provide more information 
both on the role of H9 in ERK1/2 activation as well as the role of H9 in 
desensitization. The two serine residues that are phosphorylated during 
desensitization (S426 and S430) are located in the stretch of amino acids between 
H8 and H9, so it is possible that H9 might play a role in desensitisation by providing 
or blocking access to the kinases, GRK2/3 (Figure 4-1). H9 may also mediate β-
arrestin1/2 recruitment and binding, preventing or promoting desensitisation. The 
shape of ERK1/2 activation kinetics of the mutant alone or with the additional 
phospho-null mutations would provide information on the role of H9 in 
desensitization.  
4.4.7.3 Alternative G protein coupling 
While CB1R is traditionally thought to act via Gi/o protein coupling, several reports 
indicate that CB1R also couples with GS, Gαz, Gαq/11, and Gα12/13 depending on the 
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cell type and/or agonist used (Diez-Alarcia et al., 2016; Busquets-Garcia et al., 
2018). Indeed, ACEA, the agonist that I used, is capable of activating CB1R-Gαq/11 
(Diez-Alarcia et al., 2016). Gαq/11 signalling classically activates phospholipase C 
 isoforms (PLC) but can also activate PKC which leads to ERK1/2 activation 
(Sánchez-Fernández et al., 2014). Since regions analogous to H9 in the bradykinin 
receptor and squid rhodopsin acts as the binding site for Gαq/11 (Piserchio et al., 
2005; Murakami and Kouyama, 2008), the defect in ERK1/2 activation observed in 
this chapter could possibly provide evidence that CB1R H9 mediates the coupling 
of Gαq/11 as well. G-protein coupling assays such as those described in (Diez-
Alarcia et al., 2016) would be needed to test this possibility.  
4.4.7.4 H9 and other signalling pathways 
Lastly, ERK1/2 activation is but one of the many pathways that CB1R activates. 
The most ‘classical’ effect of CB1R activation via Gi/o proteins is a decrease in 
cyclic AMP (cAMP) levels through inactivation of adenylyl cyclase (Howlett, 2005). 
The role of H9 in activation of this pathway can be tested using standard cAMP 
assays to detect CB1R-mediated reduction of cAMP under forskolin stimulation 
(e.g. (Blume et al., 2015; McDonald et al., 2007a)). 
4.5 CONCLUSION 
Taken together, these results reveal that the C-terminal domain, and H9 in 
particular, play important roles in trafficking of CB1R. These findings provide 
important insight into the mechanisms of CB1R polarity and highlight H9 as an 
important regulator of CB1R trafficking, endocytosis, and surface expression. 
Chapter 5 –   Screening for H9 interacting proteins 
131 
 
Chapter 5 –   SCREENING FOR H9 
INTERACTING PROTEINS 
5.1 AIMS 
• To determine the mechanism by which H9 increases membrane retention. 
• To screen for interacting partners of H9 that may play a role in 1) 
preferential axonal delivery and/or 2) membrane retention. 
5.2 INTRODUCTION 
5.2.1 Role of H9 in CB1R trafficking 
In Chapter 3, I showed so far that CB1R is preferentially trafficked to the axon by 
the secretory pathway and preferentially retained at the axonal membrane, 
resulting in its the characteristic axonal polarisation. In Chapter 4, I showed that 
both preferential delivery of CB1R and membrane retention of CB1R during agonist 
activation are moderated by the Helix 9 (H9) motif of the C-terminus of CB1R 
(ctCB1R). 
Building on these data I next investigated the how perturbation of H9 might mediate 
these effects. NMR and circular dichroism studies suggest that H9, like H8, is an 
amphipathic α-helix, associating with the lipid bilayer via a cluster of hydrophobic 
residues on the non-polar face of the helix (Ahn et al., 2009b). As outlined below, 
I tested the effects of addition of ‘forbidden’ prolines to perturb the predicted alpha 
helical motif due to steric hindrance and the loss of a backbone hydrogen bond 
(Bright et al., 2002). I mutated two residues of H9 into prolines (A447P and V455P) 
to perturb the motif and determine whether that its helicity is required for the 
decreased surface expression phenotype. 
H9 also contains a cysteine residue (C450), raising the possibility that post-
translational modifications such as palmitoylation, prenylation, or farnesylation at 
this site could modulate membrane association. Indeed, CB1R has been shown to 
be palmitoylated just C-terminally of H8 at C416, which affects its membrane 
association, G-protein coupling, and is required for agonist-induced internalisation 
in HEK293 cells (Oddi et al., 2012, 2017, 2018). I therefore mutated the cysteine 
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to an alanine (C450A) to determine whether deletion this residue is necessary to 
produce the reduced surface expression phenotype of CB1RΔH9. 
Because little is known CB1R C-terminal interactors in general, and none have 
been identified specifically for the H9 domain, I searched for novel interacting 
proteins with H9 by mass spectrometry as well as literature searches. 
5.2.2 Possible mechanisms underpinning preferential axonal delivery 
5.2.2.1 AP-3 sorting 
While several sorting signals and adaptors have been described for dendritic 
cargo, the mechanisms behind selective sorting to axons are less well known 
(Lasiecka and Winckler, 2011; Bentley and Banker, 2016). A recent study in C. 
elegans has suggested that sorting of cargos to axons or dendrites depends on 
binding to different types of clathrin-associated adaptor proteins (AP); axonal cargo 
bind to AP-3 whereas dendritic cargo bind to AP-1 (Li et al., 2016) Interestingly, 
AP-3 binding has been associated with CB1R trafficking to the lysosome in the 
dendritic compartment (Rozenfeld and Devi, 2008). In this paper, they found that 
knocking down AP-3 with an siRNA resulted in increased surface expression of 
somatodendritic CB1R (Rozenfeld and Devi, 2008). One possibility is that H9 may 
modulate CB1R binding to AP-3, allowing for preferential delivery to axons and 
sorting to dendritic lysosomes. More studies are needed to examine the possibility 
of H9 influencing AP-3 and CB1R interaction. 
5.2.3 Mechanisms of endocytosis 
5.2.3.1 Rab5 and Rab4 GTPases 
It has been reported that transfected CB1R colocalises significantly with Rab5- and 
Rab4-positive endosomes, but not Rab11-positive endosomes, in HEK293 cells 
(Leterrier et al., 2004). Rab5 is a small GTPase involved in the delivery of plasma 
membrane proteins to early endosomes, whereas Rab4 is involved in both fast and 
slow recycling back to the plasma membrane (see Figure 1-4). The co-expression 
of untagged CB1R with dominantly negative (DN; GDP-bound) or dominantly 
active (DA; GTP-bound) Rab5 or Rab4 changed the surface-to-total ratio of CB1R 
in HEK293 cells. DN Rab5 induces an accumulation of the proportion CB1R at the 
plasma membrane, whereas DA Rab5 induces increased endocytosis of CB1R. 
On the other hand, DN Rab4 impairs CB1R recycling, causing a decreased surface 
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to total ratio, and DA Rab4 enhances CB1R recycling, causing an accumulation of 
CB1R at the plasma membrane.  
In neurons, expression of a DN Rab5 decreases the surface polarity index (A/D) of 
expressed FLAG-CB1R-YFP due to the accumulation of the receptor at the 
somatodendritic surface (Leterrier et al., 2006). 
Together, these data suggest that under steady-state conditions, CB1R is 
constitutively endocytosed and recycled back to the membrane by Rab5- and Rab-
4 dependent means, respectively. However, I could not replicate these results 
below. 
5.2.3.2 SGIP1 
SH3-containing GRB2-like protein 3-interacting protein 1 (SGIP1) is an adaptor 
protein linked to clathrin-mediated endocytosis (Uezu et al., 2007)). SGIP1 binds 
to ctCB1R at an unknown location C-terminally of H8 where it interferes with 
agonist-induced internalisation and modulates β-arrestin association and 
downstream ERK1/2 signalling in HEK293 cells (Hájková et al., 2016). Specifically, 
(Hájková et al., 2016) co-expressed CB1R and SGIP1 in HEK293 cells and 
measured internalisation with agonist (2-AG or WIN 55,212-2) application. They 
found that co-expression with SGIP1 significantly reduced CB1R internalisation 
induced by agonist binding compared to HEK293 cells just expressing CB1R to a 
similar level as blocking internalisation with a dominant negative dynamin 
(DynK44A). They also observed a significant reduction in constitutive 
internalisation with SGIP1 co-expression in CB1R-expressing HEK293 cells 
without exogenous agonist application. An intriguing possibility is that I tested is 
that SGIP1 might interact via H9.  
5.3 RESULTS 
5.3.1 H9 perturbation: cysteine mutant, ‘forbidden proline’,  
Having found that deletion of H9 results in reduced surface expression in axons 
and in dendrites compared to CB1RWT, I next sought to parse what characteristics 
of H9 are necessary. Firstly, since H9 is an amphipathic helix, it is likely that its 
hydrophobic face is associated with the plasma membrane (Stadel et al., 2011). 
Furthermore, H9 contains a cysteine residue (C450), meaning that association with 
the plasma membrane may be further modulated by posttranslational modification  




Figure 5-1 Perturbation of H9 by mutation of C450 or incorporation of 2 proline residues result 
in a similar phenotype of reduced axonal surface expression as EGFP-CB1RΔH9. 
(A) Representative confocal images of DIV 14 hippocampal neurons expressing EGFP-CB1RWT, 
EGFP-CB1RΔH9, EGFP-CB1RC450A, or EGFP-CB1R2P. Upper panels for each condition show whole 
cell field of view and lower panels are enlargements of axonal (a) and dendritic (d) ROIs. Green = 
total; magenta = surface; blue = axon marker (Ankyrin-G). Merge: surface to total seen as white.   
(B) Quantification of data represented in (A). Perturbation of H9 either by substitution of C450 to an 
alanine residue, or by incorporation of two ‘forbidden’ prolines resulted in a similar phenotype as 
removing H9 completely – CB1R surface fluorescence was significantly reduced in axons compared 
to WT. One-way ANOVA with Tukey’s post hoc test. N = three independent experiments; n = 17-18 
neurons per condition. 
(C) Quantification of data represented in (A). No significant difference in surface polarity was 
observed between WT and the three H9 mutants. One-way ANOVA with Tukey’s post hoc test. N = 
three independent experiments; n = 17-18 neurons per condition. 
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of this residue by palmitoylation, prenylation, or farnesylation. Indeed, 
palmitoylation of a different cysteine residue located just C-terminally of H8 (C416) 
has previously been shown to alter surface stability of CB1R (Oddi et al., 2017). 
Therefore, I transformed C450 into an alanine residue (EGFP-CB1RC450A) by site 
directed mutagenesis to determine whether this cysteine residue is necessary for 
H9-mediated surface stabilisation. I also generated another mutant where I 
converted two residues into ‘forbidden’ proline residues (A447P + V455P; EGFP-
CB1R2P). Because proline is a bulky residue, steric hindrance should prevent the 
formation of an alpha helix. Analysis of this mutant would determine whether the 
helicity of H9, rather than simply its sequence, is important for its function. I then 
transfected these H9 mutants into DIV12 hippocampal neurons and compared their 
surface expression to EGFP-CB1RWT and EGFP-CB1RΔH9 (Figure 5-1 A). I found 
that perturbing H9 in these ways resulted in a reduction of CB1R surface 
expression in axons identical to that of deleting H9 compared to WT (Figure 5-1 
B). Furthermore, consistent with previous results, no mutation influenced surface 
polarity (Figure 5-1). These data indicate that both the C450 residue and the 
helicity of H9 are important for its function. 
5.3.2 Mechanisms of preferential axonal delivery: Role of AP-3? 
Having found that H9 restricts delivery of CB1R to the somatodendritic membrane, 
I next sought to determine by what mechanism this occurs. Since AP-3 binds CB1R 
(Rozenfeld and Devi, 2008) and has also been implicated in TGN-to-axon sorting 
(Li et al., 2016), I wondered whether H9 might modulate the binding of CB1R to 
AP-3. Previously, (Rozenfeld and Devi, 2008) showed that knocking down the delta 
subunit of AP-3 (AP3D1) by siRNA increased somatodendritic surface CB1R. I 
generated shRNA constructs targeting AP3D1 which knocked down AP3D1 in 
HEK293T cells compared to scrambled and untransfected controls (Figure 5-2 A). 
I then transfected DIV12 hippocampal neurons with EGFP-CB1RWT and either 
AP3D1 shRNA or a SCR21 and examined surface expression at DIV19 (Figure 
5-2 B). Consistent with (Rozenfeld and Devi, 2008), knockdown of AP3D1 resulted 
in a non-polarised distribution of surface CB1R. However, the cells did not look 
very healthy (the somas were blebbing) and lacked Ank-G staining so could not be 
absolutely identified as being neurons.  A more targeted approach would probably 
be needed in order to examine the role of AP-3 and H9 in trafficking of CB1R. 
 




Figure 5-2 Knockdown of AP3D1. 
(A) Two shRNAs targeting AP3D1 knocked down AP3D1 in HEK293T cells compared to two 
scrambled controls (SCR21, SCR19). An untransfected control (Control) was also included.  
(B) Representative confocal images of DIV 19 hippocampal neurons expressing EGFP-CB1RWT and 
either SCR21 or an shRNA targeting AP3D1 (KD#2; co-expressing mCherry). Green = total EGFP-
CB1RWT; magenta = surface EGFP-CB1RWT; red = mCherry, indicating co-transfection of shRNA; 
blue = axon marker (Ankyrin-G) indicated by white arrow. Merge: surface to total seen as white.   
 
5.3.3 Mechanisms of endocytosis: Rab5 
Because it has been previously reported that CB1R internalisation is Rab5-
dependent in both HEK293 cells (Leterrier et al., 2004) and the somatodendritic 
compartment (Leterrier et al., 2006), I sought to determine whether the increased 
endocytosis phenotype of the H9 mutant is Rab5-dependent as well. 
I therefore generated mCherry-tagged Rab5 dominant negative (GDP-bound; 
S34N; mCherry-Rab5DN) and dominant active (GTP-bound; Q79L; mCherry-
Rab5DA) from mCherry-Rab5WT. I co-expressed these constructs with either EGFP-
CB1RWT or CB1RH9 in HeLa cells and surface stained using anti-GFP antibody. 
I could not replicate the previous reports and found no difference in surface 
expression of EGFP-CB1RWT between mCherry-Rab5WT, mCherry-Rab5DN, 
mCherry-Rab5DA (Figure 5-3 B), indicating that EGFP-CB1RWT was not 
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constitutively internalised in a Rab5-dependent manner in HeLa cells. There was 
also no difference in surface expression of EGFP-CB1RH9 (Figure 5-3 B).  
5.3.4 Interacting partners screen 
To directly compare the interactomes between EGFP-tagged WT or ΔH9 ctCB1R, 
I generated Sindbis viruses that expressed an EGFP-tagged WT or ΔH9 ctCB1R 
(EGFP-ctCB1RWT and EGFP-ctCB1RΔH9) as well as one that expressed a control 
EGFP. I transduced primary cortical neurons, lysed the cells, and isolated the 
EGFP-tagged proteins and interacting partners with a GFP-Trap 
immunoprecipitation. The samples were then sent to the Bristol proteomics facility 
for analysis by Tandem Mass Tagging (TMT) quantitative proteomics by Dr Kate 
Heesom. The advantage of the TMT approach is that it not only identifies proteins 
but also allows for the relative levels of proteins to be compared between samples. 
By comparing the identities and quantities of hits between the EGFP control, 
EGFP-ctCB1RWT, and EGFP-ctCB1RΔH9 potential H9 interacting partners could be 
identified. Analysis was completed with the help of Dr Lea Hampton-O’Neil. 
Firstly, as a control, a small sample of the lysate was blotted for GFP to ensure 
that EGFP, EGFP-ctCB1RWT, and EGFP-CB1RH9 were expressed at similar levels 
(Figure 5-4 A-B), so that any difference observed in the mass spectrometry was 
due to differences in binding, not differences in expression. 
In the proteomics data, CB1R was enriched in both WT and ΔH9 compared to GFP 
(Table 5-1), indicating that the GFP-CB1R was successfully immunoprecipitated.  
Unfortunately, little else was enriched above GFP levels – most likely because the 
co-immunoprecipitations were not clean enough. For example, CRIP1a can be 
used as a positive control, since it binds CB1R at the last 9 residues of ctCB1R, 
which is included in the ΔH9 mutant. As expected, the level of CRIP1a was similar 
between ctCB1RWT and ctCB1RΔH9 (Table 5-1). However, there was also a similar 
level in the GFP sample. For a more extensive and definitive proteomics screen 
the co-immunoprecipitations will need to be more stringent and optimised with 
increased washes and salt concentrations. Nonetheless, to gain some information 
from the proteomics already carried out, compared just ctCB1RΔH9 and ctCB1RWT 
data sets, putting aside the GFP values, and screened for proteins that were 
reduced or enriched in the mutant compared to the WT that are involved in polarity 
(or preferential delivery) and/or endocytosis.   
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Figure 5-3 Constitutive endocytosis of EGFP-CB1RWT and EGFP-CB1RΔH9 not regulated by 
the Rab5 GTPase in HeLa cells. 
(A) Representative merged confocal images of HeLa cells expressing EGFP-CB1RWT (left panels) or 
EGFP-CB1RΔH9 (right panels) and co-expressing either WT Rab5 (mCherry-Rab5; top panels), a 
dominant-negative (GDP-bound) Rab5 (mCherry-Rab5DN; middle panels), or a dominant-active 
(GTP-bound) Rab5 (mCherry-Rab5DA; bottom panels). Green = total EGFP-CB1R; magenta = 
surface EGFP-CB1R; red = mCherry-Rab5; blue = DAPI. 
(B) Quantification of data presented in (A). Analysis of the surface-to-total ratio shows no significant 
difference between any of the conditions, indicating that EGFP-CB1R endocytosis is not dependent 
on Rab5 in HeLa cells. Two-way ANOVA with Tukey’s post hoc test. N = two independent 





Table 5-1 Raw proteomics data. 
 PROTEIN CTCB1RWT/GFP CTCB1RH9/GFP CTCB1RH9/CTCB1RWT 
 CB1R 13.003 6.618 0.975 
 CRIP1a 0.927 0.957 1.063 
 
 
Table 5-2 is a summary of the potential hits. Two hits that were decreased in the 
ΔH9 samples are potentially involved in polarity. Protein lin-7 homolog A (Lin-7A; 
aka velis/MALS) belongs to a family of PDZ domain-containing CASK adaptor 
proteins that are key regulators of cell polarity (van de Pavert et al., 2004). While 
mostly studied in epithelial cells, Lin-7a has been shown to be enriched in neuronal 
cell-cell junctions, as well as synapses, both postsynaptically and presynaptically 
(Perego et al., 2000; Jo et al., 1999; Matsumoto et al., 2014). MAPT (tau) is most 
famous as a hallmark aggregated protein in several types of dementias, including 
Alzheimer’s disease and frontotemporal dementia. However, physiological tau is 
an axonally localised microtubule stabiliser (Drechsel et al., 1992; Weingarten et 
Figure 5-4 The samples sent for proteomics 
expressed Immunoblots of proteomics lysates. 
Immunoblots of lysate used for proteomics blotted for 
GFP and beta-actin (housekeeping gene). EGFP, 
EGFP-ctCB1RWT and EGFP-ctCB1RΔH9 expressed at 
equivalent levels and contained similar levels of protein. 
Chapter 5 –   Screening for H9 interacting proteins 
140 
 
al., 1975) and plays a role in axonal transport (Vershinin et al., 2007; Butzlaff et al., 
2015). Further studies are needed to examine what role these proteins play in 
CB1R polarity. 
A few potential hits are involved in endocytosis. Firstly, as mentioned above, 
CRIP1a, which regulates constitutive endocytosis of CB1R, was equally present in 
both WT and ΔH9 samples, presumably because it binds to the last 9 amino acids. 
Interestingly, all the subunits of AP-2 (µ, α2, β, σ), the adaptor complex that 
controls clathrin-mediated endocytosis (Rappoport, 2008), were moderately 
enriched in the ΔH9 sample compared to the WT sample. Lastly, Src homology 3-
domain growth factor receptor-bound 2-like (endophilin) interacting protein 1 
(SGIP1) was moderately decreased in the ΔH9 sample compared to WT sample. 
5.3.5 Mechanisms of endocytosis: SGIP1 
I followed up on SGIP1 for several reasons: 
 
1. SGIP1 has previously been shown to bind to ctCB1R. The exact site is not 
known, but it binds C-terminally of H8 (Hájková et al., 2016). 
2. SGIP1 is primarily located presynaptically, colocalising with bassoon and 
synaptotagmin (Hájková et al., 2016; Lee et al., 2019). 
3. Co-expression of SGIP1 and CB1R increases CB1R surface expression. 
4. SGIP1 bound ctCB1RH9 less than ctCB1RWT in my proteomics screen. 
5.3.5.1 Cloning an SGIP1 overexpression construct 
To obtain an SGIP1 overexpression construct, I designed primers for the start and 
end of the mRNA sequence for Rat SGIP1 available on Uniprot. I then extracted 
the SGIP1 sequence from a cDNA library derived from mRNA extracted from DIV 
21 primary cortical neurons by PCR amplification. I cloned this sequence into 
pFLAG in order to add an N-terminal FLAG tag. The sequence of the construct I 
extracted corresponded to predicted SGIP1 transcript variant X21 (NCBI; Figure 
5-5). This 660-amino acid variant differs from the full-length Uniprot version by two 
deletions: a single residue deletion in the membrane phospholipids binding domain 
(MP; Q34) and a 165-residue deletion in the proline-rich domain (PRD). Given that 
this variant was directly extracted from our primary neuronal cultures it is likely to 
be the dominant form expressed in our system. Throughout this chapter, I will refer 
to this this variant as SGIP1. 
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Table 5-2 Summary of proteomics: list of potential ctCB1R interactors 
 PROTEIN  REFERENCE 
CTCB1RΔH9/ 
CTCB1RWT 
 KNOWN FUNCTION(S) BINDING SITE ON CB1R 
Protein lin-7 
homolog A 
N/A  0.784 
Polarity complex involved in asymmetric distribution of 
channels and receptors at the cell membrane. 
Not known 
MAPT (Tau) N/A  0.866 




(Niehaus et al., 2007; 
Mascia et al., 2017) -  1.063 
Inhibits constitutive endocytosis of CB1R. Selectively blocks 
agonist induced signalling.  
Last 9 aa 
AP-2 µ 
subunit 
N/A  1.321 





 1.370   
AP-2  
subunit 
 1.168   
AP-2  
subunit 
 1.120   
SGIP1 
(Hájková et al., 2016; 
Lee et al., 2019)  0.790 
Endocytic adaptor – widely distributed but enriched in axon 
terminals. Interferes with CB1R internalization and signalling.  
Not known; C-terminally of H8 




Figure 5-5 Schematic of SGIP1 isoform, designated as SGIP1. 
Predicted SGIP1 transcript variant X21 was cloned out of a cDNA library extracted from rat primary 
cortical cultures. This variant of SGIP1, named SGIP1β, is 660 amino acids long. This variant differs 
from the “full-length” variant on Uniprot (which corresponds to predicted transcript variant X10) by 
two deletions – a single residue deletion (Q34) in the MP domain and a 165-residue deletion in the 
PRD (black hatched regions). The blue cross-hatched region in the µHD indicates the area where 
that binds ctCB1R (Hájková et al., 2016). MP = membrane phospholipids binding domain; APA = AP-
2 Activator motif; PRD = Proline-Rich Domain; µHD = µ Homology Domain. 
 
5.3.5.2 SGIP1 increases CB1R surface expression independently of H9 in 
HEK293T cells. 
Firstly, I attempted to replicate the results from (Hájková et al., 2016). I co-
expressed EGFP-CB1RWT (without the SBP tag) and either FLAG-SGIP1 or 
empty FLAG vector in HEK293T cells. I then used surface biotinylation to separate 
surface and total fractions to determine the effect of FLAG-SGIP1 co-expression 
on surface levels of CB1RWT (Figure 5-6). At the same time, also co-expressed 
EGFP-CB1RH9 with FLAG or FLAG-SGIP1. If H9 is the binding site of SGIP1, 
then co-expression of FLAG-SGIP1 should have no effect on the surface 
expression of the mutant.  
However, I found that co-expression of FLAG-SGIP1 increased both EGFR-
CB1RWT and EGFP-CB1RH9 surface expression at steady state (Figure 5-6 B), 
indicating that SGIP1 increases CB1R surface expression independently of H9. 
As a control, I also blotted for EGFR, which has been previously shown to be more 
surface expressed with SGIP1 overexpression (Uezu et al., 2007). However, for 
EGFP there was only a non-significant trend to increased surface-to-total ratio with 
FLAG-SGIP1 overexpression (Figure 5-6 C).  
 




Figure 5-6 SGIP1 increases CB1R surface expression independently of H9 in HEK293T cells. 
(A) Representative immunoblots from surface biotinylation experiments showing surface and total 
fractions of EGFP-CB1RWT or EGFP-CB1RΔH9 and EGFR in HEK293T cells. EGFP-CB1R was co-
expressed with either an empty FLAG control or FLAG-SGIP1.  
(B) Quantification of data shown in (A). Co-expression with FLAG-SGIP1 increased the surface 
expression of both EGFP-CB1RWT and EGFP-CB1RΔH9. Two-way ANOVA with Sidak’s post hoc test. 
N = twelve independent experiments. 
(C) Quantification of data shown in (A). Expression of FLAG-SGIP1 non-significantly increased 
EGFR surface expression. Each experiment is the average value between WT vs. ΔH9 samples. 
Unpaired t-test. N = twelve independent experiments. 
 
5.3.5.3 SGIP1 knockdown reduces surface expression of CB1RWT, but not 
CB1RΔH9 in primary hippocampal neurons.  
Although HEK293T cells are a useful model they lack the complexity and polarity 
of neurons. I therefore next determined the role of SGIP1 in CB1R surface 
expression in hippocampal neurons. I generated an shRNA knockdown construct 
targeting SGIP1 using the 25mer sequence from (Uezu et al., 2007) that targets all 
known isoforms of SGIP1. This shRNA sequence knocked down overexpressed 
FLAG-SGIP1 by 88% compared to a non-targeting 29mer scrambled control 
(SCR29) when co-transfected into HEK293T cells (Figure 5-7 A-B). 
I next added the SGIP1-targeting shRNA or SCR29 to pXlg3-EGFP-CB1RWT and -
CB1RΔH9 and transfected DIV 9 hippocampal neurons with the constructs, left them 
for 5 days to ensure efficient knockdown, then surface stained using anti-GFP 
 




Figure 5-7 Validation of SGIP1 shRNA knockdown. 
(A) Representative immunoblots showing shRNA knockdown (KD) of overexpressed FLAG-SGIP1 
and a beta-actin housekeeping control in HEK293T cells. The first two lanes are duplicate SGIP1 KD 
conditions. FLAG-SGIP1 and SGIP1-targeting shRNA or SCR29 control shRNA were co-
transfected into HEK293T cells and left for 3 days. 
(B) Quantification of data represented in (A). A 25mer shRNA targeting SGIP1 knocked down 
overexpressed FLAG-SGIP1 by about 88% compared to a scrambled (non-targeting) 29mer control 
(SCR29). 
 
antibody (Figure 5-8 A). Because the shRNA and overexpression cassettes are 
on the same plasmid, any neuron expressing EGFP-CB1R must also be 
expressing SCR29 or SGIP1 KD. However, I was not able to unequivocally confirm 
SGIP1 knockdown because commercial SGIP1 antibodies have only recently been 
developed and marketed (Lee et al., 2019) and were not available and validated 
when I was performing these experiments. 
Intriguingly, SGIP1 KD reduced the surface expression of EGFP-CB1RWT to levels 
similar to that of the mutant EGFP-CB1RΔH9 in both axons (Figure 5-8 B) and 
dendrites (Figure 5-8 C) compared to the SCR29 control. Importantly, this 
reduction of surface expression was occluded for EGFP-CB1RΔH9 where  there 
was no significant further reduction by SGIP1 KD on surface expression in either 
axons (Figure 5-8 B) and dendrites (Figure 5-8 C) compared to the SCR29 
control. 
These data strongly suggest that the reduced surface expression phenotype of the 
H9 mutant is due to an inability of SGIP1 to bind in neurons, even though it can 
bind in HEK293T cells. Although more work is needed, my current interpretation of 
these results is that the binding may not be direct, or SGIP1 competes for binding 
with a third-party present in primary hippocampal neurons but not HEK293T cells. 




Figure 5-8 SGIP1 KD reduces surface expression of CB1RWT, but not CB1RΔH9.  
(A) Representative confocal images of DIV 14 hippocampal neurons expressing EGFP-CB1RWT or 
EGFP-CB1RΔH9 and either a 25mer shRNA targeting SGIP1 (SGIP1 KD) or a non-targeting 
scrambled 29mer control (SCR29). Cells were transfected at DIV 9 and left for 5 days to ensure 
knockdown then surface stained with anti-GFP antibody. Upper panels for each condition show whole 
cell field of view and lower panels are enlargements of axonal (a) and dendritic (d) ROIs. Green = 
total; magenta = surface; blue = axon marker (Ankyrin-G). Merge: surface to total seen as white.   
(B and C) Quantification of data represented in (A). In axons (B) and in dendrites (C), knockdown of 
SGIP1 causes a significant reduction in surface expression of EGFP-CB1RWT identical to the reduced 
surface expression phenotype of EGFP-CB1RΔH9. The effect of SGIP1 KD is occluded for EGFP-
CB1RΔH9. Two-way ANOVA with Sidak’s post hoc test. N = three independent experiments; n = 18-
19 neurons per condition. 




5.4.1 Summary of results 
In this chapter, I attempted to determine by what mechanism H9 stabilises CB1R 
at the membrane. Firstly, I attempted to narrow down the characteristics necessary 
of H9 to mediate its effect. I inserted two bulky proline residues into H9 in order to 
prevent it from forming an α-helix. I also mutated a potentially modifiable cysteine 
residue to alanine. I found that both modifications caused a reduction in surface 
expression of CB1R identical to the phenotype of deleting H9 (Figure 5-1). These 
data indicate that the C450 residue and the α-helical nature of H9 is necessary for 
its function. 
Next, I searched for interacting proteins of H9 that may mediate surface 
expression. I found that knocking down SGIP1 resulted in a phenotype identical to 
deletion of H9 – reduced surface expression of CB1RWT in both axons and in 
dendrites (Figure 5-8). Furthermore, this effect was occluded for CB1RΔH9 (Figure 
5-8), signifying that H9 interacts with SGIP1 to stabilise CB1R at the surface of 
hippocampal neurons.  
5.4.2 CB1R and Rab5 
CB1R has previously been reported to be internalised in a Rab5-dependent 
manner in both HEK293T cells and primary hippocampal neurons (Leterrier et al., 
2004, 2006). I was unable to replicate this result (Figure 5-3). However, I used 
HeLa cells rather than HEK293T cells because they are more conducive to 
confocal imaging. Furthermore, closer examination of the CB1RWT/Rab5DA 
condition does reveal visible co-localisation (Figure 5-9), even though it did not 
translate into reduced surface expression (Figure 5-3).  
Reproducibility in the CB1R trafficking field has been plagued by the problem that 
different cell lines produce different results. This may be in part due to a 
misinterpretation of the difference between CB1R intrinsic constitutive activity and 
constitutive agonist-induced activation (Turu and Hunyady, 2010; Ladarre and 
Lenkei, 2017). CB1R is thought to be an intrinsically constitutively active receptor 
due to instability in its ‘ionic lock’ holding it in the inactive conformation (D’Antona 
et al., 2006). This seems to be confirmed by the fact that in cell lines and in native 
tissues, CB1R shows a high degree of activity that can be blocked by application 
of inverse agonists (Pertwee, 2005). However, because 2-AG is produced by a 
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common lipid metabolism pathway it is present in most tissues (Sugiura et al., 
2004), indicating that what is thought to be intrinsic constitutive activation of the 
receptor may actually be due to tonic levels of eCBs (Turu and Hunyady, 2010; 
Ladarre and Lenkei, 2017). Therefore, different cell lines may contain different 
levels of eCBs, affecting CB1R signalling and trafficking. It is possible that HeLa 
cells contain lower levels of eCBs, resulting in lower levels of Rab5 mediated 
internalisation that were undetectable in my experimental setup. More experiments 
will be needed, preferentially in primary hippocampal neurons, to examine the role 
of Rab5 in CB1R internalisation. 
 
 
5.4.3 SGIP1: role in endocytosis 
I show that knockdown of SGIP1 recapitulates the phenotype of CB1RΔH9 and that 
this effect is occluded in neurons expressing the mutant (Figure 5-8). However, 
co-expression of FLAG-SGIP1β and EGFP-CB1RWT or -CB1RΔH9 in HEK293T cells 
resulted in an identical increase in surface expression of CB1R (Figure 5-6), 
indicating that SGIP1β can bind CB1RΔH9. These data suggest that the effect of 
SGIP1 knockdown may be neuron-specific, potentially involving an additional 
interacting protein.  
If SGIP1 is a member of the clathrin-mediated endocytosis complex, why does 
SGIP1 overexpression prevent CB1R internalisation (Figure 5-6) whereas 
knockdown increases CB1R internalisation (Figure 5-8)? (Hájková et al., 2016) 
suggest that SGIP1 competes for binding with FCHo1/2 proteins. SGIP1 and 
FCHo1/2 members of the muniscin family of cargo adapters, containing an N-
terminal membrane biding domain, an AP-2 activator domain, a proline rich 
domain, and a C-terminal µ homology domain (Hollopeter et al., 2014; Dergai et 
al., 2010). However, the membrane binding domain of FCHo1/2 is an F-BAR 
domain capable of plasma membrane shaping during pit formation, while the MP 
Figure 5-9 CB1RWT visibly colocalises with 
Rab5DA. 
Enlargement of HeLa cell co-expressing EGFP-
CB1RWT and mCherry-Rab5DA (dominant active) 
reveals visible colocalization (white arrows 
heads). 
Green = total EGFP-CB1R; magenta = surface 
EGFP-CB1R; red = mCherry-Rab5; blue = DAPI. 
Scale bar = 20 µm. 
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domain of SGIP1 has no sequence similarity suggesting that due to differential 
membrane binding, it may act as a kind of ‘dominant negative’ to the rest of the 
muniscin family. Alternatively, SGIP1 interacts with endophilin 3, which has been 
suggested to actually inhibit endocytosis (Zhang et al., 2015; Sugiura et al., 2004).  
On the other hand, knockdown of SGIP1 has been reported to selectively impair 
internalisation of the pre-synaptic protein synaptotagmin during synaptic vesicle 
recycling (Lee et al., 2019). Other synaptic vesicle proteins including 
synaptophysin and VAMP2 were not affected by SGIP1 knockdown (Lee et al., 
2019). SGIP1 also reportedly activates AP-2 (Hollopeter et al., 2014) and is 
actually capable of membrane tubulation (Uezu et al., 2007). More experiments 
are required to resolve this issue. 
5.4.4 Mechanism of preferential delivery 
While most data in this chapter has focused on the mechanism behind H9-
mediated membrane retention, I also found that H9 plays a role in the preferential 
delivery of CB1R from the secretory pathway to the axonal membrane. While I 
show very preliminary evidence confirming previous results that knocking down 
AP-3 results in a nonpolarized distribution of CB1R (Figure 5-2; (Rozenfeld and 
Devi, 2008)), more targeted approaches are needed to examine the role of H9 and 
AP-3 in CB1R trafficking. For example, co-immunoprecipitation experiments could 
determine whether CB1RWT and/or CB1RΔH9 binds to AP-3. RUSH could also be 
used to determine whether co-localisation of CB1R and AP-3 at the TGN, indicating 
a role for AP-3 in sorting CB1R to the axonal membrane (Li et al., 2016). 
Furthermore, my proteomics screen highlighted Lin-7A as a potential H9 interactor. 
Interestingly, Lin7a belongs to a family of PDZ domain-containing CASK adaptor 
proteins that are key regulators of cell polarity (van de Pavert et al., 2004). This hit 
would first need to be validated by co-immunoprecipitation experiments with 
ctCB1RWT and ctCB1RΔH9. Next, CB1R surface distribution could be examined in 
the presence of Lin-7a knockdown or overexpression.  
5.5 CONCLUSION 
Taken together, these data reaffirm the importance of H9 in membrane stability of 
CB1R and indicate that the mechanism is likely due to 1) the presence of a cysteine 
residue and 2) interaction with SGIP1. 
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Chapter 6 –   GENERAL DISCUSSION 
6.1 SUMMARY 
In this thesis, I have examined the trafficking of CB1R using the time-resolved 
RUSH assay. I have presented several advances in our understanding of CB1R 
trafficking, which are listed below. 
1. Newly synthesised CB1R is preferentially delivered to the axonal 
membrane by the secretory pathway. 
o Following release from the secretory pathway, SBP-EGFP-CB1RWT 
rapidly entered the axon (Figure 3-8). 
o SBP-EGFP-CB1RWT was delivered to the axonal membrane quicker 
and at higher levels than to the dendritic membrane (Figure 3-10). 
2. Newly synthesized CB1R is preferentially retained at the surface of 
axons and removed from the surface of dendrites. 
o SBP-EGFP-CB1RWT that was delivered to the dendritic surface was 
not retained at the dendritic surface (Figure 3-11). 
3. CB1R is trafficked by the canonical, somatodendritic secretory 
pathway. 
o During ER retention, no SBP-EGFP-CB1RWT was detected in axons 
(Figure 3-8). 
o Blocking the Golgi prevented CB1R from entering the axon or going 
to the plasma membrane (Figure 3-13). 
4. The carboxy terminal domain of CB1R (ctCB1R) plays a role in axonal 
polarisation. 
o A chimera of non-polarised transmembrane protein CD4 fused to 
ctCB1R (CD4-ctCB1RWT) was more axonally polarised in both total 
and surface distribution than CD4 alone (Figure 4-2). 
5. ctCB1R triggers constitutive (i.e. activity-independent) internalisation 
specifically in dendrites but not axons, independently of H9. 
o  CD4-ctCB1RWT and CD4-ctCB1RΔH9 chimeras internalised more 
than CD4 in dendrites than in axons (Figure 4-3). 
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6. H9 plays a role in trafficking of total CB1R to the axon. However, H9 
is not necessary for full-length CB1R total polarisation, indicating the 
presence of compensatory motifs/pathways of CB1R axonal entry. 
o The CD4-ctCB1RΔH9 chimera did not display axonal polarisation of 
total protein; CD4-ctCB1RWT did (Figure 4-2). 
o Newly synthesised SBP-EGFP-CB1RΔH9 entered the axon slower 
than SBP-EGFP-CB1RWT (Figure 4-5 A). 
o However, there was no difference in total polarisation between 
EGFP-CB1RWT and EGFP-CB1RΔH9 at steady state (Figure 4-6 D). 
7. H9 mediates polarised delivery of newly synthesised CB1R. 
o More newly synthesised SBP-EGFP-CB1RΔH9 than -CB1RWT was 
delivered to the dendritic membrane. There was no difference in 
delivery to the axonal membrane. (Figure 4-5 C-E) 
o EGFP-CB1RΔH9 displayed a reduced axonal surface polarity when 
agonist-induced internalisation was blocked with inverse agonist 
treatment (Figure 4-10).  
8. H9 stabilises CB1R at the surface in both axons and dendrites, 
preventing agonist-induced endocytosis. 
o EGFP-CB1RΔH9 was less surface expressed and more internalised 
than EGFP-CB1RWT in both axons and dendrites (Figure 4-10 B). 
However, there was no difference in surface expression in 
HEK293T cells (Figure 4-8 D-E). 
o EGFP-CB1RΔH9 showed a higher level of agonist-induced 
endocytosis than EGFP-CB1RWT in axons (Figure 4-9). 
o Treatment with inverse agonist increased EGFP-CB1RΔH9 surface 
expression in both axons and dendrites. There was no difference in 
EGFP-CB1RWT surface expression with inverse agonist treatment. 
(Figure 4-10). 
9. H9 modulates downstream signalling of CB1R. 
o EGFP-CB1RΔH9 activated ERK1/2 to a lesser degree with ACEA 
treatment than EGFP-CB1RWT (Figure 4-8). 
10. The helicity of H9 is important for its function. 
o Perturbing H9 by the addition of ‘forbidden’ prolines resulted in a 
similar phenotype of reduced surface expression as deleting H9 
(Figure 5-1). 
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11. Residue C450 of H9 is important for its function. 
o Perturbing H9 by mutating C450 to an alanine residue resulted in a 
similar phenotype of reduced surface expression as deleting H9 
(Figure 5-1). 
12. In neurons, interaction between SGIP1 and H9 (likely) stabilises CB1R 
at the surface and prevents agonist-induced endocytosis. 
o Knocking down SGIP1 resulted in the same phenotype of reduced 
surface expression as deletion of H9. The effect of knocking down 
SGIP1 on surface expression was occluded in the ΔH9 mutant 
(Figure 5-8). 
o However, in HEK293T cells, overexpression of SGIP1β increased 
surface expression of both EGFP-CB1RWT and EGFP-CB1RΔH9 
(Figure 5-6). 
6.2 MODEL OF CB1R POLARITY 
6.2.1 Proposed models of CB1R polarity 
Three groups have proposed three different models for how CB1R axonal surface 
polarity is established and maintained (for details see 1.3.6 Three currently 
proposed models of CB1R polarity):  
1. Lenkei group: non-polarised delivery to surface followed by differential 
endocytosis from dendritic vs. axonal compartments driven by the 
constitutive presence of 2-AG in the dendritic membrane. Internalised 
dendritic receptors are then trafficked to distal axons via transcytosis 
(Thibault et al., 2013; Simon et al., 2013; Ladarre et al., 2015; Ladarre 
and Lenkei, 2017; Leterrier et al., 2004, 2006).  
2. Irving group: polarity is driven by constitutive (i.e. activity-
independent) internalisation of dendritic CB1R and retention of axonal 
CB1R (McDonald et al., 2007a). 
3. Devi group: dendritic CB1R is not targeted to the surface, but rather 
sent immediately for degradation. Under unknown conditions, CB1R 
can be rerouted to axons (Rozenfeld and Devi, 2008; Rozenfeld, 2011). 
6.2.2 Updated model of CB1R polarity 
Using a genetically-targeted and time-resolved approach, I found that newly 
synthesised CB1R is preferentially delivered to the axonal membrane by the 
secretory pathway. Nevertheless, a small proportion of CB1R is delivered to the 
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dendritic membrane, from which it is immediately removed. Internalised 
somatodendritic CB1R may then be rerouted to the axon, as proposed by the 
Lenkei group, or degraded.  
I show that ctCB1R mediates polarisation independently of CB1R activation, since 
the CD4-ctCB1R chimera was both polarised to the axonal compartment and 
differentially internalised in dendrites vs. axons. However, surface polarisation of 
this chimera was not complete, there was still CB1R present on the dendritic 
surfaced, indicating that agonist-induced internalisation may play a role in 
furthering CB1R polarity following the establishment of polarity by decreased 
delivery to the dendritic membrane and constitutive endocytosis. 
6.2.2.1 The role of tonic agonist-driven internalisation in CB1R trafficking 
The disagreement between the Lenkei group and the Irving group about whether 
internalisation of dendritic CB1R is agonist-induced or constitutive, respectively, 
comes from the observation that incubation with AM281, an inverse agonist of 
CB1R, results in increased dendritic surface expression of CB1R for the Lenkei 
group (Leterrier et al., 2006) and no difference in CB1R surface expression for the 
Irving group (McDonald et al., 2007a).  
Here, I found that incubation with AM281 resulted in an ultimately non-significant 
trend to increased dendritic surface expression of EGFP-CB1RWT (Figure 4-10). 
However, there was a significant increase in dendritic surface expression of EGFP-
CB1RΔH9 with AM281 incubation. 
Importantly, the Lenkei group use a C-terminally tagged CB1R construct whereas 
the Irving group and I use an N-terminally tagged CB1R construct. C-terminally 
tagged constructs can interfere with C-terminal binding proteins. Indeed, two 
ctCB1R binding proteins that prevent agonist-induced internalisation have been 
described: CRIP1a (Blume et al., 2016) and SGIP1 (Hájková et al., 2016). 
Furthermore, direct comparison between an N-terminally tagged CB1R construct 
and a C-terminally tagged construct revealed that the C-terminally tagged 
construct showed 2-3-fold increase in surface expression compared to N-terminally 
tagged construct in HEK293 cells and N2A cells (Rozenfeld and Devi, 2008). The 
fact that Lenkei’s C-terminally construct act more like my mutant ΔH9 construct 
than the WT construct suggests that the C-terminal tag is, perhaps, disrupting the 
same interaction that is disrupted by deleting H9.  
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To examine this further, I searched the literature for examples where surface 
localisation was examined after incubation with inverse agonist. Table 6-1 consists 
of a table of the results, including an rough estimate of the effect size observed 
(updated from table presented in (Rozenfeld, 2011)). Firstly, there was a huge 
range of effect sizes, due to a large range of cell types, inverse agonist type and 
concentration, and time scales used. However, focussing firstly on experiment in 
primary neurons, it is clear that there is a difference in effect size depending on the 
tag used: C-terminally tagged CB1R shows effect sizes of around 170-200%, 
whereas N-terminally tagged CB1R either shows no increase or smaller effect 
sized (no more than 133%).  Indeed, even within the Lenkei group, the effect size 
seen for endogenous CB1R is far smaller than the effect size for C-terminally 
tagged exogenously expressed protein. A similar pattern is seen in HEK293 cells 
– the is an exaggerated phenotype with C-terminally tagged construct compared 
to the N-terminally tagged construct. Furthermore, in N18TG2 cells, which 
endogenously express both CB1R and CRIP1a, the inverse-agonist-induced 
increase in surface expression was small and transient, returning to basal levels 
after 60 minutes (Blume et al., 2016). These data indicate that the role of agonist-
induced internalisation in CB1R polarity has been exaggerated due to the C-
terminal tag perturbing the role of the C-terminus in trafficking. 
Consistent with their observations, the Lenkei group also reported a high amount 
of internalisation in dendrites compared to axons as well as non-polarised delivery 
after BFA retention and release assay (Leterrier et al., 2006). This phenotype is 
more consistent with my ΔH9 mutant, which is trafficked more to the surface of 
dendrites than WT CB1R and is then is subsequently more internalised in my more 
targeted RUSH approach. Furthermore, they observed Rab5 dependent 
constitutive internalisation of CB1R-GFP in HEK293 cells (Leterrier et al., 2004), a 
finding that I could not replicate with my EGFP-CB1R in HeLa cells (Figure 5-3).  I 
therefore suggest that the C-terminal tag interferes with both TGN sorting and 
internalisation, causing increased delivery to dendrites and increased 
internalisation analogous to perturbation of ctCB1R by H9 deletion.  
Therefore, polarity is established from the outset due to preferential delivery to the 
axonal compartment and decreased delivery to the dendritic compartment. 
Dendritic CB1R is removed from the surface by a combination of constitutive 
internalisation and a small amount of agonist-induced internalisation. 
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Table 6-1 Summary of experiments examining the effect of inverse agonist on CB1R trafficking. 
INVERSE AGONIST AFFECT 
SURFACE EXPRESSION? 
TAG CELL TYPE INVERSE AGONIST  TIME REFERENCE 
Trend 122% N-tagged GFP Primary neurons 10 µM AM281 3 hr This thesis 
No 
N tagged GFP, 
endogenous 
Primary neurons 
10 µM AM281          
SR-141716A 
3 hr, 24 hr      
18hr 
(McDonald et al., 2007a) 
No Endogenous 
Primary neurons,  
F-11 cells 
SR-141716A 16 hr (Coutts et al., 2001) 
Yes ~ 132% Endogenous Primary neurons 10 µM AM281 3 hr (Leterrier et al., 2006) 
Yes ~ 171% 
C-tagged GFP   
N-tagged FLAG 
Primary neurons 10 µM AM281 3 hr (Leterrier et al., 2006) 
Yes ~200 
C-tagged GFP   
N-tagged FLAG 
Primary neurons 
WT vs. inactive 
mutant 
N/A (Simon et al., 2013) 
ΔH9 mutant: Yes 215% N-tagged GFP Primary neurons 10 µM AM281 3 hr This thesis 
Yes: transient peak 133%, 
returns to basal after 60 min 
Endogenous N18TG2 10 nM SR-141716A 
5 min – 114%    
15 min – 133% 
60 min – 106%  
(Blume et al., 2016) 
Yes: 220% (also increase in 
total) 
Endogenous Neuro-2a 1 µM SR-141716A 5 hr (Grimsey et al., 2010) 
Yes: 175% (also increase in 
total) 
N-tagged HA AtT-20 1 µM SR-141716A 5 hr (Grimsey et al., 2010) 
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No N-tagged HA HEK293 100 nM SR141716 45 min (Wickert et al., 2018) 
Yes: 150% (also increase in 
total) 
N-tagged HA HEK293 1 µM SR-141716A 5 hr (Grimsey et al., 2010) 
Yes ~ 600% C-tagged CFP HEK293 SR-141716A 3 hr (Ellis et al., 2006) 
Yes ~200% C-tagged GFP HEK293 7 µM AM281 3 hr (Leterrier et al., 2004) 
Yes (not quantified, described 
as “substantial difference”) 
C-tagged GFP HEK293 
WT vs. inactive 
mutant 
N/A (D’Antona et al., 2006) 
Yes (not quantified, described 
as “slight but significant”) 
N-tagged C-myc CHO cells 50nM SR 141716 
30 min, 1 hr, 4 
hr, 20 hr 
(Rinaldi-Carmona et al., 1998) 
Yes: 140% (also increase in 
total) 
N-tagged HA CHO cells 1 µM SR-141716A 5 hr (Grimsey et al., 2010) 
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6.3 H9 IN CB1R TRAFFICKING AND SIGNALLING  
Previously, very little was known about the role of the putative amphipathic helix 9 
(Stadel et al., 2011; Ahn et al., 2009b). Here, I show that H9 plays a role in both 
the trafficking and signalling of CB1R. H9 plays a role in forward trafficking of 
CB1R, restricting delivery of CB1R to the dendritic membrane (Figure 4-5). H9 
also prevents agonist-induced internalisation (Figure 4-6; Figure 4-7; Figure 4-9; 
Figure 4-10), potentially by interaction with SGIP1 (Figure 5-8). 
Deletion of H9 also causes a reduction of ACEA-induced ERK1/2 activation 
(Figure 4-8). H9 sits right between the two sets of phosphorylatable sites that 
regulate desensitisation (central sites) and internalisation (distal sites), suggesting 
that H9 may regulate β-arrestin1/2 mediated desensitisation, internalisation, and 
signalling via ERK1/2 activation (Jin et al., 1999; Kouznetsova et al., 2002; Daigle 
et al., 2008a; Morgan et al., 2014; Straiker et al., 2012a; Daigle et al., 2008b). 
Furthermore, analogous H9 motifs in the bradykinin receptor and squid rhodopsin 
constitute a Gαq binding site (Piserchio et al., 2005; Murakami and Kouyama, 
2008). Gαq activation potentially triggers ERK1/2 phosphorylation as well 
(Sánchez-Fernández et al., 2014). It would be interesting to determine whether 
CB1R H9 also forms a Gαq binding site, especially since CB1R has been shown to 
signal via Gαq in astrocytes (Navarrete and Araque, 2008). Indeed, I have entirely 
focussed on trafficking in neurons, but it would be interesting to determine whether 
the ΔH9 mutant displays a similar reduced surface expression phenotype in 
astrocytes, especially since it does not in HEK293 cells of HeLa cells (Figure 4-8; 
Figure 5-3). 
The helicity of H9 and the presence of residue C450 are important for H9 function 
(Figure 5-1). Interestingly, this is similar to reported H8 function: H8 helicity is 
dynamic, and it can unravel due to the de-palmitoylation of a nearby cysteine 
residue (C416), potentially removing some interaction sites, and revealing others 
(Sensoy and Weinstein, 2015; Gopala Krishna et al., 2002). Therefore, it is 
possible that the palmitoylation state of C450 is important for H9 helicity and 
function. Since H8 is highly conserved in class A GPCRs, but H9 is not, this would 
add another layer of complexity for CB1R signalling and function. However, firstly 
it would be necessary to confirm that C450 is palmitoylated as it has been 
suggested that C416 is the only site of CB1R palmitoylation (Oddi et al., 2012).   
Chapter 6 –   General Discussion 
157 
 
6.4 FUTURE DIRECTIONS 
6.4.1 Sorting mechanism 
While I have shown that CB1R is sorted by the secretory pathway for preferential 
delivery to the axonal compartment, the sorting mechanism remains unknown. 
Indeed, comparatively little is known about sorting mechanisms to axons compared 
to sorting mechanisms to dendrites (Lasiecka and Winckler, 2011; Bentley and 
Banker, 2016; Bonifacino, 2014). However, relatively recent evidence suggests 
that AP-3 may mediate axonal secretory vesicle budding from the TGN, analogous 
to the better understood role of AP-1 and AP-4 in budding of dendritic secretory 
vesicles (Li et al., 2016; Guardia et al., 2018). 
It has been reported that CB1R binds to AP-3 and that knockdown of AP-3 results 
in a non-polarised surface distribution (Rozenfeld and Devi, 2008), a result that I 
corroborated in a very preliminary experiment (Figure 5-2). However, I found that 
these neurons also appeared to lack Ankyrin-G staining. While this, in itself, may 
be interesting, pointing towards a potential role of AP-3 in generating and 
maintaining the AIS, the disruption of a clearly defined axon does not answer 
whether CB1R is specifically sorted by AP-3. Therefore, more targeted approaches 
are needed to examine AP-3/CB1R binding.  
One way to do this would be to RUSH CB1RWT and see if it co-localises with AP-
3, but not AP-1/4 in the TGN. Indeed, it would be very interesting to co-RUSH 
CB1RWT and a transmembrane protein that is exclusively somatodendritically 
polarised to determine at what point they are sorted and diverge in their trafficking. 
Another way would be to determine the binding site of AP-3 to CB1R. It is possible 
that H9 mediates this interaction seeing as SBP-EGFP-CB1RΔH9 was missorted to 
dendritic membrane as well as the axonal membrane, although it does not contain 
any of the di-leucine or tyrosine-like motifs that usually bind AP-3. Deletion of the 
AP-3 binding site and RUSHing the mutant would provide insight into the role of 
AP-3 in the forward trafficking of CB1R. 
Lastly, my proteomics screen highlighted Lin-7A as a potential H9 interactor. 
Interestingly, Lin7a belongs to a family of PDZ domain-containing CASK adaptor 
proteins that are key regulators of cell polarity (van de Pavert et al., 2004). This hit 
would first need to be validated by co-immunoprecipitation experiments with 
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ctCB1RWT and ctCB1RΔH9. Next, CB1R surface distribution could be examined in 
the presence of Lin-7a knockdown or overexpression.  
6.4.2 Fate of internalised receptors? 
While I have shown that CB1RH9 displays increased internalisation compared to 
WT, further studies are also needed to determine the fate of the internalised WT 
and H9 receptors in both dendrites and axons. Studies in cell lines and primary 
culture suggest that after agonist induced internalisation, CB1R is sent for 
degradation via GASP1 (Tappe-Theodor et al., 2007; Grimsey et al., 2010; Martini 
et al., 2007). However, several questions remain: Is the fate of internalised 
receptors the same in axons vs. dendrites? Are dendritic endosomal CB1Rs 
rerouted to the axonal surface (transcytosis; (Simon et al., 2013))?  Are dendritic 
endosomal CB1Rs preserved as a discrete signalling pool (Rozenfeld, 2011; 
Grimsey et al., 2010)? 
The degradation of internalised CB1R can be examined by adding lysosomal 
inhibitors such as bafilomycin or leupeptin to constitutive or agonist-induced 
endocytosis experiments, staining for a lysosomal marker such as LAMP1, and 
screening for colocalization with LAMP1 in axons vs. dendrites.  
6.4.3 Trafficking to the presynapse 
I show that CB1R is preferentially delivered to the axonal compartment. However, 
once in the axonal compartment it is not known how CB1R is recruited to, and 
retained at, the presynaptic terminal.  
My data showed that SBP-EGFP-CB1RWT was trafficked internally at least 100 µm 
down the axon 10 minutes before it was delivered to the surface (Figure 3-12), 
indicating that CB1R may traffic to distal areas of the axon intracellularly via 
secretory vesicles.  secretory vesicles traffic to distal areas of the axon.  
Alternatively, my data also indicate that CB1R is rapidly surface expressed in the 
axonal membrane immediately distal to the AIS, a pattern that is not present at 
steady state, indicative that CB1R preferentially reaches the surface immediately 
distal to the AIS and then moves along the axon by lateral diffusion (Figure 3-11). 
Therefore, it is possible that, analogous to AMPARs at the postsynapse, CB1Rs in 
the axonal membrane laterally diffuse until ‘trapped’ at the presynapse (Penn et 
al., 2017). 
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One way that CB1R trafficking to distal areas can be tested by live imaging of 
axons in microfluidic chambers during RUSH release to determine whether SBP-
EGFP-CB1RWT fluorescence enters distal areas, including the presynapse, in 
punctate vesicles (indicative of intracellular secretory vesicular transport 
mechanism) or as diffuse fluorescence (indicative of lateral diffusion), as has been 
done recently in a similar experiment with AMPA receptors (Hangen et al., 2018). 
6.4.4 The role of ECS and synaptic activity on CB1R forward trafficking 
The Henley lab has shown previously using RUSH that activation of receptors at 
the cell surface can impact the forward trafficking of receptors of the same type 
(Evans et al., 2017). Interestingly, (Grimsey et al., 2010) reported that in a variety 
of cells, inverse agonist treatment resulted not only in increased surface 
expression of CB1R but also increased total expression (Table 6-1).  Furthermore, 
blocking synthesis by cycloheximide treatment blocked the inverse-agonist 
mediated increase of both surface and total expression, indicating that the increase 
in surface expression is not due to blocking agonist-induced endocytosis, but 
rather due to the delivery of newly synthesised CB1R (Grimsey et al., 2010). 
Although I did not observe an increase in axonal surface expression with AM281 
incubation, I did observe an increase in total CB1R in axons for both WT and ΔH9 
(Figure 4-10). It is possible that this increase was made up of newly synthesised 
receptors being delivered to the axon to repopulate blocked receptors, which would 
have occurred at a later timepoint. This hypothesis can be tested by concurrently 
adding cycloheximide to AM281 incubation as well as by extending the timepoints 
to determine whether axonal surface CB1R increases. If this hypothesis is correct, 
it would indicate that activation or inactivation of CB1R at the surface affects the 
forward trafficking of newly synthesised receptors. 
The influence of activity on trafficking of CB1R can be tested by treatment with cell 
permeable and cell impermeable agonists and antagonists of CB1R either during 
or directly prior to RUSH biotin-mediated release. This is important because is 
would provide basic molecular understanding of the dynamic regulation of the ECS 
as well as provide insight of the effect of that cannabinoid intake may have on this 
system. 
Since CB1R acts as a synaptic feedback mechanism and eCBs are produced “on 
demand” in response to synaptic activity (Kano et al., 2009), it would also be 
interesting to examine the role of synaptic activity on CB1R forward trafficking. 
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Treatment with tetrodotoxin (TTX), a potent Na+ channel blocker, or bicuculine, a 
GABAA receptor antagonist, downregulate or upregulates inherent synaptic 
activity, respectively. Furthermore, synaptic plasticity, both long term potentiation 
(LTP) and long-term depression (LTD), can be chemically induced in cultured 
primary neurons. Examining the trafficking of CB1R under these conditions would 
provide insight into how physiological and pathological synaptic activity impacts 
CB1R trafficking and surface expression, and therefore function. 
6.4.5 SGIP1 and H9 
I have shown that knockdown of SGIP1 in primary hippocampal neurons reduced 
the surface expression of CB1R, recapitulating the phenotype of the ΔH9 mutant 
(Figure 5-8). Furthermore, the effect of knocking down SGIP1 on surface 
expression was occluded in the ΔH9 mutant, strongly suggesting that SGIP1 binds 
H9 to prevent agonist-induced internalisation of CB1R. However, in HEK293 cells, 
co-expression of FLAG-SGIP1β increased surface expression of CB1R 
independently of H9 (Figure 5-6). Therefore, the next step would be to overexpress 
FLAG-SGIP1β in primary neuros with either EGFP-CB1RWT or EGFP-CB1RΔH9. If 
SGIP1 binding is mediated by H9 in neurons, then overexpression of FLAG-
SGIP1β would increase EGFP-CB1RWT, but not EGFP-CB1RΔH9 surface 
expression.   
Co-immunoprecipitation of EGFP-CB1RWT/ΔH9 and SGIP1 in primary neuronal 
cultures and GST pulldowns of purified proteins would determine whether 
SGIP1/H9 binding is direct or indirect. Importantly, SGIP1 has been shown to bind 
CB1R directly (Hájková et al., 2016).  
6.4.6 Functional effects 
While I have shown that deletion of H9 affects trafficking of CB1R in neurons and 
ERK1/2 signalling in HEK293T cells, I did not have the chance to examine the 
functional effects of H9 deletion in primary hippocampal neurons. To do this, I could 
have measured presynaptic CB1RWT vs CB1RΔH9 signalling by live cell imaging of 
eCB-mediated suppression of electrically-evoked presynaptic Ca2+ responses 
(SyGCaMP3) and vesicular neurotransmitter release (SypHy; (Girach et al., 2013; 
Tang et al., 2015)). Comparing the function of WT and the ΔH9 mutant with 
application of cell permeable and cell impermeable agonists and antagonists could 
also potentially provide insight into the role of the endocytic pool in CB1R signalling 
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since the mutant is more internalised and less surface expressed. Furthermore, 
the results could be compared to conditions where SGIP1 has been knocked down. 
We could also examine the effect of H9 deletion and SGIP1 knockdown on 
depolarisation-induced suppression of excitation or inhibition (DSE and DSI), the 
classical electrophysiological measures of presynaptic CB1R function in neurons 
(Straiker and Mackie, 2005). These experiments would provide insight into the role 
of H9 and SGIP1 on CB1R function.  
6.4.7 Therapeutic potential 
There has been a lot of interest recently in the possibility of using cannabinoid 
compounds to treat a range of diseases including epilepsy, chronic pain and 
inflammation, and multiple sclerosis (Kogan and Mechoulam, 2007). This has led 
to the legalisation of medical cannabis in 33 US states and the legalisation of a 
specific cannabinoid-based medication for MS, Sativex, in the UK, as well as the 
emergence of cannabidiol availability in cafés, vapes, and corner shops. 
Additionally, there is a substantial academic and commercial interest in the 
development of new strains of cannabis and synthetic agonists and antagonists. A 
major focus of research into the endocannabinoid system (ECS) has been 
understanding its complex pharmacology (Pertwee, 2015). However, cannabinoid-
based treatments and clinical trials have been plagued by off target side effects, 
which does not necessarily come as a surprise given the wide-ranging roles and 
effects of the ECS in brain function and behaviour (Khurana et al., 2017; Freeman 
et al., 2019; Johansson et al., 2009; Kaur et al., 2016b; a).  
In contrast, relatively little work has been published on CB1R trafficking and the 
mechanisms and importance of axonal polarisation of the various components of 
the ECS. However, understanding the molecular mechanisms and protein 
interactions underpinning CB1R trafficking and surface expression could provide 
novel targets to enhance or reduce ECS signalling without the need to directly 
activate or block the receptor.  
For example, both SGIP1 and CB1R are strongly associated with diet-induced 
obesity (DIO; (Trevaskis et al., 2005; Bellocchio et al., 2010; Cardinal et al., 2015). 
SGIP1 was first discovered because it was upregulated in the hypothalamus of two 
rodent models of obesity (Trevaskis et al., 2005). Mice lacking CB1R in Sim1-
positive glutamatergic paraventricular nucleus (PVN; Sim1-CB1R-KO mice) 
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neurons are resistant to DIO (Cardinal et al., 2015). Given that overexpression of 
SGIP1 increases CB1R surface expression (Figure 5-6; (Hájková et al., 2016)) 
and SGIP1 knockdown decreases CB1R surface expression, likely via interaction 
with H9 (Figure 5-8), I hypothesize that disrupting CB1R/SGIP1 binding in the 
Sim1-postive PVN neurons would prevent diet induced obesity (DIO). 
Therefore, it would be interesting rescue the Sim1-CB1R-KO mice with either 
CB1RWT or CB1RΔH9 and/or specifically knock down SGIP1 in Sim1 positive cells 
compare the phenotype and examine the effect on obesity. 
6.5 CONCLUSIONS AND SIGNIFICANCE 
In conclusion, the data presented in this thesis has met the original aims of the 
project, providing novel insight into how CB1R polarised surface distribution is 
established and maintained. Analysis of ctCB1R has reaffirmed the importance of 
this region in the forward trafficking and internalisation of the receptor and has 
uncovered the crucial contribution of the Helix 9 motif to these processes.  
Understanding the basic molecular mechanisms and protein interactions that 
underpin CB1R trafficking has far-reaching therapeutic potential, providing novel 
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